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ABSTRACT 
Background. West Nile Virus (WNV), a mosquito-borne flavivirus, is one of an 
increasing number of infectious diseases that have been emerging or re-emerging in the 
last two decades. Since the arrival ofWNV to Canada to present date, the Niagara Region 
has only reported 30 clinical cases, a small number compared to the hundreds reported in 
other regions of similar conditions. Moreover, the last reported human case in Niagara 
was in 2006. As it has been demonstrated that the majority of WNV infections are 
asymptomatic, the question remains whether the lack of clinical cases in Niagara truly 
reflects the lack of transmission to humans or if infections are still occurring but are 
mostly asymptomatic. 
Objectives. The general objective of this study was to establish whether or not active 
WNV transmission could be detected in a human population residing in Niagara for the 
2007 transmission season. To fullfil this objective, a cross-sectional seroprevalence study 
was designed to investigate for the presence of anti-WNV antibodies in a sample of 
Mexican migrant agricultural workers employed in farms registered with the Seasonal 
Agricultural Workers Program (SAWP). Due to the Mexican origin of the study 
participants, three specific research objectives were proposed: a) determine the 
seroprevalence ofanti-WNV antibodies as well as anti-Dengue virus antibodies (a closely 
related virus prevalent in Mexico and likely to confound WNV serology); b) analyze risk 
factors associated with WNV and Dengue virus seropositivity; and c) assess the 
awareness of study participants about WNV infection as well as their understanding of 
the mode of transmission and clinical importance of the infection. 
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Methodology: After obtaining ethics clearance from Brock University, farms were 
visited and workers invited to participate. Due to time constraints, only a small number of 
farms were enrolled with a resulting convenience and non-randomized study sample. 
Workers' demographic and epidemiological data were collected using a standardized 
questionnaire and blood samples were drawn to determine serum anti-WNV and anti-
Dengue antibodies with a commercial ELISA. All positive samples were sent to the 
National Microbiology Laboratory in Winnipeg, Manitoba for confirmation with the 
Plaque Reduction Neutralization Test (PRNT). Data was analyzed with Stata 10.0. 
Antibody determinations were reported as seroprevalence proportions for both WNV and 
Dengue. Logistic regression was used to analyze risk factors that may be associated with 
seropositivity and awareness was reported as a proportion of the number of individuals 
possessing awareness over the total number of participants. 
Results and Discussion. In total 92 participants working in 5 farms completed the study. 
Using the commercial ELISA, seropositivity was as follows: 2.2% for WNV IgM, 20.7% 
for WNV IgG, and 17.1 % for Dengue IgG. Possible cross-reactivity was demonstrated in 
15/20 (75.0%) samples that were positive for both WNV IgG and Dengue IgG. 
Confirmatory testing with the PRNT demonstrated that none of the WNV ELISA positive 
samples had antibodies to WNV but 13 samples tested positive for anti-Dengue 
antibodies (14.1 % Dengue sereoprevalence). The findings showed that the ELISA 
performance was very poor for assessing anti-WNV antibodies in individuals previously 
exposed to Dengue virus. However, the ELISA had better sensitivity and specificity for 
assessing anti-Dengue antibodies. 
111 
.. -
West Nile Virus in the Niagara Region 
Whereas statistical analysis could not be done for WNV seropositivity, as all samples 
were PRNT negative, logistic regression demonstrated several risk factors for Dengue 
exposure_ The first year coming to Canada appeared to be significantly associated with 
increased exposure to Dengue while lower socio-economic housing and the presence of a 
water basin in the yard in Mexico appeared to be significantly associated with a 
decreased exposure to Dengue_ These seemingly contradictory results illustrate that in 
mobile populations such as migrant workers, risk factors for exposure to Dengue are not 
easily identified and more research is needed. Assessing the awareness of WNV and its 
clinical importance showed that only 23% of participants had some knowledge of WNV, 
of which 76% knew that the infection was mosquito-borne and 47% recognized fever as a 
symptom. The identified lack of understanding and awareness was not surprising since 
WNV is not a visible disease in Mexico. Since WNV persists in an enzootic cycle in 
Niagara and the occurrence of future outbreaks is unpredictable, the agricultural workers 
remain at risk for transmission. Therefore it important they receive sufficient health 
education regarding WNV before leaving Mexico and during their stay in Canada. 
Conclusions. Human transmission of WNV could not be proven among the study 
participants even when due to their occupation they are at high risk for mosquito bites. 
The limitations of the study sample do not permit generalizable conclusions, however, the 
study findings are consistent with the absence of clinical cases in the Niagara Region, so 
it is likely that human transmission is indeed neglible or absent. As evidenced by our 
WNV serology results, PRNT must be utilized as a confirmatory test since false positivity 
occurs frequently. This is especially true when previous exposure to Dengue virus is 
likely. 
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CHAPTER 1: INTRODUCTION 
Globalization of infectious diseases have become more evident with the movement of 
West Nile Virus (WNV) to the American continent [1]. An RNA flavivirus, WNV is 
considered the most geographically widespread arbovirus in the world and exists in an 
enzootic cycle between birds as the natural and amplifying reservoir and mosquitoes as 
the arthropod vector [2]. Humans and horses are the most susceptible hosts, although the 
attained level of viremia is not sufficient to allow further vectorial transmission [3] . 
Worldwide, human WNV infection is asymptomatic in approximately 80% of all those 
infected, with the remaining 20% manifesting flu-like symptoms and sometimes a 
roseolar skin rash. Clinical and epidemiological studies have demonstrated that less than 
1 % of those with symptoms will develop neurological disease [4, 5]. 
West Nile Virus was considered a minor human pathogen until 1996 when a number of 
epidemics began to occur resulting in an unprecedented increase of neurological disease 
and death [6, 7]. First isolated in 1937, from a woman with febrile disease living in the 
West Nile province of Uganda [8], the virus is now endemic in Africa, Asia, Europe, 
Australia, and, as of 1999, North America [4]. Within North America, the 
unpredictability of WNV transmission during the last ten years has been puzzling. The 
virus entered the continent apparently through New York City in 1999, when animals and 
humans were unequivocally identified with a WNV strain 99.8% homologous to a strain 
causing an epizootic in geese in Israel [9, 10]. At present, although the year-to-year 
number of cases varies considerably, WNV is considered endemic in the United States 
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(US), as human, bird, or mosquito infections have been reported from all states except 
Hawaii and Alaska [11]. 
In Mexico, thanks to active surveillance systems, serological evidence of WNV 
transmission was found in birds and horses in 2002. Isolation of the virus was first 
demonstrated in a raven in 2003 and the first human case was reported in 2004 [12-16]. 
To date, despite favorable ecological conditions, human cases are almost non-existent in 
the country. Moreover, as opposed to the case of US and Canada, the infection in horses 
and other mammals in Mexico have shown exceptional low rates in both morbidity and 
mortality [12]. 
In Canada, on the other hand, WNV activity started in August 2001, when the virus was 
found in dead birds and mosquito pools in southern Ontario [17]. The first human case 
was detected in Ontario in 2002 and in the following years the number of cases have 
varied tremendously: an upward trend in Canada was identified from 2002 to 2003 (with 
414 and 1,481 cases for each year, respectively), followed by reduced numbers in 2004 to 
2006 (25, 225 and 151 cases, respectively), which rose again in 2007 (2,215 cases). In 
2008, at the end of the WNV transmission season, a total of only 36 cases had been 
reported in Canada [17]. Human cases of WNV infections in the Niagara Peninsula have 
shown similar unpredictable trends: the largest-albeit small-numbers of cases were 
reported from 2002 and 2003 (18 and 5 cases, respectively), with very few cases reported 
from 2004 to 2006 ( 1, 3, 3 cases, respectively) and no cases have been reported in 2007 
and 2008 [18]. 
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When companng the widespread WNV transmission in the United States with the 
isolated epidemics in Canada and the almost non-existent human infection in Mexico, it 
is difficult to explain the differences of WNV transmission in North America. The 
epidemiological triangle with the ever changing interactions between agent, host, and the 
environment, is naturally at the heart of the explanation as to why the disease patterns of 
WNV are occurring with no apparent consistent predictors. Could it be that WNV is a 
virus that requires very specific elements of the epidemiological triad to be fulfilled in 
order for the virus to be successful in causing epidemics and establishing itself as an 
endemic virus to any particular geographical area? Historically, through Europe and the 
Middle East, a pattern of recurrent outbreaks have occurred in previously established 
endemic areas [2]. Silent periods as long as two decades have been observed between 
epidemics/epizootics in Europe and the Mediterranean basin. Although Niagara currently 
appears to have low transmission, WNV is still present in the avian population as of 2008 
and has been found in one mosquito pool to date of this year [18]. Thus it is prudent to 
continue surveillance and preventive measures as a new epidemic could occur. 
To advance the understanding ofWNV transmission in Niagara Region, the present study 
aimed to establish whether or not active WNV transmission (as determined by the 
presence of specific circulating antibodies) could be detected in a population, that due to 
their occupation as agricultural workers, were more likely than the general population to 
have been exposed to vectorial transmission should this be taking place at sufficient 
levels in Niagara. 
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CHAPTER 2: REVIEW OF LITERATURE FOR WEST NILE VIRUS AND 
WEST NILE VIRUS INFECTION AND DISEASE 
2.1 History of West Nile Virus infection and disease 
Alexander the Great was thought to have succumbed in Babylon in 323 BC to the 
neurological manifestations ofWNV [19, 20]. Babylon, located in the area of present day 
Iraq, was along the Tigris and Euphrates rivers as well as being surrounded by swamp. 
The geography at the time is thought to have been able to support a large mosquito as 
well as large bird populations. Plutarch, the Greek historian wrote, "when he arrived 
before the walls of the city he saw a large number of ravens flying about and pecking one 
another, and some of them fell dead in front of him"[20]. Alexander is thought to have 
developed a febrile disease accompanied by signs of encephalitis and acute flaccid 
paralysis. Polioencepha10myelitis, influenza, poisoning, and other parasitic diseases are 
considered; however, the behaviour and the deaths of ravens preceding Alexander's death 
are similar to the situation that occurred in New York City in 1999. In a letter to the 
editor, Cunha (2004) attempted to discount this proposal and indicated that typhoid is the 
most likely explanation for the demise of Alexander the Great [19]. It is possible that 
WNV has been around for many centuries and was not recognized until 1937 when a 
Ugandan woman suffering from febrile disease was diagnosed [8]. 
Since 1937 the virus has established itself as an endemic infectious disease of humans on 
every continent except the Antarctica. Initially endemic in Africa, Asia, Europe, and the 
Middle East the virus crossed the Atlantic in 1999 to infect North America. The virus 
exists in an enzootic cycle between the mosquito vector and birds with humans and 
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horses being the most common incidental hosts. Prior to 1996 the disease appeared as 
sporadic epidemics with rare neurological cases and deaths. Since 1996 the virulence of 
this virus has increased through a series of accumulated mutations, particularly in North 
America, where it is the most common arbovirus to have affected the continent [4]. The 
virus has not yet been diagnosed beyond very rare cases in Mexico, Central America, and 
South America [12]. 
2.2 Etiological viral agent 
2.2.1 Taxonomy 
WNV is a single stranded enveloped RNA virus with a positive sense polarity. RNA 
viruses are categorized into 3 superfamilies based on their RNA-dependent RNA 
polymerases (RdRP) with WNV belonging to superfamily 2. WNV is part of the family 
Flaviviridae and genus Flavivirus. It is further categorized into the Japanese encephalitis 
serocomplex based on serological cross-reactivity. Other viruses within the Japanese 
encephalitis serocomplex include Alfuy, Cacipacore, Japanese encephalitis, Koutango (a 
distant African variant of WNV), Kunjin, Murray Valley encephalitis, St. Louis 
encephalitis, Rocio, Stratford, Usutu, and Yaounde. Other viruses in the genus Flavivirus 
but not in the Japanese serocomplex include Dengue and Yellow Fever [21]. 
The virus is further categorized into 2 distinct phylogenetic lineages based on nucleotide 
sequences. Lineage I viruses have been isolated from all continents except Antarctica and 
are responsible for most of the neurological disease and death. Lineage I is further 
categorized into 4 clades: Kunjin, Indian, A, and B. Clade B has been responsible for the 
epidemic in North America. The virus strain introduced into New York City in 1999 
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(NY99) demonstrated an increase in virulence over the other strains circulating in the 
Mediterranean area at the time. NY99 was found to be 99.7% homologous with the 
concurrent epidemic occurring in Israel. Lineage II is confined to South Africa and 
Madagascar and has not been associated with epidemic transmission [4]. 
2.2.2 Morphology 
The viral particle measures 50nm with a nucleocapsid core of 30nm in diameter. It is an 
enveloped virus with a lipid bilayer containing two enveloped glycoproteins known as the 
envelope (E) and premembrane (prM) proteins. The icosahedral nucleocapsid core 
contains a single strand of positive sensed RNA complexed with multiple copies of 
capsid protein known as C. The genome is 11 kb in length with a single open reading 
frame (ORF) flanked by a 5' (100 nucleotides) and a 3' (400-700 nucleotides) noncoding 
region (NCR) with a 5' cap but lacking a 3' tail. The DNA encodes for a single 
polypeptide which is cleaved by viral and host enzymes into 3 structural proteins (C, 
prM, and E) responsible for virus particle formation and 7 nonstructural proteins 
responsible for virus replication and virion assembly (fig. 1 ) [4, 22]. 
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Fig. 1. West Nile virion and genome. WNV structure as reconstructed by cryo-electron 
microscopy. A surface-shaded view with one asymmetric unit ofthe icosahedron indicated by the 
triangle. Central section of the reconstruction showing the concentric layers of mass density. 
WNV genome, a single-stranded positive-sense RNA, approximately 11 kb in length consisting 
of a 5' untranslated region (UTR), a single long open-reading frame, and a 3' UTR. The open-
reading frame encodes three structural and seven nonstructural proteins. Kramer, Steyer, and 
Ebel (2008) [2]. 
2.2.3 Life cycle 
Following a mosquito bite, WNV initially begins its replication in the intradermal 
dendritic cells. Domain III of the E glycoprotein, a hemagglutinin, is responsible for viral 
receptor binding to the host cell (fig.2_1 st step) [5,23]. The virus then enters the cell by 
endocytosis creating a vesicle around the viral particles (fig.2_2nd step). Once inside the 
cell there is a drop in the pH causing a conformational change in the E protein exposing a 
hydrophobic domain, allowing fusion between the host and viral membranes (fig.2_3rd 
step). The virus then fuses with the prelysosomal endocytic compartment where the 
fusion between the virus and the membrane releases the nucleocapsid core (fig.2_4th 
step). The viral RNA is released into the cytoplasm making it available for translation 
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and replication (fig.2_Sth step). The viral RNA acts as mRNA and is translated on the host 
ribosomes into a polyprotein. Through enzymatic cleavage with both host and viral 
enzymes the polyprotein is cleaved in 3 structural proteins and 7 nonstructural proteins 
(fig.2_6th step). These proteins copy and assemble the viral RNA into new virions. 
Synthesis of a genome length minus strand of viral RNA is replicated on the endoplasmic 
reticulum which then serves as a template for production of further strands of positive 
sense RNA. The production of the minus strand of RNA has been detected within 3 hours 
of initial WNV infection. There are a least 10 positive strands of RNA produced for every 
minus strand template. Viral RNA accumulates in vesicles along the borders of the 
smooth endoplasmic reticulum (fig.2-ih step). The E and PrM proteins form a 
heterodimer. PrM is cleaved by furin through the Golgi network and the virion is 
rendered mature, moves to the cell surface (fig.2_8th step), is enclosed in a lipid bilayer 
and exits the cell by exocytosis ( fig.2_9 th step) [22, 24]. 
After replication in the dendritic cells, the virus moves through the lymphatic system to 
the bloodstream and then to other organs and tissues including the central nervous 
system. The pathogenesis of WNV will be discussed later. 
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Fig. 2. Viral intracellular replication. Biocarta (2007) [25]. 
2.3 Clinical aspects of West Nile Virus infection 
2.3.1 Transmission 
2.3.1.1 Vector transmission 
~ .. 
BIOCAItTA 
> 
WNV exists in an enzootic transmission cycle with over 65 species of mosquitoes, most 
commonly Culex species, as the vectors and over 300 species of wild birds as the 
amplifying hosts. Migratory birds introduce the virus into new geographic areas and local 
mosquitoes then serve as the vectors to spread the virus to native wild and domestic birds 
to complete the enzootic cycle. Horses and humans are incidental or dead-end hosts, 
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since these speCIes cannot develop a sufficient magnitude of VIremIa to serve as a 
reservOir (fig.3). All other mammals, reptiles, and amphibians are susceptible to 
developing WNV. 
Recently the squirrel and the alligator have been found to develop a sufficient viral load 
to act as a reservoir and transmit WNV by way of the mosquito [2]. Platt et al. 
demonstrated in a study that the fox squirrel can develop a high enough viremia to be a 
potential reservoir host. This study also found that the fox squirrel can be persistently 
infected with WNV, with virus isolated from urine and from the oral cavity. The author 
suggests that this may lend to a non-mosquito mode of transmission [26]. Padgett et al. 
identified neurological cases of WNV in the tree squirrel with viremias similar to that 
Enzootic cycle 
Fecal-oral 
Other~ 
vectors t t + 
PersIstence Death Immuooty 
r···.. ..~ 
' ? '" ~ 
...... . 
V ~ Carrion 
FIgure 3 
Vertical 
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Epidemic 
Blood 
transfusIon 
Organ 
transplantatio~ 
Breast milk 
Intrauterine 
Epizootic 
....................... Cofeeding transmission? 
.............................. 
Infectious viremia? 
WNV transmiss ion cycle. Primary enzootic amplifi ca tion by birds and mosqu itoes may be supplemented 
by bird-to-bi rd transmission. ampl ificat ion in nonavian host s. and transmission between cofeeding 
mosquitoes. Alternative vectors most likely have a less important role. Persistent infection in vertebrates 
may allow subsequent infect ion in susceptible scavengers. predators. or mosquitoes. Vert ica l transmission 
by mosquitoes provides one mechanism of virus overwintering. Equines and humans are incidental hosts; 
however. human~to~huma n transmission may occur through blood transfusion, organ transplantation, 
breast milk. or in utero. Solid arrows represent confirmed transmission pathways; dotted arrows 
represent proposed pathways that have not been confirmed in nature. 
Fig.3. West Nile Virus transmission cycle. Kramer et al (2008) [2]. 
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found in symptomatic birds suggesting that the tree squirrel may play a role in the 
ecology of WNV [27]. 
Feral swine have become established in 20 states of the United States. Since these pigs 
are already being surveilled for brucellosis and pseudorabies, Gibbs et al (2006) 
evaluated the blood samples for WNV antibodies and found a prevalence of 22.5% for 
222 samples collected over the years 2001-2004. The result of this study suggested that 
other mammals including the feral pig can serve as sentinels of WNV transmission [28]. 
Passerine birds, including the corvids (crows, ravens, and blue jays), have been thought 
to be of major importance in North America for the transmission of WNV. However this 
may not be the case. The corvids develop high viremias quickly but also die before 
serving as a long term reservoir of the virus. They have served as sentinels for monitoring 
movement and introduction of WNV into a new geographic area, however, other birds 
such as sparrows and finches may be better long term reservoirs [29]. Sparrows and 
finches develop sufficient viral loads to act as reservoirs and also survive for longer 
periods of time, even over the winter, to pass the virus to the vector. Migrating birds are 
important for spreading the virus long distances whereas mosquitoes and non-migrating 
birds are more important for sustaining the virus in any given geographic location [4]. 
Transmission is a dynamic mechanism involving mosquitoes, birds, and the prevailing 
environmental conditions. Hatchlings play a role in transmission as they have no 
established immunity and are more prone to mosquito bites and thus rapidly amplify 
WNV transmission. Warm dry summers are associated with an increase in WNV 
transmission. Drought conditions increase contact between mosquitoes and birds at the 
reduced water sources [30]. 
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2.3.1.2 Non-viremic transmission in mosquitoes 
Non-viremic transmission (NVT) between mosquitoes has been proposed by Higgs et al. 
(2005) as a potentially important means of transmission and long term survival for WNV. 
NVT refers to the transfer of WNV by co-feeding mosquitoes before a viremia is 
established in the host. If the quantity of WNV in the saliva secreted by the mosquito is 
of sufficient concentration then co-feeding adjacent mosquitoes can become infected 
from dermal areas without assistance from the host. The mosquito population density 
would be the limiting factor. NVT enhances transmission times and changes the role of 
the incidental host, giving them a key role with the regards to the long term survival of 
WNV [31, 32]. 
2.3.1.3 Other modes of transmission 
Horizontal transmission among birds has also been proposed by direct contact from bird 
to bird through preening or fighting, through the fecal-oral route, and from ingestion of 
infected carrion [2]. Banet-Noach et al. (2003) demonstrated horizontal transmission of 
WNV in flocks of geese through feather picking and cannibalism [33]. Organ 
transplantation has also been documented as means of transmission. In August of 2002, 
four U.S. patients received various organs from a common donor and became ill with a 
fever. Three of the four patients developed encephalitis. All 4 tested positive for WNV. 
The source of WNV in the donor was traced back to a blood transfusion the donor 
received after sustaining life threatening injuries [34]. 
In the United States in 2002, 23 patients developed WNV through the blood supply. 
Thirteen of these donors developed meningoencephalitis [34]. Since 2003 both Canada 
and the United States screen all blood for the presence of WNV using nuclear 
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amplification antigen tests. In 2002, WNV also appeared in the Mexican blood supply. 
An evaluation of the Mexican blood supply was performed in a study by Sanchez-
Guerrero et al (2006) which discovered one positive sample among 3856 specimens [35]. 
This study suggested that 0.03% of the blood supply was viremic for WNV. The donor 
was a 41 year old farmer from the state of Chihuahua. His home was close to a river and 
bird sanctuary with a dense mosquito population. The individual did not recall any illness 
in the past year. He had not travelled from the area in the past 16 years. Genetic 
sequencing was not performed [35]. Since 80% of all cases are asymptomatic it is 
possible that there are other blood donors that have had past infections. 
2.3.2 Entomology 
WNV has been found in over 65 mosquito species with the Culex species of mosquitoes 
being the predominant amplifying vectors for WNV in North America. Culex pipiens is 
primarily ornithophilic however there are zoophilic forms that can serve as bridge 
vectors. Bridge vectors are the mosquitoes transmitting the virus from birds to mammals 
[36]. 
Culex tarsalis and Culex nigripalpus are important bridge vectors since they switch 
feeding from birds to humans. Culex quinquefasciatus and Culex salinaris feed 
indiscriminately on both birds and mammals. The competence of the mosquito vector is 
critical for the transmission ofWNV. 
Ochlerotatus trivittatus, one of the most abundant mosquito species in the North and 
North Central United States, is anthropophilic but will also feed on other mammals and 
avian species. In a study by Tiawsirisup et al (2005), Aedes albopictus was found to be a 
more efficient vector when fed bloodmeals with high viral titers whereas Culex pipiens 
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and Dchlerotatus trivittatus were more efficient vectors when fed bloodmeals with lower 
viral titers [36]. After the mosquito ingests a bloodmeal the virus enters the midgut. 
Transmission appears to depend on the ability of the virus to escape the midgut to the 
salivary gland and then escape into the saliva [36]. 
Theilman and Hunter (2006) surveilled the Niagara Peninsula from 2001 to 2004 for 
Dclerotatus japonicas, a mosquito native to south-east Asia. This mosquito was found to 
breed in containers of standing water with little organic debris and is thought to have 
been imported to North America in the international used tire trade. Dc. Japocicus is 
known to bite mammals and some birds but do not seem to favour biting humans. 
Although WNV has been found in this mosquito in the US, it has not been found in 
Canada. The numbers of Dc. Japonicas increased from 2001 to 2004 however the risk as 
a WNV vector is unknown [37]. 
Soft ticks (argasid) in Israel have been found to carry WNV; however, their importance 
as vectors is unknown [38]. 
In temperate climates infected mosquitoes overwinter by seeking out shelter and enter 
into a diapausing phase. In the spring the mosquito awakens and serves as a continuing 
source of the virus. WNV is also transferred vertically, with the virus entering the 
mosquito egg at the time of fertilization, ensuring infected mosquitoes will emerge in the 
spring to enter back into the enzootic transmission cycle [2, 39]. 
2.3.3 Immunopathology and host immune response 
2.3.3.1 Pathogenesis 
Following a mosquito bite the VIruS replicates in the dendritic cells of the dermis, 
disseminates to the regional lymph nodes and then spreads hematogenously creating a 
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primary viremia. The virus moves through the bloodstream to the spleen and kidney 
replicating to produce high levels of viremia. The virus then disseminates to the central 
nervous system (CNS) and targets the cerebellar purkinge cells, thalamus, basal ganglia, 
and anterior-hom cells of the spinal cord. The ability of the virus to penetrate the blood-
brain barrier is dependent on the immunocompetence of the individual. Most cases of 
neurological disease are found in apparently healthy patients over 50 years of age. 
Immune senescence is thought to be the cause, however, other risk factors include the 
presence of coexisting cardiovascular disease and hypertension, diabetes, and other 
causes of immunosuppression [40]. West Nile Virus upregulates expression of CNS 
chemokine receptor, CCR5, which creates an inflammatory response and may be a factor 
in the penetration of the blood-brain barrier. Loss of neuronal cells are due to direct viral 
damage as well as the results of the inflammatory response. The histopathology appears 
as diffuse perivascular inflammation with a predominance of CD8+ T cells, microglial 
nodules and direct neuronal degeneration [4]. Other modes of transport to the CNS 
include axonal transport, cytokine directed leukocyte diapedesis through the endothelial 
cells of the blood-brain barrier, viral release through the choroid plexus, and an increase 
in endothelial cell permeability by tumour necrosis factor alpha [41]. 
2.3.3.2 Innate immune response 
The innate immune response is achieved through the production of interferons. The RNA 
virus is recognized by receptors, such as Toll-like receptor 3 (TLR3), which results in the 
activation and expression of interferon expressing genes. Toll-like receptor 3 and the 
cytoplasmic double-stranded RNA sensors (dsRNA) are nucleic acid sensors that bind 
RNA and induce macrophages and dendritic cells to produce interferon [42]. 
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Interferons, type I (alpha and beta), type II (gamma) and III (delta), are potent antiviral 
cytokines produced upon viral invasion. Interferons alpha and beta are produced by most 
cell types by direct activation of Band T cells. The result is a restriction on the 
replication and spread of WNV despite the evasive response by the virus. Interferon 
gamma is produced by T cells, CD8 T cells, and natural killer (NK) cells and serves also 
to limit viral dissemination by increasing cell surface expression of major 
histocompatibility complex (MHC) class I molecules [41]. 
Complement is a group of serum proteins and surface molecules that recognize antigen 
and initiates clearance from the body. Complement activates direct opsonisation, 
chemotaxis, and modulation of Band T cell functions. WNV activates complement and 
initiates this immune clearance process [41]. 
Cellular innate immunity involves macrophage uptake of WNV and activation of 
interferon production of dendritic cells. [41]. 
2.3.3.3 Adaptive immune response 
The adaptive immune response to a viral infection involves both a humoral and a cellular 
response. The humoral response is the production of antibody against the virus from B 
lymphocytes. The cellular response is the production of cytotoxic T lymphocytes called 
CD4+ and CD8+ cells. 
Peak viremia occurs from 3 days before and 1 day after the onset of clinical illnesses. 
This rapid decline in viremia from the serum and peripheral organs is due to macrophage 
clearance and production of immunoglobulin M (lgM). Viremia in immunosuppressed 
patients can continue for several months. Immunoglobulin G (lgG) is not produced until 
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later in the infection. IgG is produced after viral clearance and after the virus has invaded 
the eNS (fig. 4). 
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Fig. 4. Immune response to West Nile Virus. Hazel et al Panbio Inc. Australia (2004) 
[43]. 
The E protein of the virus elicits production of neutralizing antibodies targeted to all 3 
domains of the E protein. The antibodies produced against domain III prevent viral 
fusion. Studies by Samuel and Diamond (2006) indicate that only partial epitope 
saturation by the neutralizing antibody is necessary to neutralize the virus. Most 
neutralizing antibodies bind the viral structural proteins. Nonstructural viral protein 1 
(NS 1) is a cofactor in replication and inhibits complement activation helping the virus 
evade the host immune defence. Neutralizing antibodies to NSI have been found to limit 
the ability of the virus to replicate [44]. 
The epitope specificity of a humoral response has been unknown until recently.Work by 
Oliphant et al. discovered that domain II of the E protein appeared to be 
immunodominant rather than domain III. These investigators found that the majority of E 
specific monoclonal antibodies were reactive in other regions of the E protein other than 
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domain III and in particular favoured domain II [45]. Previous work by Throsby et af. 
also indicated the immunodominance of domain II of the E protein and the weak 
neutralizing ability of the monoclonal antibodies to the epitopes of this domain [46]. A 
novel computer algorithm developed by Denisova et af. was able to identify epitopes to 5 
different monoclonal antibodies against the E protein ofWNV. This work is important as 
the methodology could lead to the development of epitope specific vaccines, not only for 
WNV but other viruses such as HIV [47]. 
The T cell response targets a limited number of conserved epitopes of the E protein [48] 
WNV infected cells are recognized by cytotoxic T cells via the expressed major 
histocompatibility molecule (MHC) and release pro inflammatory cytokines and lyse the 
cell through the delivery of perf orin and granzyme. Band T cell memory cells are 
produced once the infection is cleared [41] . 
Clearance of the virus from the CNS requires release of chemokines from circulating 
leukocytes, astrocytes, and microglial cells which attract CD8+ T cells to the site of 
infection. Brien et af. (2007) demonstrated that the transfer of CD8+ T cells into 
alymphoid mice protected them against a lethal WNV challenge. It was shown that the 
hierarchy of epitopes was maintained in the memory responses and concluded that CD8+ 
T cells can protect against a WNV challenge single-handediy [49, 50]. McMurtrey et af. 
reported the discovery of several (1 in particular) conserved and dominant WNV 
epitopes. These epitopes are presented by the class 1 human leukocyte antigen (HLA) to 
the cellular immune system and allow recognition of WNV infected cells by cytotoxic T 
lymphocytes [51]. 
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Interferon assists in clearance by mediating a noncytolytic clearance of the virus from the 
infected neurons. The virulence of WNV is based on its ability to use multiple and well 
conserved receptors in a variety of species as well as to induce apoptosis. WNV also can 
evade the innate and adaptive immune response. The NS proteins are able to modulate 
interferon responses by delaying transcription of the interferon gene [41, 52]. WNV also 
elicits the production of the proinflammatory cytokine macrophage migration inhibiting 
factor (MIF). Increased levels of MIF can be found in the serum and cerebrospinal fluid 
(CSF) of patients infected with WNV. Macrophage migration inhibiting factor has been 
found to enhance neuroinvasion by compromising the integrity of the blood- brain barrier 
[53]. The following figure summarizes, although simplistically, the innate and adaptive 
immune response (fig.5). 
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Fig. 5. WNV dissemination and immune system control. Samuel and Diamond (2006) 
[41]. 
(A)WNV is maintained in nature in an enzootic mosquito-bird-mosquito transmission cycle. 
(B) Following Culex mosquito inoculation, WNV replicates in skin Langerhans dendritic cells, which traffic 
the virus to the lymph node, where further replication ensues. Following induction of a primary viremia, 
WNV spreads to other peripheral organs. Several aspects of the innate and adaptive immune response limit 
WNV replication in the periphery. IFN-a/B acts as an antiviral agent that restricts viral translation and 
replication soon after infection. B cells and antibody (primarily IgM) modulate viral levels in serum and 
prevent early CNS seeding, while complement is required for efficient priming of humoral and cellular 
immune responses. IFN-y-secreting T cells control viral replication through direct antiviral mechanisms and 
contribute to the generation of adaptive immune responses. CD4 and CD8 T cells participate in viral 
clearance from peripheral tissues. 
(C) Following replication in the periphery, WNV spreads to the CNS possibly through TNF-a-mediated 
changes in BBB permeability. Neurons are the primary target ofWNV in the brain and spinal cord. IFN-aiB 
is required to control WNV infection in the CNS and may prolong neuronal survival. The chemokines 
CXCLlO and CCL5 and their cognate ligands CXCR3 and CCR5 aid in recruiting CD4 and CD8 T cells and 
monocytes to the CNS. where they function to clear virus from infected tissues. 
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2.3.4 Clinical Presentation of West Nile Virus Infection 
Currently, WNV infection in humans presents asymptomatic ally in approximately 80% 
of cases. General flu-like symptoms can occur in 20% of those infected. Neurological 
disease occurs in less than 1 % of all those infected with the virus. The incubation period 
is variable between 2 and 14 days after exposure. The clinical picture changed during 
1996 with the development of a more virulent strain of the virus resulting in an increased 
incidence of neurological disease and death, particularly evident with the epidemic in 
North America compared to cases occurring in the Old World. Death is due to neuronal 
dysfunction, cerebral edema, and respiratory failure [4, 5). 
2.3.4.1 West Nile fever 
Symptoms of West Nile fever include pyrexia (>39° C), lethargy, myalgia, arthralgia, 
roseolar or maculopapular skin rash involving the neck, trunk, arms or legs, 
lymphadenopathy and headache. Gastrointestinal signs can also arise including vomiting 
and diarrhea. Symptoms usually resolve within a few days and the individual will 
probably not have considered a WNV etiology. Sometimes the infection can travel 
hematogenously to other internal organs causing myocarditis, hepatitis, pancreatitis, 
orchitis, chorioretinitis, vitritis, and uveitis [4, 5, 40). 
2.3.4.2 West Nile neurological syndrome 
Neuroinvasion can lead to meningitis, encephalitis, acute flaccid paralysis and other 
neurological signs. People at risk of neuroinvasion include those with chronic disease 
such as cardiovascular disease, diabetes, cancer, and alcoholism. Those individuals 
receiving immunosuppressive medication or having immunosuppressive disease are at an 
increased risk. Almost every case of neuroinvasive disease is in an individual over 50 
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years of age. Immune senescence is thought to be the factor creating increased 
accessibility of the virus to the central nervous system [4, 5, 40]. There may also be 
genetic reasons explaining the onset of neurological disease in older people and for the 
very few cases of such disease in the people of Mexico and South America. 
Meningitis is characterized by a stiff neck with headache, photophobia and fever. The 
other signs of West Nile fever mayor may not precede the onset of meningitis. Most 
patients recover and need no further assistance. If the virus penetrates the blood-brain 
barrier and gains access to the parenchyma of the brain, then encephalitis will ensue. The 
virus will attack in various locations of the brain but it has predilection for the 
cerebellum, substantia nigra in the brainstem, and the basal ganglia. 
Symptoms include disorientation, tremors, ataxia, involuntary movements, parkinsonism, 
seizures, and altered levels of consciousness. Persistent signs of muscle weakness, 
memory loss, depression, and fatigue affect 30-60% of those after recovery from 
encephalitis. Pathological lesions include viral proliferation in the neuronal and glial cells 
resulting in necrosis and cell death, diffuse perivascular inflammation (large number of B 
lymphocytes present) and microglial nodules composed of a large number of CD8+ T 
cells. Case fatality rate for those with neurological disease ranges from 4-14% [4, 5, 40, 
54]. 
2.3.4.3 Acute flaccid paralysis 
Acute flaccid paralysis (AFP) can develop in 10% of all the neurological cases and may 
occur in the absence of the typical viral prodrome. Asymmetric paralysis can occur 
within hours of onset and is characterized by dark limbs with no motor function. Sensory 
pathways are left intact thus creating intense muscular pain. The recovery is poor leaving 
22 
--
West Nile Virus in the Niagara Region 
more than half the patients with some degree of permanent disability. AFP needs to be 
differentiated from polio encephalomyelitis and Guillain-Barre Syndrome (GBS). 
Respiratory failure can occur in 50-60 % of the cases. Cranial nerve deficits with 
dysphagia and facial weakness, is less common. The virus attacks the anterior motor hom 
neurons of the spinal cord as polio virus does. It is not clear whether the virus enters the 
anterior motor neurons directly or whether the damage is from inflammation and immune 
reaction. [54, 55]. 
2.4 Diagnosis of West Nile Virus infection 
2.4.1 Clinical diagnosis 
Diagnosis is based on clinical suspicion of adults over 50 years of age who develop 
unexplained neurological signs in the late summer or fall. The presence of other WNV 
cases in the area or travel to an area with WNV supports the diagnosis [4]. 
2.4.2 Clinical pathological parameters 
Hematology reveals anemia with lymphocytopenia in half the patients and leukocytosis 
in the other half. The total serum protein is increased. Cerebrospinal fluid (CSF) analysis 
has a consistent finding of pleocytosis (30-100 cells/ul) with lymphocytes predominating 
and elevated protein concentration of 80-105 mg/dl [56, 57]. 
2.4.3 Laboratory diagnosis 
The gold standard of laboratory testing is virus culture. However, the viremic phase has 
usually ceased by the onset of clinical signs. Other antigen tests are also of limited use 
because of the short viremic phase as well. Antibody testing is the first choice in 
serological evaluation for WNV. Of all the antibody tests available, Enzyme Linked 
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Immunosorbent Assay (ELISA) is used the most frequently. Reverse ELISA tests are 
under development and may have improved specificity with less cross-reaction with other 
flaviviruses. Hemagglutination Inhibition and Complement Fixation tests were used in 
the past but have poor sensitivity, poor specificity, are more labour intensive and are now 
rarely used. Immunofluorescent antibody tests have good sensitivity and specificity and 
are a choice if a fluorescent microscope is available. Microsphere immunoassays are 
currently under development and are showing promise with improved sensitivity with 
multiple flavivirus identification. The Plaque Reduction Neutralization Test (PRNT) is 
currently used to confirm probable results from other tests [58]. 
2.4.3.1 Enzyme linked immunosorbent assay 
Most cases are in need of serological diagnosis due to the large number of symptoms 
being nonspecific. Enzyme linked immunosorbent assay (ELISA) is the first test usually 
performed as it is inexpensive, reproducible, rapid, and employs the use of non-infectious 
agents. These serological assays are based on anti E antibody detection in the serum but 
have poor specificity due to cross-reaction from neutralizing antibodies from other 
flaviviruses due to infection or vaccination. The diagnostic antigen in ELISA's is from 
the suckling mouse brain which contains highly conserved immunodominant E 
glycoprotein epitopes responsible for eliciting the cross-reactive serum antibody. The 
initial test usually performed is for the presence of Immunoglobulin M (IgM) in CSF. 
Immunoglobulin A (IgA) was evaluated in a study by Nixon and Prince (2006) and 
results indicated that IgA levels paralleled IgM levels in the CSF. If CSF cannot be 
obtained then a serum sample is used. It is necessary to obtain an acute and convalescent 
sample in order to confirm the disease. If only an acute sample is processed then other 
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flaviviruses in the area should be tested for as well. If the highest titre is for WNV then a 
presumptive diagnosis of WNV is made. The original antigenic sin is the term applied to 
the highest titre if several flaviviruses are being evaluated simultaneously [4, 59]. 
Roberson et al (2007) demonstrated the use of viral-like particle (VLP) antigens in place 
of the suckling mouse brain antigens. The use of these VLP antigens resulted in less 
cross-reaction thus yielding higher specificity and sensitivity of the assay. The other 
advantage is safety since VLP's do not contain RNA and thus are not infectious to 
personnel preparing the antigen [60]. 
IgM antibodies can persist in the serum for up to 500 days. Therefore the ELISA test 
cannot differentiate between a recently acquired infection or an infection acquired the 
previous year. Immunoglobulin G (IgG) avidity testing can be performed to differentiate 
between recent and past exposures. The avidity refers to the net antigen binding force by 
the antibodies. New infections will have weak avidity and mature infections will have 
high avidity. When used in conjunction with IgM testing a presumptive diagnosis of 
WNV can be made. Avidity testing requires a database of acute and convalescent titres to 
establish a cutoff value. [61] . 
2.4.3.2 Plaque Reduction Neutralization Test 
For confirmatory results all positive ELISA IgM samples should be sent for the PRNT 
[59, 62]. Serum samples are incubated with live WNV virus and then cultured on vero 
cells. Plaques, which are visible areas of killed vero cells, are observed. If there are 
antibodies present in the serum they will bind to the WNV envelope proteins and 
neutralize the ability of the virus to infect the vero cells. The number of plaques will be 
reduced if antibody is present. The end point is determined when the highest serum 
25 
.. -
West Nile Virus in the Niagara Region 
dilution achieves 50-90% plaque reduction depending on laboratory protocol. If there are 
other flaviviruses in the area then PRNT for the other flaviviruses should be run in 
parallel with the WNV PRNT. Acute and convalescent samples need to be run with the 
PRNT to demonstrate a four-fold increase in titre to confirm the infection. High PRNT 
results are associated with WNV-specific IgG rather than IgM [58]. In Canada, due to the 
use oflive virus material all PRNT must be performed in a class III laboratory [62, 63]. 
2.4.4 Public Health Agency of Canada (2007) diagnostic criteria 
2.4.4.1 WNV non-neurological syndrome 
The Public Health Agency of Canada defines the clinical criteria for WNV non-
neurological syndrome to include the following: history of exposure and at least 2 of 
fever, myalgia, arthralgia, headache, fatigue, lymphadenopathy, or maculopapular rash. A 
suspect non-neurological case must include the clinical criteria in the absence of 
diagnostic results and in the absence of any other obvious cause. A probable non-
neurological case must include the clinical criteria and one of the below probable 
diagnostic test criteria in Table 1. A confirmed non-neurological case must include the 
clinical criteria and one of the below confirmed diagnostic test criteria in Table 2 [64] 
2.4.4.2 WNV neurological syndrome 
The Public Health Agency of Canada defines the clinical criteria for WNV neurological 
syndrome to include the following: history of exposure and onset of fever with the recent 
onset of at least one of encephalitis, meningitis, acute flaccid paralysis, movement 
disorders, Parkinsonism or some other neurological manifestation. A suspect case is the 
inclusion of the clinical criteria with the absence of diagnostic test criteria and in the 
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absence of any other obvious cause. A probable neurological case includes the clinical 
criteria and one of the below probable case diagnostic test criteria found in Table 1. A 
confinned neurological case includes the clinical criteria and one of the below confinned 
test criteria found in Table 2 [64]. 
2.4.4.3 WNV asymptomatic infection 
A probable asymptomatic case must include the below probable diagnostic test criteria in 
Table 1 in the absence of clinical signs. A confinned asymptomatic case must include the 
below confinned diagnostic test criteria in Table 2 in the absence of clinical signs [64]. 
2.4.4.4 Probable case diagnostic test criteria 
Table 1. Probable case diagnostic test criteria for Canada. (Public Health Agency of 
Canada,2007) [64]. 
IgM 
Option 1 Positive 
Option 2 
Option 3 
Option 4 
Option 5 
IgG 
Seroconversion 
Positive 
Single titre greater 
than 1:320 
4 fold increase 
between acute and 
convalescent 
samples 
*Hemagglutination Inhibition. **Plaque Reduction Neutralization Test 
Positive 
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2.4.4.5 Confirmed case diagnostic test criteria 
Table 2. Confinned case diagnostic test criteria for Canada. (Public Health Agency of 
Canada,2007) [64]. 
IgM IgG 
Option 1 
Option 2 
Option 3 
Option4 Positive 
Option 5 Serocon 
verSiOn 
Option 6 4 fold 
Increase 
between 
acute and 
convalescent 
samples 
4 fold increase 
between acute 
and 
convalescent 
samples 
Positive 
Positive 
Virus 
Isolate 
Positive 
isolation 
on 
culture 
Virus genome 
sequence 
Demonstration of 
genome from 
blood, CSF, or 
tissue 
*Hemagglutination Inhibition. **Plaque Reduction Neutralization Test 
2.4.5 Antigen tests 
Nucleic amplification tests are not of much value due to the short viremic period. The 
patient will usually present after the viremic state thus all antigen tests will be negative. 
Virus isolation and Real Time RT PCR are also of little value in a clinical setting 
although they are used for blood donor screening as well as research. 
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2.4.6 Histopathology 
Inflammatory lesions III the CNS are described as perivascular lymphomonocytic 
infiltrates with infected neurons found in the cerebellum, brains tern, cerebral cortex, 
hippocampus, and the ventral motor horns of the spinal cord. Multifocal glial-microglial 
nodules, neuronal necrosis, and rare neuronophagia have also been described [65]. Virus 
particles have been detected in the blood as early as day 1 and in the dermal dendritic 
cells from day 1 to 4. By day 4 the highest levels of viral replication have been achieved 
in the spleen and kidney. Virus has been found in the CNS as early as day 4 and in the 
highest levels by day 9 and 10. Cytokine and chemokine production, which are 
upregulated in WNV infections creating inflammation, precede the development of the 
histopathologic lesions. Early production of monocyte chemoattractant protein (MCP-5), 
interferon gamma inducible protein 10 (IP-I0), and monokine induced gamma interferon 
(MIG) precede the production of interferon gamma (IFN-gamma) and tumour necrosis 
factor alpha (TNF-alpha). This cascade of cytokine and chemokine production create the 
necessary inflammation so that WNV can penetrate the blood brain barrier and then 
create the inflammatory and necrotic histopathological lesions characteristic of WNV 
infection [65]. 
2.5 Treatment of West Nile Virus 
2.5.1 Clinical supportive treatment 
There are no current specific treatments for WNV infection. In WNV endemic areas all 
patients hospitalized for acute onset of neurological symptoms must be suspected as 
having neurological WNV. This must be differentiated from other causes of acute 
meningoencephalitis including Guillain Barre syndrome, herpesvirus infection and 
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bacterial meningoencephalitis. Supportive and symptomatic treatment with hydrating 
fluids, anticonvulsants, antipyretics, anti-inflammatories, respiratory support, prevention 
of secondary bacterial infection, and management of cerebral edema assist with patient 
recovery but do not enhance viral clearance. 
2.5.2 Anti-viral treatment 
The natural history of WNV involves a very short period of viremia and progression of 
the virus into the central nervous system (eNS). Any antiviral therapy needs to be 
targeted towards the cells of the eNS. Development of antiviral agents has only been 
shown to be effective in a laboratory setting or with animal models. Several antiviral 
medications are in clinical trials. 
2.5.2.1 Small Interfering RNA 
Some recent studies have worked with delivering small interfering RNA (siRNA) into 
cells to make them refractory to WNV replication. In a study by Yang et al (2008), the 
siRNA was delivered into human neuroblastoma cells by using a retrovirus as a vector. 
The siRNA was shown to interfere with viral protein synthesis and inhibit viral 
replication [66]. Kumar et al (2006) had previously demonstrated viral replication 
inhibition using a lentivirus as a vector to deliver WNV specific siRNA [67]. Neither 
study indicated that the potential therapeutic use of siRNA will be able to clear the virus 
from the eNS. 
2.5.2.2 Interferon 
Further studies are also investigating ways to block the activity of interferon antagonism 
by viral proteins. Interferon alpha 2b, a cytokine, enhances the efforts of the innate 
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immune system by inhibiting viral replication. Interferons work on cells before they are 
infected. Interferons bind to the surface of these noninfected cells triggering the 
phosphorylation of tyrosine kinase which initiates an intracellular transduction cascade 
involving several STAT proteins. These proteins are activators of transcription which 
move into the nucleus and interact with DNA leading to the production of cytoplasmic 
RNAases that inhibit intracellular viral replication upon infection [52, 68]. Clinical trials 
are in process for evaluating the effectiveness of interferons against WNV neurological 
disease in humans [2]. 
2.5.2.3 Neutralizing antibodies 
Neutralizing antibodies have been shown in the laboratory to protect mice and hamsters 
from a lethal challenge with WNV. In a study by Ben-Nathan et al. (2003) 
immunoglobulin preparations having a high titre of anti-WNV antibodies demonstrated 
the need for timely administration after the exposure to WNV. The later in the course of 
the disease that the immunoglobulin is received, the less chance of survival [69]. 
Oliphant et al. (2005) used a humanized monoclonal antibody against the WNV envelope 
protein in mice challenged with WNV. The preparation demonstrated efficacy as late as 
day five of the infection [70]. Use of monoclonal antibodies are in phase IIII clinical trials 
[2]. 
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2.6 Control of disease and exposure 
2.6.1 Vaccination 
Currently there are four licensed vaccines for horses and one vaccine licensed for geese. 
2.6.1.1 Human vaccines 
There are no vaccines approved as yet for humans, although the following four vaccines 
described are underway in clinical trials [2]. An attenuated vaccine produced by Crucell, 
requires multiple doses to achieve immunity and is in phase I clinical trials. This 
attenuated vaccine has mutations in the structural genes which interfere with virus 
replication or in the capsid gene preventing release of the virus particle from the cell. The 
National Institute of Allergic and Infectious Diseases (NIAID) and the National Institutes 
of Health (NIH) have developed a chimeric vaccine with the PrM and E genes of WNV 
with a flavivirus (yellow fever 17D) backbone as well as subunit recombinant vaccine 
administered by direct inoculation or by way of DNA plasmids or virus vectors 
expressing WNV genes. These are both in phase I clinical trials. A fourth vaccine 
produced by Acambis is also a chimeric vaccine and is in phase II clinical trials [2]. 
Chimeric vaccines are live attenuated vaccines able to generate good host immunity and 
unlikely to cause sufficient viremia that would allow mosquitoes to become infected. The 
West Nile Virus/Dengue 4 chimeric vaccine tested by Hanley et al. (2005) demonstrated 
this attenuation in both Culex tarsalis for WNV and Aedes aegyti for Dengue. It was not 
attenuated in Aedes albopictus for either WNV or Dengue. Attenuation can occur with 
the inability of the virus to replicate immediately after the bite, inability to reach the 
midgut of the mosquito, inability to escape the midgut and reach the salivary glands of 
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the mosquito, or inability of the virus to escape the salivary gland and enter into the 
saliva [71] . 
2.6.1.2 Equine vaccines 
The first equine vaccine was introduced in 200 I and used widely in North America in 
2002. The vaccine appeared to be very successful as the number of equine fatalities 
decreased in the US from 15000 in 2002 to 5100 in 2003. This vaccine is an attenuated 
vaccine requiring two initial intramuscular doses 3 weeks apart with annual boosters. A 
recombinant canarypox vaccine became available in 2003 [40]. 
2.6.2 Control of human exposure 
Prevention and control of WNV include reducing exposure and contact with the mosquito 
vector, reducing the mosquito population, and continued surveillance of mosquito pools. 
Since Culex mosquitoes bite between dusk and dawn, avoiding outdoor activities during 
these hours would seem intuitive. However, if exposure to biting mosquitoes is 
anticipated, then covering with long sleeves and long pants is advised and using 
repellents such as N,N-diethyl-methyl-toluamide (DEET), is effective for preventing 
mosquito bites. The American Academy of Pediatrics advise the use of no more than 
10% DEET on children [5]. 
2.6.3 Environmental control of mosquitoes 
Control of mosquito populations is approached by identifying breeding sites of the Culex 
species of mosquito that are serving as the bridge vectors and biting both birds and 
people. These sites should be mapped and surveilled, and targeted spraying of mosquito 
habitat should occur early in the year to disrupt the enzootic transmission cycle. Spraying 
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with insect growth regulators such as methoprene is advised to prevent development of 
the larvae into adult mosquitoes. Both biting and oviposition behaviours occur 2 hours 
after sunset, so spraying targeted areas at this time is most effective [72]. Methoprene is 
not associated with any serious side effects. Using adulticide sprays, such as the 
pyrethroids, should be reserved for WNV outbreaks. Pyrethroids are associated with 
cholinergic symptoms such as nausea, vomiting, diarrhea, dizziness, headaches, seizures 
and pulmonary edema [5] 
Mosquito control can also be addressed by elimination of the larval habitats. Removing 
standing water and organic material from roof gutters, wading pools, old tires, and other 
areas around the home will help reduce the number of breeding sites and thus effectively 
reduce the mosquito population. Biopesticides including toxins from Bacillus 
thruingiensis israelensis and Bacillus sphaericus have been shown to have good 
larvicidal activity against Culex species of mosquitoes [73]. 
New methods of mosquito control with the use of mass traps using attractants such as 
heat have met with some success in the southern US states [74]. Other simple techniques 
at interfering with the larval habitat have been suggested including the use of floating 
layers of polystyrene beads. These beads form a barrier over the surface of the water 
preventing the larvae from surfacing to breathe [75]. 
2.7 Surveillance 
Transmission of WNV relies on adequate numbers of mosquitoes and passerine birds and 
is enhanced by high summer temperatures and low precipitation. Active surveillance in 
areas experiencing the above conditions has been the cornerstone to predicting a WNV 
outbreak. 
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2.7.1 Mosquito pool surveillance 
Sampling of mosquito pools for the presence of WNV indicates the presence of the virus 
in a given geographical area however this alone cannot be used to predict an outbreak. 
Early season detection, when infection rates are low, requires a large sample of mosquito 
pools for adequate power of detection [76]. 
2.7.2 Dead bird surveillance 
Surveillance for dead birds has been a cornerstone for predicting WNV outbreaks in 
humans since avian deaths precede human and equine WNV mortalities. Roberts et al. 
(2006) demonstrated a strong positive association between avian risk of WNV death and 
equine WNV risk, although vaccination can be a confounder or effect modifier. Human 
population density can also be a confounder since more dead birds will be found and 
reported in areas of greater population densities. Detection bias is another concern since 
people may be more likely to submit dead birds if they are aware of the presence of 
WNV in their area of residence. On the other hand relying on public participation has 
been shown to lose effectiveness over time in endemic areas [2]. Public education 
regarding the presence of positive mosquito pools and instructions on how to avoid 
mosquito exposure is important in WNV endemic areas. 
2.7.3 Syndromic surveillance 
Syndromic surveillance includes monitoring hospital discharge meningoencephalitis 
diagnoses of unknown etiology, laboratory requests and testing of CSF, and monitoring 
neurological disease in horses. This surveillance system was used in the Netherlands 
from 1999-2004 but did not reveal an endemic WNV problem in either humans or horses 
[77]. 
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2.7.4. Temperature and rainfall surveillance 
Weather variations have also been established as predictors of WNV transmission. 
Higher than normal summer temperatures, particularly the minimum temperature during 
this period of the year has been found to be a good indicator for an increase in the number 
of mosquitoes. The Romanian (1996) and the New York City (1999) epidemics occurred 
after a sustained heatwave in the summer [78]. High temperatures increase the mosquito 
population as well as shortening the extrinsic incubation period resulting in increased 
vector competence. A period of drought, followed by heavy rains, also increases the 
population and competence of mosquitoes. Drought is thought to result in standing pools 
of water being richer in organic matter which Culex species requires for breeding. 
Drought also encourages birds to congregate into smaller areas increasing their contact 
with mosquitoes and enhancing the enzootic transmission cycle. Israel has had several 
epidemics throughout the last half of the twentieth century in which there were warmer 
summers than in earlier years. The summers of 1998, 1999, and 2000 were extremely hot 
and are considered to be a factor in the epidemic of 2000 in Israel. Paz (2006) has 
determined that recent outbreaks occurred 3-9 weeks after a sustained intense heatwave 
[78]. It is of interest that the outbreak in Saskatchewan in 2007 followed a dry spring and 
hot summer to the degree not previously seen since WNV was introduced into the 
province in 2003 [79]. 
2.7.5 Wetland surveillance 
Wetland area conservation has been seen to have a positive correlation with WNV 
transmission. Diversity in the host amplifier species and the passerine: non-passerine 
ratio can influence the amplification and transmission of WNV. There are over 130 
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species of passerine birds that can amplify and transmit WNV but the non-passerine 
species interrupt the transmission of WNV. Conserving a large wetland suitable to 
support a large diversity of birds, particularly allowing the increase in numbers of non-
passerine birds, reduces the transmission ofWNV. On the contrary wetland conservation 
does not have a positive correlation with mosquito density and transmission of WNV 
[80]. 
2.8 Epidemiology 
2.8.1 Global epidemiology 
In 1937, the first case of WNV was diagnosed in a woman living in Uganda. The virus 
was isolated from a blood sample taken during the febrile period. No antibodies were 
found in this sample from the febrile period however 3 months later antibodies were 
detected in the convalescent sample [8]. The first virologically proven epidemic of WNV 
occurred in Israel in 1951. A total of 123 cases were found with no fatalities . The virus at 
this time caused disease in children with half of the reported cases in children less than 6 
years of age [7, 81]. Those children under 3 years of age were most febrile however all 
recovered with no neurological progression. In Egypt, an ecological study was conducted 
between 1951 and 1954 with serological evaluation and experimental infection of 
humans (now would be viewed unethical), equines, birds and mosquitoes which revealed 
the enzootic cycle of WNV. It was also determined that 60% of the population along the 
Nile River demonstrated the presence ofWNV antibodies [81]. 
Between 1951 and 1996 there were sporadic epidemics with only rare neurological cases 
and very few deaths. In 1957, another epidemic occurred in Israel resulting in an 
unrecorded number of children and adults having West Nile fever, with 12 elderly 
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individuals developing severe meningoencephalitis. Four of these neurological patients 
died [7]. These were the first deaths definitively attributed to have occurred from 
neurological invasion of WNV. In 1962, an outbreak occurred in the Camargue region of 
France causing neurological disease in 80 horses, characterized by ataxia and weakness, 
with deaths occurring in 25-30% of them. This epidemic lasted until 1965 with a total of 
thirteen human reported cases and 1 death. From 1965 to 1996 there were few reported 
outbreaks, the most significant occurring in South Africa in 1974 and an outbreak in 
Israel in 1980. Another outbreak was recorded in Algeria in 1994 with 50 neurological 
cases and 8 deaths [6, 81]. In Morocco in 1996, 94 horses were diagnosed with WNV 
neurological disease and 42 died. In 1997, an outbreak in Tunisia claimed 5 lives out of 
111 positive cases. Fourteen horses in Tuscany contracted WNV in 1998 and 6 of these 
were fatal [81]. In 1996 a series of epidemics began to occur throughout Europe and then 
in 1999 WNV crossed the Atlantic Ocean and appeared in New York City. Within 3 
years the virus moved across both Canada and the United States causing an 
unprecedented number of avian, equine, and human neurological cases and deaths. The 
increase in virulence is thought to be due to a mutated viral genome and naive host 
populations. 
Since its discovery, WNV has appeared in unpredictable epidemic and epizootic patterns. 
All cases diagnosed are seasonal and in temperate climate zones with cases emerging 
from August through October. Above average summer temperatures with less than usual 
precipitation appear to favour the increase in the number of mosquitoes. As water bodies 
begin to dry, the organic content increases, which favours the development of larvae. In 
urban areas mosquitoes will go indoors looking for standing water in basements, bringing 
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the mosquito in closer proximity to its host. Higher temperatures also favour the extrinsic 
incubation period for the WNV within the mosquito, enhancing transmission rates. 
2.8.2 West Nile Virus in Europe 
2.8.2.1 Romania 1996 
The epidemic in Romania in 1996 occurred in the city of Bucharest, along the Danube 
River, where 393 cases of meningoencephalitis occurred with 17 deaths ensuing. This 
was the largest epidemic globally to date, involving a record number of neurological 
cases. From 1997 to 2000, there were 39 further recorded cases with 5 deaths [82]. 
Seroprevalence surveys indicated that the overall infection rate in Bucharest was 10% 
during the epidemic year of 1996 [83]. There was no recognized WNV disease in either 
birds or horses. This is not unusual when compared with other WNV 
epidemics/epizootics that have occurred elsewhere in the world. WNV behaves very 
unpredictably affecting different species with different degrees of severity. Some of the 
reasons contributing to this Romanian epidemic include poverty, weather, vector 
competence, and avian competence. During this period in Romania, the urban dwellings 
known as blockhouses were found to be in severe deteriorated condition, with basements 
often flooded with water or sewage creating a favourable larval habitat for Culex pipiens. 
Family homes were also in close proximity to their poultry sheds, bringing the 
mosquitoes in close approximation with the amplifying hosts. This particular summer 
also lacked precipitation creating summer drought conditions. It is also suspected that 
migratory birds introduced a strain of WNV into the Bucharest area for the first time. It is 
possible that the strain may have been previously present but had been absent for some 
time, creating a naive population. 
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2.8.2.2 V olgograd Russia 1999 
Volgograd City and Volzskii City are located along opposite banks of the Volga River in 
southern Russia. In the summer of 1999, a WNV epidemic occurred with 394 confirmed 
neurological cases and 40 deaths. Sixty percent of the deaths were in individuals over 60 
years of age. Ninety-five percent of these cases originated from the urban area. There was 
also 428 individuals suspected of West Nile fever leading to the suspicion that 5% of the 
population had been infected with WNV [84]. 
Genomic sequences from non-survivors indicated that the Volgograd strain of WNV was 
99.6% homologous with the Bucharest strain from 1996. Sporadic cases of WNV had 
been seen in individuals living in the Volga delta area. The outbreak in 1999 was 
unexpected and was not diagnosed until very late in the season. Initially meningococcal 
meningitis had been suspected however most cases historically occur in February to 
March in Russia. These WNV meningoencephalitis cases had arisen in late summer and 
fall indicating that the meningococcal organism was not likely the causative etiological 
agent. As well, meningococcal meningitis historically causes high mortality in young 
children, while with this Russian outbreak the higher number of lethal cases involved 
people over 60 years of age. As in the Bucharest outbreak, mosquitoes were found in 
85% of the dwellings in Volgograd. Also concordant with the Bucharest outbreak was the 
presence of a dry hot summer causing mosquitoes to seek places such as damp basements 
bringing the mosquitoes in close approximation to its hosts. 
The epidemics in Bucharest and Volgograd emphasize the common features that favour 
an urban epidemic such as close proximity to a large body of water, urban dwellings in 
disrepair harbouring standing water, and high temperatures [82-84]. 
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2.8.2.3 Israel 1999-2000 
In 1998, Israel experienced an outbreak of WNV in migratory birds and farmed geese. 
Serological studies revealed an 86% seropositive result among those individuals who had 
contact with the geese, 28% in people along migratory bird flyways, and 27% of the 
general population. Israel is located along many migratory bird flyways from Europe to 
Africa. Two fatalities occurred in 1999 and then in 2000, 439 people were confirmed 
with WNV with 29 fatalities. Phylogenetic studies revealed WNV positive individuals 
living in the central region of Israel homologous to a 1999 New York flamingo isolate. 
West Nile Virus positive individuals living in the northern region of Israel were found 
homologous to a 1997 Romanian mosquito isolate [85, 86]. This particular outbreak was 
found in all highly populated areas of Israel in contrast to previous outbreaks which were 
more contained. It is speculated that migratory birds introduced the Romanian strain into 
Israel geese, which were highly susceptible and served as very efficient amplifying hosts. 
Also of interest was the presence of a dry hot summer in 2000 in Israel, which was also 
evident in Romania in 1996 and in Russia in 1999 [85]. 
In September of 1998, migrating white storks that had not previously flown over Israel 
were forced into a different flyway by strong, hot westerly winds. They were forced to 
land in Eilat, a town in southern Israel. Serological analysis revealed the presence of 
WNV neutralizing antibodies. Sequence analysis was homologous to the isolate from a 
goose which had died later in 1998. It is assumed that the storks were infected from 
seropositive storks from Germany and subsequently spread WNV into the naive goose 
population of Israel [87]. 
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West Nile Virus has been endemic in Israel for decades however the epidemic of 2000 
produced more neurological cases and deaths than all previous epidemics combined. It 
also involved all parts of the country, both urban and rural areas. The reasons for WNV 
re-emerging in Israel with increased virulence are unclear. One theory is that of waning 
herd immunity since there had not been on outbreak since 1980 [88]. WNV epidemiology 
has demonstrated a consistent appearance with increased neuroinvasiveness and a high 
case-fatality rate since 1996. The epidemics in Romania, Russia, and Israel have all been 
affected by a virus with increased virulence. It is also of interest that long term death 
rates were found to be increased in WNV survivors. Prognostic factors included older 
age, male sex, diabetes and dementia. The reasons are unclear [89]. 
2.8.2.4 Camargue France 2000 
The Camargue is a conservation wetland in the south of France, which includes a dry area 
to the north and west of the wetlands. The Camargue, located in the Rhone delta, is home 
to a large diversity of avian species. The area serves as a breeding area, migration stop-
over, or wintering ground. These birds are often migrating from the African continent. 
Migrating birds introduce WNV into the delta where the virus is amplified in other 
resident birds. Spreading birds then disperse the disease from the wetlands to the dry 
areas. There are 111 species of passerine and shore birds that visit the Camargue for 
breeding or a stop-over. Eighty-seven of these are likely responsible for the ongoing re-
introduction of new strains of WNV into the Camargue. Eighteen species have been 
identified as spreading the virus to the dry areas to the north. In 2000, in the dry area of 
the Camargue, 76 horses were diagnosed with WNV and 21 of the cases were fatal. No 
human cases were reported [90]. The results of a serosurvey in horses in 2000 suggest 
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that WNV is not endemic in the Camargue but occurs in sporadic outbreaks with long 
silent periods [91]. 
2.8.3 West Nile Virus in USA and Canada 
2.8.3.1 New York City 1999 
In early August of 1999 a large number of crows were found dead around the grounds of 
the Bronx Zoo. By late August some of the birds at the zoo began to die, including three 
Chilean flamingos. Zoo veterinarians submitted samples to the National Veterinary 
Laboratory in Ames, Iowa. A flavivirus was identified and the sample was forwarded to 
the Center for Disease Control (CDC) in Atlanta, Georgia. The CDC isolated the virus on 
culture and identified it as WNV. Concurrently 5 patients with symptoms of encephalitis, 
between the ages of 57 and 87, were admitted to a hospital in Flushing, New York. Four 
of the five patients developed acute flaccid paralysis. What was initially thought to be St. 
Louis encephalitis turned out to be WNV [9, 10]. Sequence analysis identified the virus 
as homologous by 99.8% to the strain currently causing an epizootic in geese in Israel. 
Called NY99, the WNV had undergone a single amino acid substitution creating a new 
strain with increased virulence. It is speculated that the mutation arose in Israel before 
arriving in New York City. The actual transport of the virus likely occurred in the 
mosquito by plane or perhaps in a smuggled bird. Armed with enhanced virulence and a 
naive population of birds, people and horses, WNV moved across the continent to 
become endemic in 48 states and 5 provinces within 4 years [9]. 
2.8.3.2 Westward spread across USA and Canada 
A typical pattern has developed in North America over the last several years. After the 
introduction of WNV into a new geographic area and successful overwintering, an 
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explosive epidemic is seen to occur. Following this, a low endemic situation is 
established with intermittent outbreaks. Since its introduction into the United States, St. 
Louis encephalitis has been reported at record low levels. This is thought to be due to a 
cross protective effect from WNV. If an individual survives a WNV infection then that 
individual will also be protected against St. Louis encephalitis. The reverse has not been 
found to be true [10]. 
By the end of 1999, WNV spread through New York State, Connecticut, New Jersey, and 
Maryland. During the year 2000, WNV had been detected in 12 Atlantic coast states with 
21 human reported cases and 2 deaths. By 2001 WNV was found in 21 states and had 
moved across the border into Ontario. Human cases in Ontario were not detected until 
2002 with 66 reported cases and 9 deaths. In 2002 the virus reached California with 4156 
cases being reported in the United States with 2946 neurological cases and 284 deaths 
(10%). Also in 2002, 14751 horses were reported with WNV in the US and the case-
fatality rate was almost 30%. [92]. The epidemic/epizootic was the largest flavivirus 
encephalitis outbreak ever recorded in the western hemisphere [93]. The number of 
positive reported cases from 2002 to 2006 in Canada and the United States are indicated 
in Table 3. 
Table. 3. West Nile Virus reported human clinical cases in Canada and the United States, 
2002-2007 [11, 17]. 
2002 2003 2004 2005 2006 2007 2008 
Canada l 66 1495 25 229 151 2215 36 
US2 4156 9862 2539 3000 4261 3630 918 
lpublic Health Agency of Canada, 2008; 2Center for Disease Control, 2008. 
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In Texas in 2003, a distinctly different strain ofWNV was identified. This new genotype, 
WN02, displaced the original strain NY99. This new genotype appears to be have an 
increased transmission efficiency in the Culex mosquito [2]. The new genotype only 
differed from NY99 by 0.27% [93]. The change occurred so rapidly that the decreased 
prevalence of NY99 was not immediately detected. The extrinsic incubation time for 
WN02 in Culex pipiens was decreased by 2 days, explaining how this strain displaced 
NY99. Less incubation time leads to an increase in vector capacity. Recently, another 
strain has been identified and termed the 'North American' strain differing only 0.18% 
for NY99 and 0.55% from the Texas strain [94]. However in 2007, epidemic numbers re-
emerged in Canada. This situation is not different than the patterns established in Europe. 
The numbers in Canada and in the United States for 2007 and 2008 are depicted in the 
maps below (fig.6 -9). The numbers have markedly decreased in 2008 in both Canada 
and the United States[ll , 17]. See Table 4 below for numbers in Canada from 2002-
2008. 
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Fig.6. Human West Nile Virus clinical cases in Canada: 2007. 
Public Health Agency of Canada (PHAC) 2007 [17]. 
Fig.7. Human West Nile Virus clinical cases in Canada: 2008 
Reported to the PHAC as of Oct 18,2008 [17]. (See Table 4) 
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Table 4. West Nile Virus in Canada for 2002-2008.West Nile Virus Monitor: Public 
Health Agency of Canada, 2008 [ 17]. 
Province 2002 2003 
Territory Totat2 Total2 
NFLD and 0 0 
Lab. 
PEl 0 0 
Nova Scotia 0 24 
New 0 14 
Brunswick 
Quebec 20 17 
Ontario l 3943 893 
Manitoba 0 1423 
Sask. 0 9373 
Alberta l 0 2723 
British 0 205 
Columbia 
Yukon 0 14 
NWT 0 0 
Nunavut 0 0 
Canada 414 1481 
2004 
Total6 
0 
0 
0 
0 
33 
133 
3 
53 
14 
0 
0 
0 
0 
25 
2005 
Total2 
0 
14 
14 
14 
4 
953 
55 
583 
103 
0 
0 
0 
0 
225 
1. These totals include both probable and confirmed WNV cases. 
2006 
Totat2 
0 
0 
0 
0 
1 
423 
50 
193 
393 
0 
0 
0 
0 
151 
2007 
Totat2 
0 
0 
14 
0 
24 
123 
578 
12853 
3183 
194 
0 
0 
0 
2215 
2. Total clinical cases is the sum of WNV neurological syndrome + WNV Non- neurological 
syndrome + WNV unclassified/unspecified. 
3. These totals include some cases related to travel outside the province/ territory. 
4. All related to travel outside the province/ territory. 
2008 
Totat2 
0 
0 
0 
0 
2 
3 
12 
174 
14 
1 
0 
0 
0 
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Fig.9. West Nile infections in the USA: 2008. Center for Disease Control [11]. 
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2.8.4 Mechanisms of disease emergence 
The overall encompassing question is how WNV has emerged in Canada and the United 
States with an increased virulence resulting in higher numbers of neurological disease 
and death in humans, birds, and horses. Examination of the epidemiological triangle with 
respect to WNV transmission indicates the complex interactions that take place between 
the virus, its hosts, and the environment. Changes in transmission cycles, host range, and 
evolution of the virus have all played a role. For instance, a single amino acid mutation in 
the envelope gene V159A that was found in 2002 in the US has also been found in strains 
circulating through Europe. Since there have been increased numbers in both 
neuroinvasive disease and in mortality since 1994 worldwide a mutation such as that 
mentioned above could account for enhanced virulence [2, 4]. Increases in reported cases 
of neurological disease during outbreaks started in Romania in 1996 followed by Russia 
and Israel. Equine epizootics occurred during these same years but in different countries 
including France, Tunisia, and Israel. The virus found its way to New York City in 1999 
and caused an unprecedented avian epizootic and deaths in corvids. Although the NY99 
virus was 99.8% homologous to the Israeli strain the host range increased to eventually 
infect 61 species of mosquitoes, 300 species of birds and 30 species of non-avian hosts. 
Evolution of the virus towards a more virulent strain is enhanced by new geographical 
territory and never before exposed non-immune hosts. Is has been hypothesized that 
viruses that have obligate alternating replication cycles between an arthropod vector and 
an amplifying host will have a decreased adaptation potential. However this is not the 
case for West Nile Virus. To date, West Nile Virus has demonstrated a propensity to 
mutate and cause an inconsistent pattern of epidemics in Canada and the United States. 
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Although the virus appears to have established itself and become endemic in the US, it 
has not yet given enough evidence in Canada whether it will become endemic causing 
constant low levels of transmission or become epidemic causing annual or intermittent 
outbreaks. As long as birds remain as efficient amplifying hosts then epidemics will 
likely continue, however, if a resistance develops in the avian population, then virulence 
may decline [93]. Other amplifying hosts have been identified in Canada and in the 
United States such as the squirrel and alligator which indicates the ability of this RNA 
virus to expand and adapt to new hosts [2]. Other risk factors have been identified such as 
urbanization. Brown et al. (2008) demonstrated in a study that urbanization enhances 
environmental conditions for mosquitoes that are ornithophilic and bridge vectors [95]. 
Culex sp are the predominant vectors and have been found to reproduce the most 
efficiently in standing containers of organically rich water which are frequently found in 
urban areas. The predominant species of mosquito present will also influence the risk of 
disease. Lindsay et al. (2008) have found that Culex tarsalis and culex quinquefasciatus 
are predominant species in the Great Plain states and mid-southern states, respectively 
and are associated with high incidence of WNV nonneurological disease [96]. Along with 
an appropriate vector population and urbanization there must be an adequate population 
of amplifying hosts. 
2.9 West Nile virus in Saskatchewan 
West Nile Virus first made its appearance in Saskatchewan in 2003 with 937 reported 
human cases. The incidence in the following years then decreased until 2007 when a 
record number of 1285 cases were reported. This was the largest number for any province 
since the appearance of WNV in Canada in 2001. Although there have been 17 species of 
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mosquitoes found to carry WNV in Saskatchewan only 3 of these have a high vector 
capacity to transmit WNV. The principal transmitter of WNV in Saskatchewan is Culex 
tarsalis which acts as both ornithophilic as well as a bridge vector. The female take more 
than one blood meal and there are several generations produced per season. As well as 
overwintering, vertical transmission has also been observed. All of the above factors 
enhance the competence of Culex tarsalis as a vector for transmission to humans. Culex 
tarsalis is not a vector in Ontario which may help explain the difference in transmission 
rates between Saskatchewan and Ontario. Culex restuans is present in Saskatchewan as it 
is in Ontario although it has only been found in small numbers and is primarily 
ornithophilic. Culiseta inornata has been identified in Saskatchewan as a competent 
transmitter to horses but not humans. Although Aedes vexans is the most abundant 
mosquito in Saskatchewan it rarely feeds on birds and is not a common vector for WNV 
transmission. The more southern areas of Saskatchewan have higher numbers of Culex 
tarsalis than further north due to higher temperatures and higher wetland densities and 
this has a positive correlation with the number of WNV cases, more being reported from 
the southern areas of the province [97]. Culex tarsalis appears to be a more competent 
vector than Culex pipiens if just the vectors are used as predictors for WNV epidemics 
when considering the number of reported cases in Saskatchewan and Ontario. However, 
Culex pipiens has proved to be a very competent vector in the northeastern states of the 
United States. Other predictors must be considered including avian amplification and 
their interaction with the resident mosquito vectors as well as environmental conditions 
[97]. 
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2.10 West Nile Virus in the Niagara Peninsula 
Surveillance and control programs for WNV were instituted in Niagara in 2001 . The first 
reported human case of WNV in Niagara was in 2002. This was concurrent with a large 
mortality of crows in Niagara and a report of a high mortality rate of owls at the Owl 
Foundation in Vineland, Ontario. Mortality rate in the owls varied among the species, 
with the older and larger owls more susceptible. A large infestation of the louse fly, 
Icosta Americana, were found on all the dead owls. Of all the flies tested for WNV, 
88.9% were found to contain WNV RNA. Of 125 owl deaths, 98 were tested with RT-
peR for WNV and 80 (81.6%) were positive. All the affected owls were housed outside 
and also susceptible to mosquito bites. It is unknown whether WNV was transmitted by 
the louse or if the louse was an incidental host [98]. 
Since the first case was reported there have been 30 confirmed cases ofWNV infection in 
humans, 47 birds, and 33 mosquito pools, with the last reported human case of WNV in 
Niagara was in 2006. One mosquito pool and 2 birds were found positive in 2007 and 14 
birds been found positive to date in 2008. 
There are several species of mosquitoes found in Niagara but only Culex pipiens, Culex 
restuans, and Culex salinarus have been found positive for WNV. Of these three, only 
Culex salinarus is a bridge vector feeding on both birds and mammals. The larval habitat 
for Culex pipiens and Culex resutans is in artificial containers of water with decaying 
matter such as catch basins and gutters making an urban area more conducive for 
amplification of these mosquito populations. Culex salinarus has been found to have 
larval habitats in bodies of natural water that have decaying vegetation making rural areas 
as well as urban areas more conducive for amplification of this species of mosquito. The 
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population peak for Culex pipiens is in early summer and for Culex restuans in late 
summer. Culex salinarus appear to have a consistent population thoughout the summer 
but dependent on environmental conditions. These facts lead to some important 
questions. Amplification is dependent on both a competent mosquito population as well 
as a competent local avian population. If the omithophilic mosquitoes and those acting as 
bridge vectors are located in different geographic areas, can the bridge vector become 
sufficiently infected to transmit the virus to humans? It would become dependent on the 
infected birds moving from the urban areas of Culex pipiens and Culex restuans in the 
early summer to the less urbanized areas of Culex salinarus in the later summer in order 
for Culex salinarus to have a sufficient number of mosquitoes to transmit to humans. 
However the majority of the Niagara human population lives in urban or suburban areas. 
This question may help explain why there has been such a low transmission of WNV to 
humans in the Niagara Region (Table 5). 
Table 5. West Nile Virus reported cases for the Niagara Peninsula 2002-2008. Niagara 
Regional Public Health Department, 2008 [18]. 
Y ear-to-Year Comparisons of WNV Surveillance in Niagara Region 
2002 2003 2004 2005 2006 2007 2008 
Human 18 5 1 3 3 0 0 
Cases 
Positive 11 8 4 5 5 1 14 
Birds 
Pos.Mosq. 15 0 0 10 7 1 0 
Pools 
Positve 12 2 0 1 1 0 0 
Horses 
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Despite initial low transmission the Niagara Regional Department of Public Health 
developed a yearly three tier mosquito control program in 2002. The first tier is aimed at 
reducing the source population. Public education campaigns with production of literature 
and web page encouraged residents to eliminate the urban larval habitat. This involved 
removing standing water in artificial containers, particularly those with decaying 
vegetative matter. Personal protection was also encouraged with covering of the entire 
body with clothing at dawn and dusk when these mosquitoes are biting as well as using 
mosquito repellents such as DEET. The Public Health Department also places 21 
mosquito traps across Niagara every year to monitor the mosquito population for the 
species that are present and the presence of WNV. The public is encouraged to report 
dead bird sightings to the Public Health Department and the health inspectors will decide 
whether to pick the dead bird up for evaluation of the presence ofWNV. The bird cannot 
be decomposed and must be from the corvid family of birds. All birds are sent to the 
Canadian Cooperative Wildlife Health Centres in Guelph, Ontario or Saskatoon, 
Saskatchewan. According to the Public Health Agency of Canada's website, after 5 birds 
have been diagnosed with WNV no further birds are submitted. This appears to have 
been adopted procedure after 2003 since more than 5 birds were reported positive in 2002 
and 2003. For 2008, the submissions have continued past the cutoff of 5 positives and 
there are 14 positive birds to date. 
Tier two is aimed at mosquito larval control in catch basins and artificial and natural 
bodies of water. Methoprene, an insect growth inhibitor, has been placed in catch basins 
throughout the region in 4 cycles from June through August. The catch basins are labeled 
with coloured indicators informing the public of placement of methoprene pellets in the 
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catch basins. Sensitive bodies of water are treated with biological larvicides such as 
Bacillus thuringiensis israelensis (Bti), a bacterial spore that destroys the mosquito 
larvae's intestinal lining when consumed. This biological larvicide is only active in the 
alkaline gut of the mosquito and is of no risk to humans, birds or other mammals. It is a 
low impact pesticide and will not damage the environment. However, it may kill other 
insects besides mosquitoes and this could potentially impact the ecosystem. All public 
use of larvicidal agents must be registered with the Pest Management Regulatory Agency 
Health Canada and applied by a licenced exterminator. A commercial product, known as 
Aquabac which contains Bti, is available to use around the household for mosquito larval 
control. 
The third tier involves the spraying of Malathion, an organophosphate insecticide, for 
adulticide activity. The use of Malathion is determined by the public health department if 
it appears that a WNV epidemic is developing. The public must be informed by two 
different forms of media. Application of sprays to the environment must be done at dawn 
and dusk with appropriate environmental conditions. It is not effective to spray during 
rain or fog although a light wind will enhance thorough coverage. Adulticides have not 
been used in Niagara. Natural mosquito predators can be considered to decrease the adult 
mosquito population. Purple martins and dragonflies both ingest adult mosquitoes but are 
active during daylight hours when the Culex species of mosquitoes carrying WNV are 
quiet. Bats are active at the same time as the Culex species of mosquitoes however 
increasing the bat population may increase the risk of rabies transmission since bats are 
the natural reservoir host for the rabies virus. 
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The Niagara Regional Health Department continues to encourage residents to take 
preventive measures against WNV as the virus is still present in the area [18]. 
The number of recorded cases of WNV in humans, birds, and mosquitoes in Niagara 
never reached epidemic proportions as in other parts of Canada such as Saskatchewan. 
Since horses are now vaccinated and dead bird sightings are few the following study has 
been developed to evaluate a population of agricultural workers in the Niagara Region for 
the presence of anti-WNV antibodies. The study population selected is the migrant 
agricultural worker. These men and women spend most of their working and leisure 
hours outdoors and are a substantial risk of mosquito bites. There has been no previous 
study examining this population of people in the Niagara Region. Since the workers 
originate from Mexico, a Dengue endemic country, presence of anti-Dengue antibodies 
will also be assessed since both WNV and Dengue are flaviviruses and can cross-react 
with most antibody tests. 
2.11 West Nile Virus in Mexico 
West Nile Virus was first serologically detected in horses and birds in Mexico in 2002. 
However the widespread transmission that has been seen in both Canada and the USA 
has not occurred in Mexico or the rest of Latin America. Reported cases in humans 
curiously have been very rare. Explanations for this apparent low rate of transmission of 
WNV throughout Mexico and Latin America will be discussed below. 
2.11.1 Avian WNV isolates 
Since the introduction of WNV into Canada and the USA, the morbidity and mortality in 
birds has been dramatically increased from that previously observed in Europe, Asia, 
Africa, and Australia. Corvids in particular have died in large numbers throughout 
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Canada and the USA and smaller birds such as the sparrow have been found to amplify 
and transmit the virus for longer periods of time than corvids. This same pattern has not 
been observed in Mexico. There appears to be more than one entry ofWNV into Mexico. 
West Nile Virus was first isolated in Mexico from a raven in the southern state of 
Tabasco in 2003. Nucleotide sequence of the premembrane (PrM) and envelope (E) 
structural protein genes were found to be divergent from the strains circulating in the 
northern Mexican states along the Texas border. In this raven from Tabasco, an E-156 
proline residue, which ablates the glycosylation site, was not found in the variants in the 
northern Mexican states [14, 99]. Loss of the E protein glycosylation is associated with 
attenuation of the virus and thus reduced neurovirulence [100]. It is likely that the virus 
isolated in Tabasco came from the Caribbean or the southeastern United States as the 
Mississippi migratory bird flyways cross these states and the Yucatan Peninsula [14, 
100]. Note the map in Fig. 10 depicts the presence of WNV in Mexico compared with 
that in the USA for 2006. The pattern in birds in Mexico is of a clustering nature and not 
widespread as seen in the USA. Of the 943 birds tested for WNV, only 117 were found 
positive. The positives were found, in order of decreasing number of reports, in the states 
of Chihuahua, Oaxaca, Sinaloa, Nuevo Leon, Baja California Sur, Sonora, Baja 
California, and Taumaulipas [101]. Hidalgo-Martinez et al. (2008) conducted a 
serological study in two zoos in Tabasco. Using ELISA serology, the prevalence of anti-
WNV antibodies found in a variety of species of birds was 29.5% which is close to that 
reported in the United States at 34%. However PCR on these samples did not detect the 
presence of the virus. The study demonstrates the presence of WNV in Mexico in birds 
and could be an indicator for possible transmission to people [102]. 
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943 muestras estudiadas 
117 con serologia positiva 
Fig.l0. Prevalence and location of WNV positive birds in Mexico in 2006 compared to 
the United States. Mexican Ministry of Health, Mexican Ministry of Agriculture, United 
States Geological Survey (USGS), and the Center for Disease Control (CDC), 2006 
[101]. Translation: pink are areas with evidence of WNV infection; green are areas 
studied without evidence of infection, yellow are areas without any information. As of 
December 20, 2006 943 samples were tested with 117 found serologically positive. 
2.11.2 Equine WNV isolates 
Serosurveys have been performed in horses since 2002 to monitor for WNV. A small 
study with 24 equine serum samples from the northern state of Coahuila, adjacent to the 
Texan border, was conducted in 2002 and 62.5% of the samples demonstrated WNV 
antibodies [15]. Another serosurvey was conducted with 441 equine serum samples from 
14 states in Mexico from 2002-2003. The samples were from horses with neurological 
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disease. West Nile Virus antibodies were found in 22% of the samples indicating that 
WNV is well established in the equine but is clustered in particular geographical areas in 
Mexico. The number may be higher than actual since the samples were not random and 
were all from neurological cases [13]. There are other flaviviruses in horses including 
Western Equine encephalitis, Eastern Equine encephalitis, and Venezuelan Equine 
encephalitis, which may have cross-reacting properties affecting the results of antibody 
testing. In 2003, WNV was isolated from a euthanized horse from the northern state of 
Nuevo Leon suffering from neurological disease. On phylogenetic analysis it was 
determined that the virus originated from inland Texas [103]. In 2006, 553 equine serum 
samples were positive for WNV out of 1586 tested in Mexico. Positives were found in 21 
states with over 40 cases reported in each of the states of Chihuahua, Nuevo Leon, 
Tamau1ipas, Baja California, Coahuila, and Campeche [101]. Note however in the map in 
Fig. 11 the lack of wide spread transmission as compared to the transmission in the 
United States. 
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1.586 muestras astudladas 
553 con sefologJa POSltIVa 
Fig.11. Prevalence and location of WNV positive horses in Mexico in 2006 compared 
with the United States. Mexican Ministry of Health, Mexican Ministry of Agriculture, 
United States Geological Survey (USGS), Center for Disease Control (CDC) 2006 [101]. 
Translation: pink are areas with horses infected with WNV infection; green are areas 
studied without evidence of infection, yellow area areas without any information. As of 
December 20,2006 1,586 samples were tested with 553 found serologically positive. 
2.11.3 Human WNV isolates 
The first WNV human isolate was from a 62 year old woman from the state of Sonora in 
2004. The woman first visited a hospital with symptoms of WNV fever. A presumptive 
diagnosis of Dengue was made and blood was drawn for serology and culture. 
Hemagglutination Inhibition was negative for Dengue, WNV, and St. Louis encephalitis. 
RT-PCR was negative for Dengue and the blood was cultured in vero cells. RNA was 
extracted from the culture and R T -PCR was performed and identified a WNV strain 
similar to that circulating in the western states of USA [16]. The human incidence 
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reported for WNV for 2004 in the United States was 2470 cases however only seven 
cases were reported from Mexico [14]. In 2006 there was only one human case reported 
in Mexico but there were 4015 reported cases in the United States as depicted in fig 12. 
The only positive reported case in a human in 2006 was in the state of Oaxaca [101]. 
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Fig.12. Prevalence and location of WNV in humans in Mexico for 2006 compared with 
the United States. Mexican Ministry of Health, Mexican Ministry of Agriculture, United 
States Geological Survey (USGS), Center for Disease Control (CDC) 2006 [101]. 
Translation: pink are areas with individuals infected with WNV infection; green are areas 
studied without evidence of infection, yellow area areas without any information. As of 
December 20, 2006 203 samples were tested with 1 person found serologically positive. 
Fernandez et al. (2007) conducted a serological study for the presence of anti-WNV 
antibodies and anti-Dengue antibodies in humans visiting walk-in clinics and hospitals in 
the 3 northern states of Mexico that border Texas. Of the 237 people tested, 40 % were 
positive for ELISA WNV IgG, 0% positive for ELISA WNV IgM, and 79% were 
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positive for ELISA Dengue IgG antibodies. This study indicates the difficulty in 
diagnosing WNV in a country such as Mexico where there are other flaviviruses 
circulating such as Dengue. There is cross-reaction on ELISA between the antibodies for 
the different flavivirus antigens [104]. 
The extremely low number of reported WNV disease in humans in Mexico and the rest of 
Latin America are puzzling. There are a number of hypothetical explanations for this 
apparent lack of transmission. First, the isolate found in 2003 from a bird in Tabasco had 
an attenuating mutation leading to decreased virulence. However, this mutation was not 
found in the other strains circulating in Mexico. Second, since all flaviviruses are similar 
phylogenetic ally, a cross-protective effect from the immune system due to exposure to 
another flavivirus endemic within Mexico, namely Dengue, may be occurring. With 
cross-protection a diseased state from infection with West Nile virus may not clinically 
develop or may be less severe in those with pre-existing cross-protective heterologous 
flavivirus antibodies. Other flaviviruses such as St. Louis encephalitis virus, Ilheus, 
Bussuquara, Cacipacore, Rocio, and Iguape are of too low of prevalence in Mexico to be 
considered for offering cross-protection [99]. Third, Deardorff et al. (2006) have 
suggested that insufficient surveillance for WNV due to limited availability of resources 
and funds or misdiagnosis as Dengue could lead to gross under-reporting and hence an 
apparent lack of transmission of WNV [14]. Fourth, the competence of the native 
mosquito species and the interaction of the vector with the amplifying host may be 
different in Latin America and have an effect on transmission. The abundance of WNV 
infected mosquitoes are directly related to the risk of human disease. Abundance of 
mosquitoes may be diluted with increased biodiversity as seen in Mexico. The relative 
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supply of ornithophilic mosquitoes versus the supply of bridging vectors will playa role 
in both the amplification and the transmission of WNV to other species. Certain species 
of Culex have preferred avian sources of blood. The availability of preferred amplifying 
hosts as well as the ability of the amplifying host to survive a high and prolonged viremia 
will affect the transmission. Fifth, migration patterns through Mexico and Latin America 
are different than in the United States and Canada and may not be as conducive for the 
spread ofWNV. 
Finally, Mexico and the rest of Latin America have a different climate which may affect 
vector and host competence and interaction between the vector and the host. Availability 
of larval habitat is important for the ongoing transmission of WNV within the mosquito 
population [99]. All of the above could explain the lack of transmission in Mexico and 
the rest of Latin America however all are conjecture and there is nothing proven. It still 
remains a perplexing phenomenon to explain. [12, 16,92]. 
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CHAPTER THREE: METHODOLOGY 
This West Nile Virus study was developed with assistance from the tuberculosis study 
conducted by co-investigator Angela Duarte, MSc, and supervisor Ana Sanchez, PhD. 
The same participants from the tuberculosis study were approached to participate in the 
WNV study. Since the present study was performed concurrently with the tuberculosis 
study, logistic costs were absorbed by the latter. Extra costs (i.e., lab reagents) were paid 
by Dr. Sanchez' Professional Development Fund. 
3.1 Research Objectives 
3.1.1 General Objective 
To advance the understanding ofWNV transmission in Niagara Region, the present study 
aimed to establish whether or not active WNV transmission could be detected in a 
mosquito exposed human population residing in Niagara during the 2007 season. 
3.1.2 Specific Objectives 
In a study population considered high for WNV exposure (i.e., originating from a country 
with low human WNV infection and with an occupation that allows for an increased 
exposure to mosquito bites than in the general population), the present study aimed to: 
1. Conduct a seroepidemiological investigation to examine the presence of anti-
WNV acute and memory antibodies as a proxy for natural infection in serum 
samples of healthy Mexican adults working in Niagara Region for the 2007 
agricultural season. 
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l.a. Since Dengue virus, a related flavivirus endemic to Mexico, is highly cross-
reactive with WNV, serological studies were extended to rule out potential false 
positive results to WNV by examining participants' samples for the presence of 
anti-Dengue memory antibodies 
2. Analyze risk factors that might be associated with WNV and DEN seropositivity. 
3. Assess the awareness of study participants about WNV infection as well as their 
understanding of the mode of transmission and clinical importance of the 
infection 
3.2 Research Ethics 
3.2.1 Research Ethics Board approval 
A research ethics application was accepted and approved by the Brock University 
Research Ethics Board (REB) File # 06-363 Mergl (Appendix A-C). The application 
provided the rationale for the study and the risks and benefits for the participants. The 
application provided details regarding the collection of data and blood samples and 
ensured methods of maintaining confidentiality. 
3.2.2 Biosafety 
The investigators have all received Biosafety Awareness Training administered by the 
Office of Environment, Health and Safety, Brock University. The investigators adhered 
to Brock University's Policy on Safety and Liability for Field Research. A written 
protocol was prepared describing blood collection technique as well as methods to handle 
accidental spills, needle sticks, and disposal of biohazard materials. Gloves were worn 
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during blood collection and handling of all blood collection equipment. All investigators 
wore clothing indicating their presence from Brock University as well as name tags. 
3.2.3 Biosafety level II laboratory 
Dr. Ana Sanchez' laboratory located in MC C307 A is certified as a Biosafety level II 
laboratory (Appendix D). Proper laboratory protocol and safety precautions were 
followed for all investigators working in the laboratory. Proper clothing, gloves and eye-
ware were worn during all procedures. 
3.3 Research design 
This was a cross-sectional study among the migrant Mexican agricultural workers of the 
Niagara Peninsula using a convenience sample of volunteers. The group was chosen as a 
high risk population for exposure to WNV since most of their daylight and evening hours 
are spent out of doors. Bender et al (2006) have suggested that agricultural workers are an 
index group for many emerging infectious diseases [105]. 
High risk populations are used to investigate the epidemiology and ecology of an 
infectious agent for the purpose of disease monitoring. By detecting the presence or 
evidence of an infectious agent early there can be a rapid response to prevent larger and 
longer outbreaks of disease. With low or near zero prevalence other conventional 
surveillance procedures may not detect the index cases. With prevalence near zero the 
necessary sample size may be so large that it approaches the size of the population. 
However, use of a high risk population (that being a population at higher risk of 
exposure) permits a smaller sample size, presuming they have a higher infection rate 
[106]. 
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Supporting factors for using the Mexican workers as our sample population include the 
following. First, as previously explained in the background section (p. 61 to 62), WNV 
transmission to humans is negligible in Mexico therefore any anti-WNV antibodies 
detected in research participants will most likely have been developed in response to 
exposure to the virus in Canada. Second, agricultural workers spend more time outdoors 
than the general population and are at higher risk of mosquito bites which increases 
probability of mosquito-borne infections. Third, the study population is believed to be 
susceptible to WNV infection (i.e., there have been no genetic studies to prove that the 
population is resistant to WNV infection). Finally, the study population individuals are by 
requirement healthy and assumed immunologically competent and are able to generate an 
immunological response. 
3.3.1 Study period 
The study was conducted from July to October 2007, the year with highest number of 
cases recorded in Canada, with the blood samples drawn during the months of August 
and September, the period in which WNV transmission occurs in Canada. 
3.3.2 Sample size 
The sample size for this study was dependent and limited to the samples from the 
tuberculosis study conducted by Angela Duarte, MSc, and Ana Sanchez, PhD. The 
sample was thus a convenience sample and any study results will be at best preliminary. 
Since there are no previous WNV studies of this particular group of individuals, it was 
difficult to determine a sample size that would be representative of the group in Niagara. 
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Fonnulas exist that assist in calculating the necessary sample for the study. However, 
those fonnulas require known parameters such as a priori prevalence estimate of the 
existing disease with confidence intervals, maximum tolerable error, and the population 
size [106]. Since there are no WNV prevalence studies in Niagara either in the general 
population or in this particular group of Mexican migrant workers, a cross-sectional study 
was ideal to obtain preliminary data, even though using a convenience sample is an 
important limitation. 
Before providing the details of the methodology, the following flowchart depicts the 
steps taken to implement the study. 
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3.3.3 Flowchart for methodology ofWNV serosurvey July to October 2007 
Study Design: June to July 2007 
• Literature review 
• High risk human population selected for sample group 
• Seasonal Agricultural Workers Program lists received 
and. reviewed 
• Study period determined 
Farm Selection: July 2007 
• Farm Listings in Niagara reviewed 
• Initial contact made with farm owners 
• Consent from farm owners to approach workers 
Meetings with Workers: July to August 2007 
• Initial informational meeting and consent to participate 
Second Meeting: August to September 2007 
• Questionnaire administered and blood samples drawn 
during the WNV transmission period in Niagara 
Laboratory Analysis: October 2007 
• Blood samples processed with ELISA WNV and Dengue 
• Positive WNV and/or Dengue sent for Plaque Reduction 
Neutralization n$t to National Microbiology Laboratory 
Third Meeting: October 2007 
• Return of participants' results 
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3.3.4 Study population selection 
This study was conducted in partnership with a Mexican tuberculosis study by co-
investigator Angela Duarte, MSc, and supervisor Ana Sanchez, PhD, who conducted a 
study with this group of workers enrolled in the Seasonal Agricultural Workers Program 
(SA WP). A list of farms employing migrant workers was requested under the Municipal 
Freedom of Information and Protection of Privacy Act in the Niagara Peninsula. Farms 
were then visited personally in the St. Catharines and Niagara-On-The-Lake areas and 
farmers were presented with a verbal description of the study and an invitation to 
participate. Farm owner consent was necessary to gain access to their property and their 
workers. It was expected of the farm owner to support the study but not to influence the 
workers decision to or not to participate. It is necessary that the workers decide after 
understanding the benefits and harms of participating. All meetings occurred in the 
evening after normal working hours. An information sheet, in both English and Spanish, 
inviting the workers to a meeting were left for the farm owner to distribute (Appendix E). 
3.3.5 Enrolment of the study participants 
Initial contact with the workers was through the farm owner or supervisor. It was stressed 
to the farm owner to inform the workers of the study and not encourage or require the 
workers to participate. It was also emphasized to the farm owner that all results are 
confidential and cannot be shared with the farm owner. The voluntary aspect of the 
participation was stressed to both the farm owner and the worker. In order to participate, 
the worker must fully understand the study's risks and benefits and signed written 
consent must be given to the investigators. The only inclusion criteria were that the 
participant was a migrant Mexican worker and was determined to be in good health by 
70 
.. -
West Nile Virus in the Niagara Region 
the usual screening tests perfonned before leaving Mexico. There was no need to exclude 
individuals not in their first year in Canada since the immunological response to the 
WNV antigen will result in production of IgM, indicating a new immunological response. 
The limiting factor would be the fact that IgM can last up to 500 days so the exposure 
may have been the previous year [4, 5]. However, since there is almost negligible human 
detection in Mexico, the antibody response would be the result of exposure in Niagara, 
unless other travel occurred. 
3.4 Meetings 
There were three meetings conducted with each group: the initial infonnation meeting, 
followed by the meeting to conduct the questionnaire and collect the blood sample, and 
then a final meeting to distribute the results. All verbal explanations and interviewing 
were done by co-investigator Angela Duarte, MSc, supervisor Ana Sanchez, PhD, and 
other Spanish speaking assistants. The fann owner or supervisor organized the time and 
provided a space for the investigators to meet with the workers. The workers were given 
an explanation of the study in Spanish with some literature they could understand 
(Appendix F) as well as the requirements for voluntary participation, confidentiality, 
risks and benefits. A written invitation in Spanish to participate was read to each 
interested person (Appendix G). The consent fonn in Spanish was read and explained and 
if the participant chose to consent, the fonn was signed and a copy was provided for the 
participant (Appendix H). During the second meeting, the questionnaire was administered 
in a private area with the investigator explaining and recording each answer. Afterwards a 
blood sample was collected in a serum separator tube. The final meeting was conducted 
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to give the participants their results in a private area with an explanation of any positive 
findings. 
3.5 Questionnaire 
3.5.1 Description of the questionnaire 
The questionnaire (Appendix I) was designed by Ron Mergl, DVM, co-investigator 
Angela Duarte, MSc, and supervisor Ana Sanchez, PhD and was based on known risk 
factors for the transmission of WNV. The questionnaire was entirely bilingual. That ts, 
each question was typed both in English and in Spanish. The components are explained 
under the following headings: 
1. Demographics: name, age, sex, address and contact phone number if available 
2. Length of time and location of participation in the agricultural workers program 
3. Living conditions on the farms in Niagara: includes condition of the home as well 
as the number of people in the home and sharing a bedroom. 
4. Socio-demographic data from their home in Mexico: includes city and state in 
Mexico as well as the condition of the housing. Also includes any animals that are 
owned and kept on the property. 
5. Participant's evaluation ofhis/her own health. 
6. Knowledge ofWNV and presence of associated symptoms. 
7. Working conditions, mosquito exposure, and recognition of dead birds. 
Each questionnaire was assigned a 6 digit code to help ensure confidentiality and that 
code was recorded in the top right comer. The first 2 digits apply to the town; the second 
2 digits apply to the farm and the last 2 digits to the individual. 
72 
--
West Nile Virus in the Niagara Region 
3.5.2 Administration of the questionnaire 
Each participant was treated to a private seSSIOn with an investigator to ensure 
confidentiality. The participant was assured of the privacy of the recorded answers. The 
questions were asked verbally in Spanish and then recorded in Spanish and English on 
the document by the investigators. Each answer was repeated back to the participant to 
ensure accuracy. The participant was encouraged to ask questions to resolve any 
apprehensions or doubts he or she may have. The research code was assigned and this 
number was used to identify the blood sample as well as all further recording of results 
and information. 
3.5.3 Blood collection 
The blood was collected by Angela Duarte, MSc, a certified phlebotomist, from the 
median cubital vein of the forearm. The skin was disinfected with 70% ethanol and a 
tourniquet was applied above the puncture site. A sterile blood collecting needle was 
introduced into the vein and a vacutainer serum separator tube attached and 3 ml of blood 
collected. The needle was then withdrawn and a sterile pad applied to the puncture site. 
The participant was instructed to keep pressure on the pad and bend the elbow for a few 
minutes to allow the site to coagulate. A band-aid was then applied and the participant 
informed of any expected problems that may occur with the site such as bruising. The 
blood samples and all biohazard waste were transported to the laboratory in MC C307 A 
at Brock University by research co-investigator Angela Duarte, MSc, who received 
Transportation of Dangerous Goods (TDG) training. The tubes were centrifuged at 3000 
rpm for 10 minutes. The serum was aspirated by a pipette and aliquots of 1 ml placed in 
serum storage tubes, identified with the participant's research number, and frozen. 
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3.6 Antibody determinations 
Antibody testing involved a profile of anti-WNV antibodies including IgM, IgG and 
avidity testing for the IgG. Antibody testing for anti-Dengue antibodies was also run 
since the participants may have been exposed to Dengue wl)ile in Mexico. All laboratory 
work was performed by Ron Mergl, DVM. Commercial Enzyme-Linked Immunosorbent 
Assay (ELISA) was chosen to evaluate the serum for anti-WNV and anti-Dengue 
antibodies. A Capture IgM ELISA for WNV was chosen to evaluate for an acute WNV 
antibody response and an Indirect IgG ELISA for WNV was chosen to look for memory 
antibody. The Indirect IgG ELISA test for Dengue was chosen since the participants 
originated from a Dengue endemic country and may have anti-Dengue antibodies in 
memory which could crossreact with the WNV antibody tests. The ELISA test kits were 
purchased from Panbio (Australia) on recommendation from researchers using the tests 
for Dengue antibody at the National University in Tegucigalpa, Honduras (Ivette de 
Rivera, personal communication). Panbio tests are standardized for clinical use (i.e., as an 
aid in the diagnosis of patients with symptoms consistent with WNV). The tests have not 
been used for seroprevalence studies and the interpretation guidelines were established 
for clinical cases. In addition to doing antibody determination, positive WNV samples 
were confirmed by Plaque Reduction Neutralization Test (PRNT). 
3.7 WNV IgM Capture ELISA 
The WNV IgM Capture ELISA detects IgM antibodies to WNV in serum. Panbio reports 
a sensitivity of 96.7% (CI 88.7-99.6%) and a serological specificity of 85.5% (CI 75.0-
92.8%) using PRNT as the gold standard but states that all positive results must be 
confirmed by the PRNT or by using current CDC guidelines for diagnosis of the disease 
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[107]. In brief, the principle of this test is as follows: microwell test strips provided with 
the kit are coated with sheep anti-human IgM antibodies adhered to the polystyrene 
surface of the well. When positive serum is added, the IgM antibodies bind with the anti-
human IgM antibodies. When the WNV antigen/monoclonal antibody complex is added, 
it then binds to the complex. A colour substrate is added and identifies the presence of the 
positive complex with a colour change, with the optical density evaluated by a 
spectrophotometer [107]. For details of the ELISA procedure see Appendix J. 
3.8 WNV IgG Indirect ELISA 
The WNV IgG Indirect ELISA is for the qualitative presumptive detection of IgG 
antibodies to WNV in serum. Panbio reports a sensitivity of79.0% (CI 69.7-86.5%) and a 
specificity of 90.5% (CI 85.6-94.2%) using PRNT as the gold standard but states that all 
positive results must be confirmed by the PRNT or by using current CDC guidelines for 
diagnosis of the disease. There is cross-reactivity with other flavivirus antibodies as well 
as to antibodies to cytomegalovirus, Epstein-Barr virus, and rheumatoid factor. The 
principle of this test is as follows: the polystyrene surfaces of the microwells are coated 
with WNV antigen. Serum antibodies combine with this antigen and when horse radish 
peroxidase (HRP) conjugated anti-human IgG is added, it binds to the serum IgG. When 
tetramethylbenzidine (TMB) is added, HRP, present in the positive complex, hydrolyzes 
the TMB and produces a colour change, with the optical density evaluated by a 
spectrophotometer [108]. For details of the ELISA procedure see Appendix K. 
3.9 WNV IgG Avidity 
In addition to running an Indirect IgG WNV ELISA an avidity test of IgG WNV was 
used. Avidity refers to the antigen binding force of IgG antibodies. Low avidity 
75 
"'-
West Nile Virus in the Niagara Region 
antibodies are produced in acute infections and develop into high avidity antibodies as 
time progresses_ The IgG avidity test is useful in differentiating recent from past 
infections. The avidity reagent is a protein denaturing solution which removes low 
avidity antibodies and changes the IgG absorbance indicating past infections only as 
positives. Since the participants are from Mexico, they may have been exposed to 
Dengue virus and have circulating IgG antibodies against Dengue. If this were the case, a 
marked cross-reactivity will be observed between WNV and Dengue IgG ELISAs, 
making it impossible to determine the true result. In the absence of further confirmatory 
tests, the avidity test may be helpful in establishing the true result. An assumption is 
made that if the participants have been exposed to Dengue and if it is their first time in 
Canada, then the antibodies detected with the ELISA will more likely be anti-Dengue 
antibodies. Therefore they would show high IgG avidity. If they have only been exposed 
to WNV in the current year, they will have low avidity antibodies. Naturally the avidity 
test will only be useful for first time participants. A low avidity index, that is < 40%, 
indicates a recent infection, therefore more likely WNV. A high avidity index, that is :::: 
40%, indicates a past infection, therefore more likely Dengue [109]. A high avidity 
indicates a primary WNV of at least 40 days or an anamnestic response from a previous 
flavivirus infection [61]. It is also important to include the fact that these antibody tests 
are being performed in the absence of clinical signs. For details of the IgG Avidity 
ELISA procedure see Appendix L. 
3.10 Dengue IgG Indirect ELISA 
ELISA's for Dengue were performed to investigate the cross-reactivity between WNV 
and Dengue antibodies. Since the participants are coming from a Dengue endemic 
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country, the IgG Indirect ELISA was selected to look at the possible presence of past 
Dengue infections and the presence of IgG Dengue antibodies. Panbio reports a 
sensitivity of 97.9% (CI 92.5-99.7%) and a specificity of 100% (CI 96.6-100%) against 
Hemagglutination Inhibition (HI). The principle of this test is as follows: the polystyrene 
surfaces of the microwells are coated with Dengue antigen. Serum antibodies combine 
with this antigen and when HRP conjugated anti-human IgG is added, it binds to the 
serum IgG. When TMB is added, HRP, present in the positive complex, hydrolyzes the 
TMB and produces a colour change, with the optical density evaluated by a 
spectrophotometer [110]. For details on the procedure for IgG Dengue see Appendix M. 
3.11 Plaque Reduction Neutralization Test 
As mentioned earlier, positive WNV ELISA samples were confirmed with the PRNT, 
which measures the ability of neutralizing antibodies to neutralize a virus and is the most 
viral specific test for the flaviviruses . This test can only be performed in a Level III 
biosafety laboratory due to the use of live virus. Our positive samples were transported to 
McMaster University and then to the National Microbiology Laboratory (NML) in 
Winnipeg Manitoba. All samples were re-tested with WNV IgM Capture ELISA, WNV 
IgG Indirect ELISA, Dengue IgG Indirect ELISA, as well as Dengue IgM Capture 
ELISA. PRNT were performed in parallel for both WNV and Dengue. The principle of 
this test is as follows: sample sera are serially diluted and incubated with live WNV or 
Dengue virus and cultured on vero cells. After a period of incubation an overlay of 
culture medium is added to prevent virus diffusion beyond plaque formation. After 
further incubation plaques are counted and compared to the starting concentration of the 
virus to determine the percent reduction in the number of plaques. Since the 
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concentration of the virus is a constant, the highest dilution reducing the number of 
plaques by 50% is reported as the endpoint [111, 112]. For details on the PRNT see 
Appendix N. 
3.12 Interpretation of antibody determination 
Table 6. Combined interpretation of Panbio ELISA tests for WNV infection. Panbio 
Australia 2005 [108] 
IgG positive 
IgG negative 
IgM positive IgM negative 
Presumptive diagnosis Presumptive diagnosis 
of current or past WNV of past WNV infection 
infection or other or other flavivirus 
flavivirus infection 
Presumptive diagnosis 
of current WNV 
infection or other 
flavivirus infection 
infection or exposure 
Presumptive negative 
diagnosis 
3.13 Return of the participants results 
The final meeting on each farm was to give each of the participants their results in 
private. All results were recorded on an information results card and handed to the 
participant (Appendix 0). Farm owners' participation was also acknowledged with a 
Certificate of Recognition (Appendix P). These certificates were distributed personally 
and the farm owners were thanked for their cooperation. 
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3.14 Data analysis 
3.14.1 Data management 
All data from the questionnaires and laboratory results were recorded into an Excel 
spreadsheet using Microsoft Office 2007 using the participant's research code. All 
information was checked for accuracy_ Data was checked for errors and missing values 
and then entered into STATA version 10.0 (StatCorp_ 2005, USA) for analysis. 
3.14.2 Statistical analyses 
For Objective No_ 1 and la (determine the presence of antibodies to WNV and Dengue 
virus), the presence of antibodies was reported as seroprevalence proportions (# positive 
samples out of the total analyzed) with 95% confidence intervals_ When possible, 
predictive values for ELISA were calculated_ 
For Objective No_2 (analyze risk factors that might be associated with seropositivity), 
logistic regression was used to identify risk factors for seropositivity_ Odds ratios (ORs) 
and their 95% confidence intervals were calculated_ Factors associated with seropositivity 
in univariate analyses were considered with a p value <0.15 for incorporation into a 
multivariate regression modeL Previous research studies conducted to investigate risk 
factors for Dengue have utilized a p value of < 0.15 in order to control confounding in the 
model for multivariate analysis, particularly when the sample size is small [113-116]. 
Those factors that had a p value <0.15 in univariate analysis were selected for 
multivariate analyses by backwards selection and the risk factors that resulted with a p 
value of < 0_05 were considered statistically significant 
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For Objective No_3 (Assess the awareness of study participants about WNV infection as 
well as their understanding of the mode of transmission and clinical importance of the 
infection), a descriptive analysis was performed and data was presented as percentage of 
individuals possessing the characteristics in question out of the total number of 
participants. 
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CHAPTER FOUR: RESULTS 
This West Nile Virus (WNV) seroprevalence study was conducted during the WNV 
transmission season of 2007 among the Mexican agricultural workers of the Niagara 
Region. Since there is no public registry of farms operating in the Region, nor is it public 
domain how many employ Mexican workers, an attempt was made to get such registry 
information through the Niagara Regional Municipality. The information from the 
Niagara Region gave only the addresses where the workers lived but not the location of 
the farm of employment. In all, Niagara had 378 housing facilities registered to 229 farms 
in the cities and towns of Beamsville, Grimbsy, Jordan, Jordan Station, Lincoln, Niagara 
Falls, Niagara-On-The-Lake, Pelham, Smithville, St. Anns, St. Catharines, Vineland, and 
Wainfleet for the 2007 season. 
Since it was necessary to obtain consent first from the farm owners to approach his or her 
workers on their land, the initial contact needed to be with the farm owner. Due to the 
need for many farm visits and time constraints of the WNV transmission season, only 
farms in the nearby cities were eligible for invitation. Letters of WNV information and 
invitation to participate were prepared for 132 farms in the cities and towns of Niagara-
On-The-Lake, St. Catharines, Jordan Station, and Vineland. Letters were personally 
delivered to 54 (41 %) farm owners during several field trips occurring between June 15, 
2007 and July 15,2007. Letters could not be delivered to 78 out of the 132 farms due to 
invalid addresses, empty houses or lack of a principal office or home of the farm owner. 
During the initial conversation with farm owners, the study was presented, discussed and 
questions were answered. Out of the 54 farms owners visited, 12 (22.2%) agreed during 
the first visit; their number of employees ranging from 2-80. The remainder wanted more 
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time for consideration and were given a contact at Brock University should they decide to 
participate. None of the owners would give specific reasons for not wanting to participate 
beyond the general statement that the workers were too busy with long working hours. 
Some appeared reluctant but it was not evident as to why. These were subjective 
observations by this researcher. Only two farms owners contacted Brock later during the 
study period but it was too late to accommodate them in the study. Out of 12 farms, five 
(two farms had two sites) were selected to proceed with initially, due to their larger size 
and proximity to Brock University. This gave an overall participation proportion of 5/54 
or 9.3%. We did not contact the remaining seven farms due to time constraints of the 
WNV transmission season. Map 1 indicates the location of the farms selected for the 
study. All farms are reasonably close to water sources and thus mosquito habitat. 
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Map 1. Location of participating farms III the Niagara Region (Niagara Peninsula 
Conservation Authority) 
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Further, the largest five farms were selected, based on the need for several visits, the 
short WNV transmission season, and the departure dates of the workers leaving the 
Niagara Region for their homes in Mexico in September or October. Two of the five 
farms had two locations, giving a total of seven locations for the study. Four farm owners 
agreed that the researchers could approach all their workers and one requested 
preselecting the workers to be approached for invitation. That particular farm supervisor 
chose 10 workers to participate but did not reveal his reasons for the selection. In total, 
125 Mexican workers were invited to the study (as mentioned earlier, the WNV study 
was an additional study of that being undertaken by Angela Duarte, MSc and supervised 
by Ana Sanchez, PhD and therefore was limited to their enrolled participants). 
An initial information meeting was planned for each farm and the workers were invited to 
participate. Of 125 invited, a total of 93 consented to participate and provide data for the 
questionnaire as well as a blood sample for serological evaluation. One participant 
dropped out after the questionnaire, making the final study sample of 92 individuals 
(73.6% response rate). The initial plan was for 3 meetings: the first for information and to 
gain participation, the second to administer the questionnaire and take the blood sample, 
and the third to give results. Since the participants had to meet with us after their normal 
working hours on six out of the seven farms, the questionnaires and the blood samples 
were obtained during the first visit. This was due to a high level of interest and 
convenience for the participants. The results with discussion were given during the 
second meeting. Farm owners were recognized with a certificate of appreciation and 
appeared pleased at the level of participation, particularly since the meetings occurred 
after normal working hours. They were not surveyed for interest in future studies. 
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4.1 Characteristics of research participants 
Of 125 invited, a total of92 persons (73.6%) completed the study. Most participants were 
male (78.3%) and their age ranged from 22 to 65 years (mean 38.5±9.5). The workers 
originated from 17 Mexican States, most commonly from Mexico State (32.6%), 
Tlaxcala (12.0%), Puebla (7.6%) and Guanauato (6.5%). More than one-half of the 
participants (52.0%) had completed primary school and 61.9% worked as farmers in their 
horne country. See Table 7 for a list of other characteristics. 
Living conditions of research participants in Mexico and Canada 
The WNV questionnaire (App.I) also collected data regarding the living conditions and 
type of housing both in Mexico and Canada. The housing condition questions were 
developed based on the standard measurement of living conditions and access to basic 
services suggested by the Government of Mexico. For this study, housing conditions 
were classified from I to V based on the presence or absence of indoor running water, 
indoor flushing toilet, indoor electricity, and concrete (tile or cement) floor in entire 
house. Type I included all the 4 amenities whereas type II to V included only three, two, 
one, or none respectively [117]. Most of the workers lived in type I and II housing in 
Mexico (94%). The majority of workers (80%) also lived at the same address for more 
than 20 years indicating permanency in their geographic area. The number of persons per 
house as well as their ages can be viewed in Table 7. 
Almost all the workers lived in the equivalent of type I housing in Niagara (97%). Only 3 
workers lived in a trailer adjacent to a house and with all the basic services. There were 
4-16 workers per house and 1-6 people per bedroom. See Table 8 for details per farm. 
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Table 7. Demographic characteristics of study participants (n=92) 
Characteristic 
Sex 
Male 
Female 
Age (yrs) 
22-31 
32-37 
38-43 
44-65 
Education 
None or Primary (completed) 
Secondary (completed) or Technical 
Missing 
Mexican State of origin 
Mexico 
Tlaxcala 
Puebla 
Guanajuanto 
Oaxaca 
Queretaro 
Veracruz 
Yucatan 
Other 
Occupation in Mexico 
Farmer 
Construction labour 
Merchant 
Other (e.g. housewife, fisherman) 
Type of Housing in Mexico' 
Type I 
Type II 
Type III 
Type IV 
Missing 
Number of people per household in Mexico 
n=92 (% of sample) 
72 (78.3%) 
20 (21.7%) 
24 (26.1%) 
22 (23.9%) 
22 (23.9%) 
24 (26.1%) 
48 (52.2%) 
43 (46.7%) 
1 (1.1 %) 
30 (32.6%) 
11 (11.9%) 
7 (7.6%) 
6 (6.5%) 
4 (4.4%) 
4 (4.4%) 
4 (4.4%) 
4 (4.4%) 
22 (23.8%) 
57 (61.9%) 
8 (8.7%) 
4 (4.4%) 
23 (25.0%) 
65 (70.6%) 
21 (22 .8%) 
4 (4.4%) 
1 (l.1%) 
1 (l.1%) 
3 12 (13.0%) 
4 16(17.4%) 
5 25 (27.2%) 
6 14 (15.2%) 
7 10 (10.9%) 
>8 15 (16.3%) 
[Type of housed stratified by presence of indoor water, indoor flushing toilet, electricity, concrete 
or tile floor. Definition: Type 1- all 4; Type 11- any 3; Type 1lI- any 2; Type IV-any l;Type V-none 
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Table 8. Number of workers per home and bedroom in each farm in Canada 
Farm number 
# workers 0101 0102 0103 0104 0105 0201 0301 
# workers per 14 16 4/8/ 141 10/1 P 7/ 111 6/ 141 8/101 
house 
# workers per 2 2-3 2-4 2-6 1-5 2-6 1-4 
bedroom 
# workers 12 8 13 21 11 12 15 
participating 
1 Each number represents the number of people per house with multiple houses on a farm 
Self -reported health status of research participants 
All individuals entering into the seasonal agricultural program in Canada must pass a 
physical exam. Workers were asked to report their health on a three point scale from 
good to fair to poor. We found 81 % workers reporting overall good health with no 
underlying medical conditions that could affect an immunological response. The 
remainder reported fair health; the problems being experienced were minor or chronic 
such as headache and backache. History of Dengue infection was assessed due to the 
potential cross-reactivity of the Dengue virus and WNV, but only 4/92 (4.3%) of the 
workers recalled having had a history of Dengue infection. 
Dietary habits, body weight, or body mass index were not examined, as they were not 
relevant to the study. However, some lifestyle choices that negatively affect health such 
as excessive alcohol consumption and smoking, which may affect behavior (more time 
outside with mosquitoes), were examined with 63% of the workers consuming alcohol to 
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varying degrees [fourteen out of 92 workers (15%) reported consuming 3 servings 3 
times a week of more] and 30% of the workers reported smoking. 
Permanency in the Seasonal Agricultural Workers Program 
The majority of participants (73%) were return workers to Canada with a range of 2-22 
seasons (mean 6.7). Nineteen workers (21 %) were first time workers for the 2007 season. 
Seventy-eight per cent of the workers reported that they have remained in Ontario. Of the 
remaining 22% working in other provinces, 70% reported working in Quebec. Within 
Ontario, movement between farms was frequently reported with 39% working in other 
cities. 
4.2 West Nile Virus point seroprevalence 
Enzyme Linked Immunosorbent Assays (ELISA), (Panbio Inc, Australia), were utilized 
to evaluate the serum samples for the presence of anti-WNV and anti-Dengue antibodies. 
Both an IgM capture and an IgG Indirect ELISA were used for the detection of anti-
WNV antibodies and an IgG Indirect ELISA was used for the detection of anti-Dengue 
antibodies. Anti-Dengue antibodies were assessed because this infection is prevalent in 
Mexico and the established cross-reactivity between flavivirus antibodies on ELISA. 
Avidity testing with the WNV IgG positive samples was also performed to attempt to 
differentiate the positive WNV IgG from the positive Dengue IgG samples. All samples 
which were positive for either anti-WNV antibodies or anti-Dengue antibodies were 
forwarded to the National Microbiological Laboratory (NML) in Winnipeg, Manitoba for 
confirmation with the Plaque Reduction Neutralization Test (PRNT). 
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4.2.1 Antibody determination 
As depicted in Table 9 below, out of 92 samples, two (2.2%) were positive for WNV 
IgM, 19 (20.7%) were positive for WNV IgG, and 16 (17.4%) were positive for Dengue 
IgG. Should these results be interpreted literally, without further confirmation, it could 
have been inferred that there were a couple of recent WNV exposures and that WNV and 
Dengue exposure in the past was frequent among these workers (with point prevalences 
of 20.7% and 17.4%, respectively). However, of the 19 positive for WNV IgG, 15 were 
concurrently positive for IgG Dengue suggesting crossreaction of the ELISA results 
between WNV and Dengue antibodies. In order to understand the magnitude of this IgG 
cross-reactivity, data were organized in the contingency table shown in Table 10 below. 
Since 15 individuals were positive for both WNV IgG and Dengue IgG there was no way 
to differentiate if workers had been exposed to both viruses or to just one of them. It is 
widely established that sera positive to Dengue will also be positive to other flaviviruses 
such as WNV (i.e., heterologous antibodies). The next step chosen to elucidate this cross-
reactivity was performance of a WNV IgG avidity test. 
Table 9. Antibody reactivity for WNV and Dengue virus in a commercial ELISA in 
the study population (n=92) 
WNVIgM+ WNVIgG+ Dengue IgG+ 
Positive 2 (2.2%) 19 (20.7%) 16 (17.4%) 
Negative 90 (97.8%) 73 (79.3%) 76 (82.6%) 
Totals 92 92 92 
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Table 10. Cross-reactivity for WNV and Dengue antibodies with a commercial ELISA 
(n=92) 
Dengue IgG 
WNVlgG Positive Negative Total 
Positive 15 (16.3%) 4 (4.3%) 19 (20.7%) 
Negative 1(1.1%) 72 (78.3%) 73 (79.3%) 
Total 16 (17.4%) 76 (82.6%) 92 
4.2.2 Avidity test 
The WNV IgG Avidity ELISA attempts to differentiate between recent and past 
infections. Early infections produce low avidity IgG antibodies as opposed to high avidity 
antibodies of past infections. The lab test involves the addition of an avidity reagent 
which removes low avidity antibodies thus only antibodies of high avidity will be 
revealed by the test. As said earlier, this test was used as an attempt to differentiate those 
individuals with both positive findings for WNV IgG and Dengue IgG. An assumption is 
that a past infection would likely be a Dengue infection acquired in Mexico and a recent 
infection would likely be WNV acquired in Canada. The avidity test would naturally be 
only useful for those individuals working and residing in Canada for their first time 
because return workers may have been infected with WNV in Canada in a previous year. 
As depicted in Table 11 below, 19 individuals found positive for WNV IgG, 6 could be 
considered recent infections and 13 past infections. Of those 6 recent infections only 1 
was a first time worker in Canada which would likely indicate WNV exposure. However, 
this individual originated from the state of Yucatan, which is endemic for Dengue and 
was later found PRNT positive for Dengue and negative for WNV. Of the 13 persons 
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considered with past infection results, 6 were in Canada for their first time so they were 
likely Dengue. 
Table 11. West Nile Virus IgG avidity results in individuals positive for WNV IgG 
(n=19) 
Worker entry into WNVIgGlow 
Canada avidity 
recent infection 
First time in Canada 1 
Return worker/resident 5 
Total 6 
WNV IgG high 
avidity 
past infection 
6 
7 
13 
Total 
7 
12 
19 
IgG avidity was not performed for Dengue because it was assumed that if any of the 
workers had anti-Dengue antibodies, they would have high avidity results from at least 
the last season spent in Mexico (there is no Dengue transmission in Canada). 
Since the 12 return workers could have antibodies to either or both WNV and Dengue, 
the avidity test did not clarify the cross-reactivity in any of the cases (i.e., 5/12 (42%) 
were interpreted as "recent" and 7112 (58%) were interpreted as "past" infections). If the 
avidity test was not performed in this study, the interpretation of the results would be the 
same. In other words the avidity test was of no assistance in interpreting the cross-
reactivity between WNV and Dengue ELISA results. Therefore further confirmation was 
required. The next step needed to differentiate and confirm for the presence of the true 
antibodies in our 15 participants with both anti-WNV and anti-Dengue antibodies was to 
send the samples for confirmation with the Plaque Reduction Neutralization Test 
(PRNT). 
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4.2.3 Plaque Reduction Neutralization Test 
Samples that demonstrated antibodies to either WNV or Dengue were forwarded to the 
NML for confirmation with the PRNT. A total of 22 samples were sent for confirmation 
with PRNT. Of those 22, two were positive for IgM WNV, 19 for IgG WNV, 16 for IgG 
Dengue, and 15 were positive for both WNV and DEN IgG antibodies. The PRNT results 
yielded 0 positive results for WNV (Table 12). 
Table 12. WNV confirmation of 22 ELISA positive samples with PRNT 
/ 
WNVPRNT 
WNVELISA1 Positive Negative Totals 
Positive O(a) 21(b) 21 
Negative O(c) l(d) 1 
Totals 0 22 22 
IPositive ELISA results include those that are positive for WNV IgG or WNV IgM. 
Sensitivity ala+c; Specificity d1b+d; Positive predictive value ala+b; Negative predictive value d/c+d 
Since only ELISA positive samples were sent for confirmation with PRNT only some of 
the ELISA test parameters could be estimated as indicated below: 
• WNV ELISA sensitivity = 010 = undefined number 
• WNV ELISA specificity = 1122= 4.5% 
• WNV ELISA positive predictive value = 0/21 = 0% 
• WNV ELISA negative predictive value = 111 = 100% 
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Conversely, Panbio's ELISAs for Dengue were much closer to the PRNT results: 13 out 
of 16 (81.3%) ELISA positives were true positives and 3 (18.8%) were false positives 
(Table 13). 
Table 13. Dengue confirmation of22 ELISA positive samples with PRNT 
Dengue PRNT 
Dengue IgG ELISA Positive Negative Total 
Positive 13 3 16 
Negative 0 6 6 " 
Total 13 9 22 
For Dengue the ELISA test parameters are as follows: 
• Dengue ELISA sensitivity = 13/13 = 100% 
• Dengue ELISA specificity = 6/9 = 66.7% 
• Dengue ELISA positive predictive value = 13/16 = 81.3% 
• Dengue ELISA negative predictive value = 6/6 = 100% 
As mentioned above, the Panbio ELISAs positive for WNV resulted negative in the 
PRNT. This degree of cross-reactivity is certainly perplexing and warrants further 
investigation in order to identify potential factors influencing cross-reactivity or at least 
predictors of it. With this in mind, WNV false positive results were aggregated and are 
presented in Table 14 and Map 2 below. 
Table 14 below shows that the 19 samples from individuals positive for WNV ELISA 
IgG originated from 11 different states, without predominance of a particular state. The 
table also includes those individuals positive for WNV IgM and those positive for 
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Dengue IgG. The lack of commonalities among the six WNV IgG ELISA+IDEN PRNT 
negative would appear to indicate another factor(s) was present eliciting the cross-
reactivity. Four individuals were men, two originated from Dengue non-endemic states 
(Puebla and Guanajuato), 5/6 of them were return workers and they all worked in 
different farms in Niagara Region. However, no conclusions can be drawn since there is a 
lack of power. Of the 13 WNV ELISA+IDen PRNT positive, all were from Dengue 
endemic states. 
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Table 14. Participants with positive ELISA results and their confirmatory PRNT (n=22) 
State of Sexl Age Dengue Years WNV WNV DEN WNV DEN Interpretation 
Origin Endemic in IgM IgG IgG PRNT PRNT 
Mx State SA WP ELISA ELISA ELISA 
Chiapas M/33 Yes First Neg Pos Pos Neg Pos WN unexp IDEN hx 
Chiapas M/38 Yes First Neg Pos Pos Neg Pos WN unexp IDEN hx 
Yucatan M/29 Yes First Neg Pos Pos Neg Pos WN unexp /DEN hx 
Yucatan M/26 Yes First Neg Pos Pos Neg Pos WN unexp IDEN hx 
Yucatan M/22 Yes First Neg Pos Pos Neg Pos! WN unexp /DEN hx 
San Luis F/29 Yes First Neg Pos Pos Neg Pos! WN unexp IDEN hx 
Guerrero M/50 Yes 7 Neg Pos Pos Neg Pos WN unexp /DEN hx 
Mexico Ml26 Yes 5 Ncg Pos Pos Neg Pos WN unexp /DEN hx 
Oaxaca M/37 Yes 6 Neg Pos Pos Neg Pos WN unexp /DEN hx 
Veracruz M/34 Yes 9 Neg Pos Pos Neg Pos WN unexp IDEN hx 
Yucatan M/29 Yes 5 Neg Pos Pos Neg Pos WN unexp /DEN hx 
Tlaxcala M/38 Yes 8 Neg Pos Pos Neg Pos WN unexp /DEN hx 
Veracruz F/42 Yes 8 Neg Pos Pos Neg Pos WN unexp /DEN hx 
Nayarit F124 Yes First Neg Pos Pos Neg Neg WN & DEN unexp 
Guerrero M/35 Yes 5 Neg Pos Pos Neg Neg! WN & DEN unexp 
Morelos F/38 Yes 4 Neg Ncg Pos Neg Neg WN & DEN unexp 
Veracruz M/35 Yes 4 Neg Pos Neg Neg Neg WN & DEN unexp 
Guanajau M/50 No 22 Neg Pos Neg Neg Neg WN & DEN unexp 
Guerrero M/43 Yes 3 Neg Pos Neg Neg Neg WN & DEN unexp 
Puebla F/33 No 8 Neg Pos Neg Neg Neg WN & DEN unexp 
Mexico M/36 Yes 5 Pos Neg Neg Neg Neg WN & DEN unexp 
Michoaca M/41 No 6 Pos Neg Neg Neg Neg WN & DEN unexp 
l These participants recalled having suffered from Dengue 
WN unexp: no previous exposure to West Nile virus; DEN unexp: no previous exposure to Dengue; DEN 
hx: Dengue infection history; Pos=positive; Neg=negative 
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Partidpant 
Map 2. Dengue positive PRNT participants. Positive individuals are represented as green 
dots within the farms (Niagara Regional Conservation Authority) 
4.2.4 Risk factors for Dengue exposure/infection 
Risk factors from the study questionnaire for Dengue PRNT positivity (as a proxy for 
Dengue exposure) were examined using regression analysis. First, a univariate regression 
analysis was performed and risk factors associated with an outcome at a p value< 0.15 
were selected for inclusion in the multivariate analysis. This study was an exploratory 
hypothesis generating study. A p value of 0.15 instead of 0.05 was chosen to control 
confounding more effectively and not to exclude possible associations that might have 
otherwise been missed [118].other studies in Dengue research have utilized a similar p 
value of 0.15 for univariate analysis [113-116]. Second, the multivariate analysis was 
performed and variables with the traditional value of p<0.05 were considered to be 
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significant. As shown in Table 15 below, suggestive associations were found between 
Dengue previous exposure and age, first year in SA WP, number of seasons in SA WP, 
low mobility within Mexico, type of housing in Mexico, water basin in yard, smoking, 
smoking frequency, alcohol consumption and number of alcoholic drinks consumed per 
day (p<0.15). The sample was broken into exposure sections for age, seasons, low 
mobility, and number of alcoholic drinks per day to look for a dose-response pattern. 
None were found apart from a trend with age thus all variables were dichotomized apart 
from age which was left continuous. 
Table 15. Univariate logistic regression analysis to identify risk factors for Dengue 
seropositivity (PRNT) in the study population of Mexican workers in the Niagara Region 
for the 2007 season (n=92) 
Variable Number % with Dengue OR (95% CI) p < 0.15 
antibodies 
(PRNT) 
Sex 
Female 20 2/20 (5%) 1.00 
Male 72 11172 (15%) 1.62 (0.33-8.00) 0.55 
Age (years) 
22-31 22 6122 (23%) 1.00 
32-37 24 3/24 (13%) 0.4 7 (0.lO-2.18) 0.34 
38-43 24 3124 (13%) 0.4 7 (0.lO-2.18) 0.34 
44-65 22 1122 (5%) 0.13 (0.01-1.18) 0.07 
Age: risk per year of age 92 0.92 (0.85-1.00) 0.05* 
Level of Education 
Primary education 48 5/48 (10%) 1.00 
Higher than primary ed. 43 7/43 (16%) 1.67 (0.49-5.72) 0.41 
First year in SA WP in Canada 
More than 1 sl year 73 7173 (lO%) 1.00 
First year in Canada 19 6119 (32%) 4.35 (1.26-15.06) 0.02* 
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Number of seasons in SA WP in 
Canada (seasons) 
1 19 6119 (31%) LOO 
2-4 24 1124 (4%) 0.09 (0.01-0.87) 0.04 
5-8 28 6/28 (21 %) 0.59 (0.16-2.21) 0.44 
9-22 21 0/21 (0%) dropped 
Seasons 1 19 6119 (31%) LOO 
Seasons more than 1 73 7/73 (9%) 0.23 (0.07-0.80) 0.02* 
Mobility within Mexico-lived in same 
home for years 
1-25 21 5/21 (23%) LOO 
26-33 24 6/24 (25%) L07 (0.27-4.17) 0.93 
34-41 24 2/24 (8%) 0.29 (0.05-L69) 0.17 
42-65 23 0/23 (0%) dropped 
Low mobility 25 yrs and less 21 5/21 (24%) LOO 
Low mobility more than 25 yrs 71 8/71 (11%) 0.41 (0.12-1.41) 0.15* 
Type of Mexican home 
Type I only 64 12/64 (19%) LOO 
Type II-V 26 1126 (4%) 0.18 (0.02- L46) 0.11 * 
Water basin Mexican yard 
No 22 7/22 (32%) LOO 
Yes 70 6/70 (9%) 0.20 (0.06-0.69) 0.01* 
Smoking 
No 64 6/64 (9%) LOO 
Yes 28 7/28 (25%) 3.22 (0.97-10.69) 0.06* 
Number of cigarettes smoked per day 
No smoking 64 6/64 (9%) LOO 
Smoke more than 1 28 7/28 (25%) 3.40 (1.20-9.64) 0.02* 
Alcohol consumed 
No 34 2/34 (6%) LOO 
Yes 58 11158 (19%) 3.74 (0.78-18.03) 0.10* 
Number of alcoholic drinks consumed 
per week 
No drinking 34 2/34 (6%) LOO 
1 per week 24 5/24 (21%) 4.20 (0.74-23.90) 0.10 
2 per week 16 1116 (6%) 1.07 (0.09-12.70) 0.96 
3 or more per week 18 5118 (28%) 6.15 (L05-35.80) 0.04 
Number of alcohol drinks 0 34 2/34 (6%) LOO 0.10* 
Number of alcohol drinks more than 0 58 11158(19%) 3.74 (0.78-18.03) 0.10 
*associations with p<0.15 
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As shown in Table 16 below, the multivariate analysis showed statistical associations 
between Dengue exposure and first year in SA WP (p = 0.006), type of Mexican home 
(p=0.029), and a water basin in the yard (p=0.004). Participants in their first year in the 
SA WP program seemed to be at an increased risk for Dengue exposure. On the other 
hand, a home of lower socioeconomic condition in Mexico appeared to reduce the risk of 
Dengue exposure. The presence of a water basin in the yard also suggested a decreased 
risk of exposure to Dengue. 
Table 16. Multivariate logistic regression analysis to identify risk factors for Dengue 
seropositivity(PRNT) in the study population of Mexican workers in the Niagara Region 
for the 2007 season using the suggested associations found with univariate analysis 
Variable OR (95% CI) p < 0.05 
First year in SAWP 
More than 1 st year 1.00 
First year 9.16 (1.90-44.30) 0.006 
Type of Mexican home 
Type I 1.00 
Type II-V 0.06 (0.01-0.75) 0.029 
Water basin Mexican yard 
No 1.00 
Yes 0.11 ( 0.03-0.50) 0.004 
4.3 Awareness of West Nile Virus 
Of the 92 participants, 21 (22.8%) indicated that they had heard or had some knowledge 
ofWNV. Of those with some knowledge, three-quarters (76.2%) knew that the infection 
was transmitted by mosquitoes, almost half (47.6%) associated the infection with a fever, 
and approximately two thirds (62.0%) had some knowledge of the symptoms caused by 
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WNV infection (see Table 18 below). Only 2/92 (2.2%) participants indicated that they 
used repellent to protect themselves from mosquito bites. It is important to note that none 
of the participants knew that all 3 symptoms of fever, pain and fatigue occur 
simultaneously with a WNV infection. 
Table 17. Awareness of West Nile Virus among study participants (n=92) 
Awareness of WNV Yes 
General awareness of 21 (22.8%) 
WNVn=92 
Knowledge of 
symptoms and 
transmission n=21 
Symptoms n=21 
Fever 
Pain 
Fatigue 
Fever, pain and fatigue 
Blindness 
None of the above 
Transmitted n=21 
Mosquito 
Water 
Food 
Unknown 
10 (47.5%) 
1 (4.8%) 
1 (4.8%) 
0(0%) 
1 (4.8%) 
8 (38.1 %) 
16 (76.2%) 
2 (9.5%) 
1 (4.8%) 
2 (9.5%) 
No 
71 (77.2%) 
11(52.4%) 
20 (95.2%) 
20 (95.2%) 
100 (100%) 
20 (95.2%) 
13 (61.9%) 
5 (23.8%) 
19 (90.5%) 
20 (95.2%) 
19 (90.5%) 
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CHAPTER 5: DISCUSSION 
It has been 10 years since West Nile Virus arrived in North America. In Canada, viral 
activity commenced in 2001 and the first human case occurred in Ontario the following 
year. Along with public awareness campaigns, Public Health Departments across the 
country rapidly implemented active surveillance strategies, control programs, and made 
available screening and confirmatory laboratory diagnosis for the infection. Clinical 
reports of WNV fever and WNV neurological disease continued to increase throughout 
2002-2003, but the downward trend experienced in the period 2004-2006 suggested that 
the epidemic could have been reaching its maximum potential. This was not the case 
across Canada, as human cases in 2007 reached record numbers (n=2,215, >50% more 
cases than previously documented). This alarming increase, however, plummeted in 
2008, when only 36 cases were reported across the country. In the present year, 2009, 
seven human clinical cases of WNV have been reported to the Public Health Agency of 
Canada [17]. 
Despite these upward and downward WNV transmission patterns in the country, the 
prevalence of the disease in humans in Niagara never developed to the degree 
experienced in other areas of Canada. Only 30 human cases have occurred in Niagara 
Region since 2002 with the last case reported in 2006 [18]. There is, to date, no clear 
explanation as to why despite having the apparent environmental conditions for 
transmission and viral activity in birds and mosquitoes, so few human WNV cases have 
occurred in Niagara. Similarly, there is no prediction model that can accurately indicate 
whether or not this pattern will continue leading eventually to the nil levels prior to 2001 
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(i.e., that WNV transmission will die out in the Region). If this were the case, does the 
neglible risk to the human population warrant continued costly disease surveillance? This 
is certainly a difficult question to answer. On the other hand, lessons learned from 
countries where WNV has re-emerged dramatically after quiet periods suggest that public 
health preparedness and active surveillance remain the best decision [78, 81-85, 88, 91]. 
This is the case of the Regional Municipality of Niagara where dead bird surveillance and 
virus determination in mosquito pools are still done. This is a well-established practice in 
North America, as sudden deaths in large numbers of birds, particularly corvids, is still 
the best sentinel for predicting an outbreak [119]. In fact, a Canadian study by Elliott et al 
(2005) reported a peak in dead corvids approximately 5 weeks before most of the human 
cases were detected, thus providing further support to this practice [120]. Additional 
surveillance methodology using strategically placed chicken flocks and horses (before 
introduction of the equine WNV vaccine) was tested early on in Canada but both methods 
underperformed compared to the results obtained from dead bird evaluation and mosquito 
population surveillance [121]. 
Human surveillance through anti-WNV antibody determination of a representative 
segment of the population has never been attempted in Niagara Region. Regardless of the 
lack of clinical cases, WNV transmission can still be occurring as research studies 
determined that the majority of WNV infections (> 80%) are asymptomatic [4, 5, 40]. A 
human seroprevalence study for WNV could help to elucidate at least the question if 
transmission is still occurring in the Region. Therefore, the aim of the present MSc 
project was to conduct an investigation in persons considered at high risk for mosquito 
bites and with low probability of past WNV exposure. As such, this study aimed to 
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investigate WNV antibodies as an indicator of transmission in a group of Mexican 
agricultural workers in Niagara. This group met the two criteria set for the study: due to 
their prolonged outdoor activities they were deemed as high risk of exposure for 
mosquito bites and their originating from Mexico minimized the probability of previous 
exposure to WNV. 
In analyzing published literature, however, it became clear at the onset of the study, that 
WNV serology in humans is plagued with problems due to the notorious cross-reactivity 
of flaviviruses in general. Moreover, the fact the study sample was originally from 
Mexico added a high degree of certainty of previous exposure to Dengue virus and thus 
of cross-reactivity. Delays in commencing the study added yet another complicating 
factor: since the workers had been already in Niagara for some time before enrolment in 
the study, no baseline serology could be established and was therefore not attempted. In 
an ideal situation, seroconversion while in Niagara would prove local transmission. If this 
was not feasible and a single-sample approach was needed, first time workers should be 
enrolled at entry. Since neither of these was viable, a mix of first-time and return workers 
were enrolled and serological tests were planned carefully, as follows: 
a) Testing for WNV IgM would permit us to discern, with 96% sensitivity and 85% 
specificity, a very recent infection by WNV 
b) Testing IgG for both WNV and Dengue would allow us to determine the cross-
reactivity 
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c) WNV IgG avidity determination would help to elucidate cross-reactive samples 
and conclude which cases could be deemed as "probable cases" (the 
epidemiological history would enable us to strengthen the conclusions) 
d) PRNT confirmation of positive samples would allow us to establish definitive 
diagnoses and compare PRNTs with ELISAs results to assess the latter's 
performance in a seroprevalence study 
5.1 Serological tests and cross-reactivity issues 
As evidenced by our results, however, antibody determination with Panbio' s ELISAs 
resulted in such high degree of cross-reactivity that any credible interpretion was 
impossible. The serological standard, PRNT, revealed that all of the samples determined 
WNV-positive by ELISA were in fact, false positives. As mentioned earlier, cross-
reactivity is a well acknowledged issue in flavivirus serology, as false positivity can be 
due to multiple causes, the most common being exposure to other flavivirus such as 
Dengue virus, St. Louis encephalitis virus and Eastern equine encephalitis virus; 
exposure to other viruses as Varicella-Zoster virus, Cytomegalovirus, Epstein-Barr virus, 
Enterovirus; or even physiological factors such as rheumatoid factor, and anti-nuclear 
antibodies. Several studies have reported cross-reactivity but no study has reported to 
date the universal cross-reactivity observed in the present work [16, 122-127]. A 
Canadian study undertaken by Loeb et al in 200S, the ELISA screening test employed 
(from CDC) performed considerably better than the one used in the present study: 100% 
sensitivity and 99% specificity and negative and positive predictive values of 100% and 
76%, respectively (n=lSOS; 60 ELISA positives of which 46 were PRNT positive) [12S]. 
It is important to mention that the quality and reproducibility of the ELISAs done at 
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Brock were at par with those done at the reference laboratory in Winnipeg, as they 
repeated ELISAs titres (using kits from a different manufacturer) obtaining almost 
identical results as the ones found with Panbio's (results not shown). 
Our study findings emphasize the superiority of PRNT over Panbio's commercial kit. 
Had we relied on the ELISA methodology alone, based on the two IgM positive 
individuals, two recent cases of WNV exposure would have been concluded. Similarly, 
erroneous conclusions would have been reached in regards to WNV exposure, due to the 
extreme cross-reactivity between the WNV and DEN IgG results. 
5.2 Study population suitability 
Before analyzing study results, it IS pertinent to discuss whether or not the study 
population was indeed at increased risk for mosquito bites. Our sample of farm workers 
spent time outdoors from dawn to dusk, both working and socializing, most of them 
averaging 12-16 hours a day/6 days a week outdoors. This is by far, longer than other 
outdoor non-agricultural workers in Niagara [128, 129]. Another reason why these 
workers may have been more suitable for a WNV study is that despite the fact that they 
were aware of the presence of mosquitoes, only 2% used repellent such as DEET 
(however all participants reported and were observed wearing long pants and long 
sleeves). Loeb et al (2005), in the Oakville study mentioned above, reported that to 
obtain protection of approximately 50% study participants needed to practice 2 or more 
personal protective behaviors. Risk of infection did not decrease for persons practicing 
only one protective behaviour [125]. Extrapoloating Loeb's et al. findings to the present 
study, we can conclude that our participants were indeed at higher risk for mosquito bites. 
Even though the use of pesticides by some farms may have exerted a protective effect 
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against mosquito bites it is likely that the length of time spent outdoors diluted this 
environmental effect 
We believe that this group of agricultural workers provided an improved study design 
and are indeed a valuable population for vector-borne infections surveillance. In fact, 
Bender et al. suggest that agricultural workers are good as sentinels for some infectious 
diseases. Farm workers are in close contact with animals and animal products and may be 
the first to acquire new or re-emerging diseases [105]. With respect to WNV it is the 
close proximity to the mosquito vector that places this group of people at a higher risk. A 
study of farm workers in Veneto Region, Italy, aimed to investigate the prevalence of 
human WNV on farms where WNV positive horses were found. A seroprevalence of 
approximately 2% (WNV PRNT positive) was found among the workers indicating 
successful transmission to humans as well as to the horses had occurred, although the 
workers were asymptomatic [130]. This study shows that the level of asymptomatic 
WNV infections may be underestimated. 
5.3 Objective 1: Conduct a seroepidemiological investigation for WNV and Dengue 
virus 
Failure to prove WNV transmission 
Our small sample size does not allow for conclusive interpretation of our findings. There 
could be a chance -albeit small- that with a larger sample size we would have different 
findings. However, our negative findings in regards to WNV exposure by these research 
participants are likely accurate (point seroprevalence 0/92 [95% CI 0%-3.9%]) as they 
are supported by the small number of cases of human disease observed in the Niagara 
Region. Even with proven intense enzootic transmission, negative human seroprevalence 
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is not an unusual finding in the literature. A human serosurvey done by McCarthy et al. 
(2001) in an area of intense transmission in the United States found zero prevalence as 
well, concluding that an intense epizootic can occur in an area without presenting a high 
risk for infection to humans [131]. In Ontario, a human surveillance study conducted in 
2000, reported no cases ofWNV infection either [123]. 
Conversely, in 2005, Loeb et al. conducted a study in Oakville, Ontario and found an 
overall 3.1 % (95% CI 2.2%-4.0%) of seroprevalence in 1,505 persons tested [125]. Ifwe 
were to assume an expected prevalence at Oakville's lower CI limit (2.2%), and setting 
the worst acceptable frequency at 0.5%, for a population of 400,000 in Niagara we would 
have needed a sample size of 286 participants to reach a 95% level of confidence (CDC, 
2002, Epi-Info Stats-Calc). Thus, with a sample size of 92 persons in the present study, 
we cannot conclude a total absence ofWNV circulation in humans in Niagara, but we can 
speculate that if this circulation occurs, it would still be very low, within zero and 3.9%. 
Instead of discouraging public health actions, low or nil seroprevalence for WNV in a 
specific area should be interpreted as a matter of concern, for an immunologically naIve 
population is more susceptible to outbreaks than one where transmission has reached a 
consistent pattern [78, 88]. For 2009 in the Niagara Region, no humans have been 
reported as yet for WNV positivity, however, 1 mosquito pool and 2 birds have been 
reported as positive for WNV [18] indicating that the human population may remain 
immunologically susceptible. 
In analyzing outbreaks elsewhere in Canada, it is difficult to explain why WNV 
transmission remains so low in Niagara. Perhaps the local populations of Culex pipiens 
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and Culex restuans are more ornithophilic thus resulting in relatively few human cases in 
Niagara over the years. It could also be possible that the population density and degree of 
urbanization in Niagara is not able to sustain mosquito-human transmission. Several 
studies have determined urbanization a risk factor for the transmission of WNV [2, 90, 
131]. The population in Niagara is spread over a wide geographic area but as 
urbanization increases in Niagara, along with age, there may be an increased risk for 
transmission ofWNV. 
Dengue exposure in the study participants 
A secondary objective of the present study was the determination of Dengue serum 
antibodies in the research participants. Although this was done primarily to rule out 
cross-reactivity, the results obtained are in themselves, worthy of discussion. Firstly, 
Panbio's ELISA performed much better for Dengue than for WNV (13 out of 16 [81.3%] 
ELISA positives were true positives and 3 [18.8%J were false positives). Secondly, of 92 
workers tested, 13 had confirmed evidence of Dengue virus infection. This amounted to 
14.1.% of point seroprevalence (95% CI 7.7%-23.0%). Other studies in Mexico report a 
wide range of seroprevalence data, depending on the type of population and the 
geographical location studied. For instance, a household survey done by Brunkard et al. 
in Matamoros, Northern Mexico in 2004, reported a seroprevalence of 7.3% for recent 
infection and 78.0% for past infection (for both sexes aged 15 -75+ years) [132]. 
Conversely, a new study by Rodriguez et al (2009) in Northern Mexico examined a 
population of febrile patients, encephalitic patients, and healthy blood donors for the 
presence of WNV and Dengue antibodies. The study found that none of the patients had 
an acute WNV infection as per CDC's guidelines, but 4.0% demonstrated antibodies to 
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WN virus in the PRNT. Additionally, of 800 asymptomatic blood donors tested, 16 
(2.0%) were positive for Dengue antibodies [126]. These studies show diametrically 
different results and demonstrate the heterogeneity of seroprevalence patterns, as well as 
illustrate the difficulty in obtaining national averages. The study population of the present 
study, on the other hand, was composed of workers from 17 different Mexican states and 
might be perhaps a more moderate assessment of the overall Dengue virus exposure in a 
Mexican study group. 
In the literature search performed for the purpose of this thesis, no studies on the 
prevalence of Dengue in migrant workers or rural workers in Mexico were found. Thus, 
the present study provides for the first time data previously not available. 
The present work also provides interesting data as to asymptomatic Dengue infections. 
Of all the workers with antibodies against Dengue virus, only 1113 (7.7%) recalled 
experiencing the disease. This suggests that similar to WNV infection, there is a greater 
prevalence of asymptomatic infection compared to those presenting clinical 
symptomology [133]. Other studies have found supporting data: a seroprevalence study 
in asymptomatic Costa Rican children in 2003 found a seroprevalence of 36.9% in the 
coastal areas and 2.9% in the inland areas [134] and another longitudinal study of healthy 
individuals in West Jakarta reported close to 50.0% Dengue infections being 
asymptomatic [135].These studies, although not in Mexico, still provide further support 
that in areas endemic for Dengue, the number of asymptomatic individuals may be of 
concern. This is critically important for the individuals since a primary infection is 
believed to increase the risk of Dengue hemorrhagic fever or Dengue shock syndrome 
upon secondary infections with a different virus type [134, 135]. When living in endemic 
108 
"'. 
West Nile Virus in the Niagara Region 
areas- like our research participants- persons with previous Dengue history should pay 
particularly attention to exercising Dengue prevention behaviours. From our findings of 
the predominance of asymptomatic Dengue, we can draw two important conclusions: a) 
Dengue clinical history is not reliable as most infections present without symptoms, and 
b) previous asymptomatic infections (as well as symptomatic) may confound the 
diagnosis of WNV infections. Therefore, when testing for any particular virus of this 
family, other circulating flaviviruses should be tested as well. Moreover, travel history 
and potential exposure should be taken into consideration when recording the 
epidemiological history of the suspect case. 
5.4 Objective 2. Analyses of risk factors associated with seropositivity 
Risk Factors for Dengue Exposure 
Since all our study PRNT results were negative for WNV it was not possible to ascertain 
variables that are associated with infection. However it was possible to do this for 
Dengue seropositivity. After identifying suggested associations through univariate 
regression analysis, these variables were analyzed in a multivariate model. Three 
variables were found to be significantly associated with Dengue seropositivity. First, the 
first year in the SA WP program increased the odds of Dengue exposure. It is intuitive 
that if an individual is spending the entire year in a country endemic for Dengue, in this 
case Mexico, then it would certainly increase the exposure to Dengue infected 
mosquitoes. Second, the Mexican home with fewer amenities (as previously described) 
decreased the odds of Dengue exposure. This is counter-intuitive as one would assume 
that homes belonging to people of a lower socioeconomic status (SES) would be 
associated with mosquito habitat (i.e., lack of running water and stagant water sitting in 
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barrels). This does not appear to be the case. It is important to note that the particular 
grading system of the Mexican home used in this study does not take into account 
parameters for preventing mosquitoes in the home. Another consideration is that these 
workers are only living in Mexico for part of the year, and during that time may be 
working in other areas of Mexico and not living in their family home. These results may 
be spurious and warrant further research and confirmation. 
Third, the presence of a water basin in the yard decreased the odds of Dengue exposure. 
The presence of a water basin indicates running water in the home and thus less 
opportunity to utilize household containers to store water. The water basin is used for 
laundry washing and the water is changed and not left to stagnate with organic matter as 
opposed to rain barrels in which water may sit for prolonged periods of time. In this 
regard, a water basin with regular running water reduces the probability of mosquito 
breeding habitats. This finding may be also associated with higher SES as laundry basins 
are usually found in people's homes with higher incomes. Water storage in open 
containers such as rain barrels has been consistently found associated with Dengue 
transmission, as evidenced in a study by Brunkard and colleagues in Mexico [132]. 
Is Dengue previous exposure affecting our WNV findings? 
In the light of our WNV negative results, the analysis of our Dengue serological data led 
us to two related and yet different interesting theories described in the literature. The first 
is the possibility that pre-existing anti-Dengue antibodies may have protected our 
research participants from establishing an infection with WNV. The second theory, of an 
even more speculative nature, the possibility that individuals with pre-exisiting anti-
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Dengue antibodies may have responded to a WNV infection with the production of more 
anti-DEN antibodies intead of producing specific anti-WNV antibodies_ 
The first theory is supported by the the scarce number of reports of human WNV disease 
in tropical and subtropical areas in the Americas, even from countries with established 
WNV surveillance systems such as Mexico_ This has led to the hypothesis that 
transmission of WNV in those areas may be modulated by the presence of partially 
protective heterotypic antibodies [99, 104l Although, there are several flaviviruses 
circulating in South America and the Caribbean, Dengue is by far the most predominant 
In fact, a number of recently published papers point to this extreme [16, 126l The 
presence of WNV circulating in mosquitoes, birds, and horses has been previously 
established in the northern parts of Mexico [13-16,100,103,104] as well as in Chiapas 
(the southernmost state in Mexico) [124] however transmissions to humans is rare_ More 
recently, a paper by Garza-Rodriguez et al (2009) suggests that the high prevalence of 
antibodies against Dengue virus in Northern Mexico may very well be the reason the 
incidence of WNV is so limited [126l If this were the case, our study sample would not 
be appropriate to assess WNV transmission in Niagara_ A paired-sample examination of 
antibodies in the research participants would have been useful in ruling out this potential 
protective effect and future studies should take this into consideration. 
The second theory is supported by the concept of the 'original antigenic sin' [136, 137] 
and is particularly attractive when trying to explain our negative results. This theory 
would make it plausible to reject our findings and argue that there may be local 
transmission in Niagara but our research population had a biological bias that prevented 
us from detecting WNV antibodies. Unfortunately, this theory remains controversial and 
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our small sample size does not allow for such speculations (considering that the Dengue-
negative portion of the research group supposedly not affected by this immunological 
interference was too small to find any positives). 
5.5 Objective 3. Assessing awareness of WNV transmission 
Only 23% (21192) of the workers had some previous awareness of WNV and only 2% 
practiced protective behaviour from mosquitoes (use ofDEET). All workers reported and 
were observed wearing long sleeves and pants which have been demonstrated to be 
protective against vector-borne diseases. This behaviour however was not related to a 
conscious behaviour of mosquito bite avoidance but rather required to prevent the 
physical hazards associated to the nature of their jobs. Conversely, in a study by Averett 
et a1.(2005), in Kansas, 97% of the general population had heard of WNV although only 
41 % of the Spanish speaking population reported this same awareness [13 8]. As in our 
participants, knowledge and awareness did not translate into the same level of 
protective behaviour. In the Kansas study, 89% indicated knowledge of one or more 
protective behaviour, but only 21 % reported using DEET. A study of Canadian First 
Nations (n=248), in 2003, indicated an overall awareness of WNV of 95% and 34 % 
reported using DEET [139]. In a study to determine retention and compliance with public 
health messaging in Oakville in 2003 researchers found that 99% of the individuals 
surveyed had heard of WNV and 61 % reported undertaking 2 or more personal protective 
behaviours against mosquito bites [120]. The fact that only 2% of our study population 
used DEET suggests a lack of awareness for using mosquito repellent however other 
reasons such as cost or fear of applying chemicals to the skin cannot be ruled out. 
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Of the participants that responded to having some awareness of the existence of WNV in 
Canada, when enquired about the infection's mode of transmission, a good proportion 
(76%) correctly identified that WNV is transmitted by mosquito bites. Conversely, the 
First Nations study mentioned above indicated that 90% of the participants had 
knowledge of mosquito transmsission [139]. Other workers in our study believed that the 
virus was transmitted by water (10%), food (5%) or they did not know (10%), 
demonstrating that there are many misconceptions about this disease transmission among 
the group. Similarly, even when workers affirmed knowing about WNV existence, their 
knowledge of the disease symptomology was inaccurate. Fifty percent recognized fever 
as a symptom of WNV infection, less than 5% were aware of any other symptom and 
none was aware that fever, pain, and fatigue occurred together as a triad of 
symptoms.The identified lack of understanding and awareness about WNV among the 
workers leads to the assumption that there is not enough health education provided for 
them prior to leaving Mexico, or that if there is, that the messages are not being retained 
by the workers. As part of this study, the participants were presented with informative 
sessions and handouts written in plain Spanish, about transmission of WNV and 
symptomology. We did not formally evaluate increases in knowledge and awareness or 
measure any behavior change -as this was not an objective of the study- but it was 
subjectively observed during conversation at the last meeting that workers had a better 
understanding of WNV. Workers also reported transmitting the messages to colleagues 
that were not enrolled in the study. As these workers are fundamental to Niagara Region's 
economy, it would be desirable that their employers, community associations and the 
public health department combined their efforts in implementing health promotion 
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activities with this population. Further promotion of WNV prevention is beneficial since 
it is not possible to predict the future transmission of WNV. A low cost intervention 
could be in the form of conducting health promotion and health education sessions as 
well providing them literature in Spanish in regards to important health issues they may 
encounter in Canada. Increasing these workers' awareness and encouraging protective 
behaviors is fundamental at both the individual and societal level. 
5.6 Study findings implications for public health 
The Public Health Agency of Canada (PHAC) recommends that all index cases positive 
for WNV IgM be confirmed with the PRNT. After an index case has been reported in a 
health region, PHAC recommends that for surveillance purposes all clinical cases 
following the index case fulfilling the probable diagnostic criteria (i.e., positive for 
ELISA WNV IgM) can be confirmed without the PRNT [17]. Our results show that IgM 
results can sometimes be unreliable. As well, recent literature shows that IgM 
determination by ELISA is not without problems. In September 2008, the Center for 
Disease Control (CDC) investigated a commercially available WNV IgM ELISA kit from 
Panbio Inc. (Australia) due to reports of a high number of false positive results. The CDC 
found false positive IgM in 72% of 166 samples tested [140, 141]. Since this test has 
failed in clinical studies, performance in epidemiological studies would also likely be 
poor. The two samples in our study that were solely positive for WNV IgM ELISA were 
negative for all other ELISA and PRNT serology. 
It would be important for public health to evaluate the tests that are being used for WNV 
diagnosis, and if possible conduct studies to determine the extent of the problem with 
false positivity for IgM [3, 124, 142-146]. Moreover, it would be beneficial if the Public 
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Health algorithm for diagnosis of WNV [17] considered the epidemiological history of 
the individual as well as the probability of exposure, and at the same time recommended 
performing serological tests, preferably PRNT, for all potential circulating flaviviruses. 
From the Mexican Public Health standpoint, knowing if these workers are at an increased 
risk for WNV infection is paramount Although the possibility of these workers being 
viremic enough to introduce the virus to Mexico is minimal (as humans do not develop 
sufficient viremia to sustain vectorial transmission), other concerns such as blood 
donation and pregnancy remain. Having resided in a WNV endemic area could be an 
important factor when screeing blood donors in Mexico. Just as in Canada, prior 
exposure to Dengue would confound WNV diagnosis, Dengue diagnosis in Mexico could 
possibly in tum be confounded by WNV exposure. This illustrates that infectious 
diseases, emerging and re-emerging, and are becoming a globalized issue [1]. 
5.7 Study Limitations 
This study used a small non-randomized convenience sample to conduct a preliminary 
investigation. The biases intrinsic to our study population and the lack of statistical power 
do not allow for a conclusive interpretation of our findings. Since no WNV 
serosurveillance studies had been done with this particular population the researchers felt 
that although the results may not be generalizable, the present work could serve as a pilot 
trial as well as a feasiblity study in which to base further research. 
Future studies set to demonstrate WNV in the Niagara Region could make use of a 
longitudinal design with a representative sample of the population. 
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5.8 Study Strengths 
Having access to PRNT confirmatory testing through PRNT at the National 
Microbiology Laboratory (thanks to Dr Mark Loeb, McMaster University) we were able 
to elucidate the high degree of cross-reactivity observed in the studied samples. Without 
the PRNT, the results of this study would have been oflittle value. 
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CHAPTER 6: CONCLUSIONS, RECOMMENDATIONS AND FUTURE 
RESEARCH DIRECTIONS 
6.1 Conclusions 
1. Our study demonstrated the limitations of ELISA antibody testing for WNV in 
individuals that are exposed to multiple flaviviruses and the need to utilize the 
confirmatory PRNT for both clinical diagnosis and surveillance purposes. 
2. A study of an infectious disease (or any other biomedical study) in the Mexican 
migrant agricultural population in the Niagara Region has never been attempted. 
The challenges with enrolling participants and conducting the study culminated 
with the collection of baseline data that is now available for further research The 
base of farm owners that did participate can be used to network to others to gain 
support for other research projects. 
3. Awareness of WNV is limited among this group of workers and those who 
understood the disease and its transmission did not utilize precautions. Greater 
attention is needed to inform the migrant worker of the potential risk to their 
health from diseases that may not be present in their native country. 
4. Mexican migrant workers are potentially at risk for WNV transmission while in 
Canada. 
5. This study did not prove WNV transmission in the study population and thus no 
predictive conclusions can be made. This study did not measure or evaluate the 
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geography, climate, or species of birds and mosquitoes, however, the Niagara 
Region is postioned geographically near many water sources, has the appropriate 
climate for mosquito breeding habitat, appropriate vectors are present, and is 
horne to many migratory passerine birds, thus making this area vulnerable for 
further transmission of WNV to the human population. 
6.2 Recommendations (These recommendations are not necessarily based on this 
study's results but also are a result of the review of the current literature) 
1. All positive ELISA findings, whether diagnostic or surveillance, should be 
confirmed with the PRNT 
2. We suggest re-examination of the PHAC's diagnostic case criteria in regards to 
the interpretation of WNV serological testing as well as the inclusion of 
epidemiological history in the diagnostic algorithm. 
3. Continued surveillance in birds and mosquitoes III the Niagara Region is 
encouraged. Mosquito surveillance for population estimates, speCIes and the 
minimum infection rate of WNV in the mosquito pools should be performed. 
Maintaining control on the mosquito population in known habitat areas should 
occur in parallel with surveillance. 
4. Partnerships of the Niagara Regional Health Department and other research 
institutions will help facilitate surveillance and enhance the development of new 
knowledge that can be applied to infectious disease control. 
5. In Niagara, in particular, designing a study involving Mexican migrant workers is 
challenging due to the barriers these workers experience including language and 
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access to adequate health care. By providing a setting for accessible health care 
other information can be collected by public health professionals (that would 
otherwise be logistically difficult to collect and not cost-feasible) to evaluate the 
population health of this group of agricultural workers. Gaining information 
regarding susceptibility to infectious disease is not only important to the health 
of the individual worker, but to the country of Mexico and the scientific 
community. 
6.3 Suggested directions for future research 
1. Historically, WNV has not established a predictable pattern of disease 
transmission and hence it has been impossible to predict an outbreak of WNV, 
beyond observation of death in corvids in North America prior to a human 
outbreak. Spatial risk assessment for WNV based on mosquito abundance, bird 
populations, and human population data through the use of Geographic 
Information Systems (GIS) can help identify areas in the Niagara Region at 
greatest risk for WNV transmission to humans. Temperature, rainfall, vegetation 
cover, and wetland data are important factors to incorporate in a spatial map for 
predicting mosquito abundance. British Columbia has been free of human 
transmission of WNV ( apart from imported cases), up to this year in which 1 
human case has been confirmed. This province has developed GIS to work as an 
early warning system for a potential outbreak ofWNV in humans [147]. 
2. Although the present seroprevalence study could not prove transmission of WNV 
to humans among the sample population, the virus is still present in the mosquito 
and bird population (as of 2009) [18J which means that it may be present, yet 
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undetected, in other small mammals so far identified. Even if undetected in the 
mosquito population the virus could be reintroduced by migratory birds. 
Therefore, proactive measures with mathematical modelling using GIS could be a 
consideration for the Niagara Region. Niagara's climate is conducive for an 
increase in the enzootic level of transmission which could lead to an increase in 
human exposure to mosquitoes. 
3. As previously mentioned, it has been suggested that surveillance of healthy 
human groups that are highly exposed to vectors and animals, as is the case of as 
agricultural workers, may be valuable when monitoring for emerging or re-
emerging disease [105]. For WNV, however (in which cross-reactivity with 
related flavivirus is a serious issue) perhaps regional permanent residents with 
different degrees of exposure to mosquito bites would be a better indicator of 
local transmission than foreign agricultural workers. In any case, surveillance of a 
resident human population would still require the confirmatory PRNT, as it did in 
our migrant worker population. 
4. Development ofWNV and other flavivirus confirmatory tests that do not require a 
high level of biocontainment should be a priority to effectively monitor the 
patterns of WNV transmission. Such tests would prove extremely necessary 
should WNV finally spread to developing countries where laboratory technology 
is not as available as in industrialized nations. 
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Supervisor Sanchez Associate Health 688-Professor Sciences 5550 x 
3882 
3. Proposed Date (dd/mm/yyyy) (a) of commencement: June 2007 (b) of completion: 
November 2007 
4. Indicate the location(s) where the research will be conducted: 
Brock University 
Community Site 
Grow Support Centre 
School Board 
Hospital 
Other 
[x I 
[ x I Specify Agricultural Farms employing Mexican 
[I workers 
[ I Specify [ I Specify 
[ I Specify 
5. Other Ethics Clearance/Permission: 
(a) Is this a multi-centered study? 
[ I Yes [x I No 
(b) Has any other University Research Ethics Board approved this research? 
[ I Yes [x I No 
If YES, there is no need to provide further details about the protocol at this time, 
provided that all of the following information is provided: 
Title of the project approved elsewhere: 
Name of the Other Institution: 
Name of the Other Board: 
Date of the Decision: 
A contact name and phone number for the other Board: 
Please provide a copy of the application to the other institution together with all 
accompanying materials, as well as a copy of the clearance certificate / approval. 
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If NO, will any other Research Ethics Board be asked for approval? 
[ ] Yes [x] No 
Specify University/College 
(d) Has any other person(s) or institutions granted permission to conduct this research? 
[ ] Yes [x] No 
Specify (e.g.,. school boards, community organizations, proprietors) 
6. Level ofthe Research: 
[ ] Undergraduate [ X] Masters Thesis/Project [ ] 
Ph.D. 
[ ] Post Doctorate [ ] Faculty Research [ ] 
Administration 
[ ] Undergraduate Course Assignment [ ] Graduate Course Assignment [ ] 
Other (specify) 
(specify course) (specify course) 
7. Funding of the Project: 
(a) Is this project currently being funded 
(b) If No, is funding being sought 
If Applicable: 
(c) Period of Funding (dd/mm/yyyy): 
(d) Agency or Sponsor (funded or applied for) 
[ ] CIHR [] NSERC [ ] SSHRC 
[ ] Yes [x] No 
[ ] Yes [x] No 
From: 
[ ] Other (specify): 
(e) Funding / Agency File # (not your personal PIN) 
8. Conflict of Interest: 
To: 
(a) Will the researcher(s), members of the research team, and/or their partners or 
immediate family members receive any personal benefits related to this study -
Examples include financial remuneration, patent and ownership, employment, 
consultancies, board membership, share ownership, stock options. Do not 
include 
I Not appJ;cabJe 
conference and travel expense coverage, possible academic promotion, or 
other benefits which are integral to the general conduct of research. 
[ ] Yes [x] No 
If Yes, please describe the benefits below. 
(b) Describe any restrictions regarding access to or disclosure of information (during 
or at the end of the study) that the sponsor has placed on the investigator(s). 
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I None 
SECTION B - SUMMARY OF THE PROPOSED RESEARCH 
9. Rationale: 
Briefly describe the purpose and background rationale for the proposed project, as well 
as the hypothesis(es)/research question(s) to be examined. 
West Nile virus exposure in the Mexican Migrant workers of the Niagara Peninsula 
West Nile virus (Flavivirus: Flaviviridae; WNV) is an emerging infectious agent that has 
established itself successfully in the United States since 1999 and in Canada since 2001. 
In the United States and in Canada, WNV is causing large numbers of human cases with 
neurological disease and death, and even greater amounts of milder disease characterized 
mainly by fever and rash. In the US, WNV is presently the leading cause of arboviral 
encephalitis. 
Even though the numbers of human cases of WNV infection in Canada remain much lower than 
in the US, the predictions are that cases will increase as the virus adapts itself in this new 
ecosystem. 
Across Canada, from 2002 to 2006, the number of reported clinical cases (both probable and 
confirmed WNV) for each year was respectively: 414 (394 in Ontario), 1481 (89 in ON), 25 (13 in 
ON), 225 (95 in ON) and 151 (42 in ON). These totals are the sum of WNV Neurological 
Syndrome + WNV Non-Neurological Syndrome + WNV UnclassifiedlUnspecified. Clearly the 
number of cases peaked in 2003 and tapered off since then. But infectious diseases show 
temporal patterns and just as the US have recently experienced a dramatic increase of 42% 
(4,261 cases of WNV disease in 2006, compared with 3,000 cases in 2005), a resurgence of WNV 
human infection in Canada could be in the making. 
Luckily, as much as 80% of people who become infected show no signs and symptoms. The 
remaining 20% may experience mild symptoms (fever headache, body aches, or skin rash) out of 
which less than 1% will present with severe symptoms and life-threatening neurological illness. 
Naturally the most important aspect of the WNV infection is the neurological disease, but it is 
important to remember that even in the absence of severe disease infected persons may still be 
reservoirs for mosquitoes or other humans through blood transmission or congenitally. The 
Centers for Disease Control estimates that for every case of severe WNV there are about 140 
cases of WNV infection either asymptomatic or not diagnosed. 
Until 2001 WNV was known in Canada as a potential threat to visitors of endemic countries in 
Africa but nowadays, Canadians are aware that the pathogen can be acquired locally; in their 
own backyards, literally. Additionally, visitors and temporary workers to Canada must be 
aware of the existence of this infectious disease and observe preventive measures to reduce the 
risk of infection. 
The single most important factor for acquiring WNV is exposure to mosquito bites during 
outdoor activities. In the absence of an effective human vaccine, prevention of WNV disease 
depends on community-level mosquito control and promotion of personal protection against 
mosquito bites, such as use of repellents and avoiding outdoor exposure when mosquitoes are 
most active (usually from dusk to dawn). Similarly, intact window screens or air conditioning 
can reduce mosquito exposure in homes. Numbers of mosquitoes can be reduced by removing 
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or emptying water from larval habitats such as flower pots, buckets, gutters, and barrels around 
human dwellings. 
Agricultural workers in the Niagara Region come to the area exactly during the WNV season 
(May to October) and spend many hours outdoors both during their work hours as well as for 
social activities. It is very important to investigate the rate of exposure of these workers to WNV 
during their stay in Canada not only to implement measures to protect them individually but 
also to estimate the potential for these workers of bringing the virus back to their countries. 
Although WNV has been isolated in wild birds and horses in Latin America, human clinical 
cases are not being reported despite several investigations. In Mexico, several species of birds 
have been found antibody-positives but the literature shows only one locally-acquired human 
case in 2005, and one blood unit out of almost 4,000 investigated. This means -at least for 
Mexico- that the human exposure is at this point in time at a very low -almost negligible- level. 
For this reason the present study is of utmost scientific and public health importance: in the 
event one of the Mexican workers became infected in Canada and went back home with a 
significant level of viruses in their blood, they could initiate a chain of transmission, if not to 
mosquitoes (so far mammals do not appear to allow sufficient viremia for mosquito infection) at 
least to other humans: transmission through blood transfusion from apparently healthy donors 
has occurred in North America, and a few cases of congenital (intrauterine) transmission or 
through human milk have been reported as well. 
The objective of the present study is to assess the level of exposure of Mexican Migrant workers 
to West Nile Virus during their stay in the Niagara Region by measuring serum antibodies 
which indicate exposure to the pathogen. Also, the level of awareness and knowledge regarding 
this infection will be measured to suggest and help implement preventive measures to decrease 
the likelihood of mosquito bites and therefore of infection. 
Methodology 
Study Population: the study will be done in conjunction with the tuberculosis study (REB file # 
06-268 Duarte et al) to access the same population (same sample size, enrolment process, etc). 
With the participant's consent, general demographic information will be shared as well as an 
aliquot of a blood sample taken for the TB testing. In addition, a specific short questionnaire will 
be administered to the participants to record history of past or present possible WNV infection 
symptoms, exposure to mosquito bites and knowledge and awareness regarding the infection. 
Lab testing: to assess West Nile virus infection/exposure, serum from participants will be tested 
for IgM antibodies against the virus (by ELISA). IgM antibodies are usually indicative of a 
recent West Nile virus infection but since anti-West Nile virus IgM can persist for 1 year or 
longer a single positive test will not necessarily be associated with the participant current 
illness, especially in the absence of illness. Additionally, since cross-reactivity with other 
flaviviruses circulating in Mexico may occur (e.g., Dengue virus), samples will be tested for 
other viruses in order to rule out false positives. For this, some samples (anonymized) may be 
sent to Honduras or a specialized Canadian lab to be assessed for Dengue (or the PI Ron Mergl 
will take them down there and do the testing himself after proper training). 
Questionnaire: Participants' general demographic information will be collected in the TB study 
and consenting individuals who consent to this study will provide consent for the researchers to 
access that information. So for the WNV study, only relevant information to WNV will be 
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additionally asked from the participants. This data collection instrument will be attached at the 
end of the TB questionnaire and the enquiry process will follow the same procedure as the TB 
study. 
Educational Activities: will be done in conjunction with the TB study. 
Ethics, workplace safety and biosafety: All research activities will be in compliance with the 
Canadian Tricouncil research ethics policies for human subjects. Similarly, all field and 
laboratory work will follow work safety and biosafety precautions and regulations. 
10. Methods: 
Are any of the following procedures or methods involved in this study? Check all that 
apply. 
[ 1 Questionnaire (mail) [ ] Focus Groups 
[ 1 Journals 
[ ] Non-invasive physical 
measurement (e.g., 
exercise, 
[ 1 Questionnaire (email/web) 
[x] Questionnaire (in person) 
[ ] Interview(s) (telephone) 
[ ] Interview(s) (in person) 
[ ] Secondary Data 
[ ] Audio/video taping 
(specify) 
[ ] Observations 
[ x ] Invasive physiological 
measurements (e.g., 
venipuncture, muscle 
biopsies) 
heart rate, blood pressure) 
[ X ] Analysis of human tissue, 
body 
[ ] Computer-administered 
tasks 
fluids, etc. (Request for Use 
of 
Human Tissue Sample 
attached) 
[ ] Other: (specify) 
*NOTE: Request for Use of Human Tissue Sample was submitted and approved for TB study 
(REB: Duarte et al 06-268) 
Describe sequentially, and in detail, all of the methods involved in this study and all procedures 
in which the research participants will be involved (e.g., paper and pencil tasks, interviews, 
questionnaires, physical assessments, physiological tests, time requirements, etc.) 
Attach a copy of all questionnaire(s), interview guides, or other test instruments. 
1. Questionnaires: The West Nile study is being done in conjunction with the latent tuberculosis 
study so the questionnaire for WNV study will be a supplement to that questionnaire. The Co-
investigator and Supervisor of the TB study are competent in Spanish and will assist the 
Principal Investigator with both verbal and written communication. The questions will be asked 
verbally, in private, and then recorded in Spanish. The questionnaire will have 2 components: 
the demographics and the West Nile virus related questions. The demographic section will not 
have to be repeated as the information can be drawn from the tuberculosis study. 
2. A blood sample to investigate antibodies will be necessary but further blood will not have to 
be drawn as the tests can be performed from the same serum samples drawn for the 
tuberculosis study. 
2. Educational Program: All questions regarding West Nile virus will be answered and a further 
program will be developed to offer information regarding other infectious diseases. This 
education program will be carried out in conjunction with the tuberculosis study. 
11. Professional Expertise/Qualifications: 
Does this procedure require professional expertise/recognized qualifications (e.g., 
registration as a clinical psychologist, first aid certification)? 
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[Xl Yes specify: Phlebotomy [xl No 
If YES, indicate whether you, your supervisor, or any members of your research team 
have the professional expertise/recognized qualifications required? 
[X 1 Yes [ 1 No Note: see (REB: Duarte et al 06-268) 
12. Participants: 
Describe the number of participants and any required demographic characteristics (e.g., 
age, gender). 
The number of participants will be restricted to the number included in the tuberculosis study, 
since the same blood samples will be used. The WNV population sample would be therefore a 
, convenience' sample. Since t his is the first research study of this nature in the Region, the 
present study is consider a pilot or preliminary study to explore if further research is warranted. 
13. Recruitment: 
Describe how and from what sources the participants will be recruited, including any 
relationship between the investigator(s), sponsor(s) and participant(s) (e.g., family 
member, instructor-student; manager-employee). 
Attach a copy of any poster(s), advertisement(s) and/or letter(s) to be used for 
recruitment. 
I We will only be using the recruits from the tuberculosis study. 
14. Compensation: 
No 
(a) Will participants receive compensation for participation? 
[ 1 
(b) If yes, please provide details. 
The compensation for the tuberculosis study will also cover the extra West Nile virus 
participants 
SECTION C - DESCRIPTION OF THE RISKS AND BENEFITS OF THE PROPOSED 
RESEARCH 
15. Possible Risks: 
1. Indicate if the participants might experience any of the following risks: 
Yes 
[ x 1 
a) Physical risks (including any bodily contact, physical stress, or [X 1 Yes [l 
No 
administration of any substance)? 
b) Psychological risks (including feeling demeaned, embarrassed 
worried or upset, emotional stress)? 
[X 1 Yes [ 1 No 
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c) Social risks (including possible loss of status, privacy, and / or [ ] Yes [X] 
No 
No 
No 
No 
reputation)? 
d) Are any possible risks to participants greater than those that the 
participants might encounter in their everyday life? 
e) Is there any deception involved? 
f) Is there potential for participants to feel coerced into contributing to 
this research (e.g., because of regular contact between them and 
the researcher)? 
2. If you answered Yes to any of 1 a - 1 f above, please explain the risk. 
[X] Yes [ ] 
[ ] Yes [X] 
[ ] Yes [X] 
la. Related to collection of blood samples., but since the samples will be taken from the LTBI 
study, the risks and minimizing measures are addressed in the respective protocol (REB: 
Duarte et al 06-268) 
lb. Concerns about the tests being positive. Information regarding the signs and symptoms as 
well as the risk factors will be discussed. If the antibody test is positive the participants will be 
explained that this is a past infection of no chronic consequences to them and there are no risks 
of transmission from them to others. The participants will be reassured that this is a private 
research project and does not involve Citizenship and Immigration Canada. 
ld. The workers have participated in previous medical questionnaires to receive access to 
Canada. However, it is not a daily event. The fact that all communication will be in Spanish will 
put the workers at ease and facilitate accuracy. 
3. Describe how the risks will be managed and include the availability of appropriate 
medical or clinical expertise, qualified persons. Explain why less risky alternative 
approaches could not be used. 
Again, this study is using the demographic questionnaire and the blood sample from the 
tuberculosis study. The only risks would be anxiety regarding a positive result for West Nile 
virus. This will be handled by providing education regarding this disease. 
The risk management for the invasive procedure (blood collection) is explained in (REB: Duarte 
et al 06-268) 
16. Possible Benefits: 
Discuss any potential direct benefits to the participants from their involvement in the 
project. Comment on the (potential) benefits to the scientific community/society that 
would justify involvement of participants in this study. 
I Benefit to the Participants 
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Knowing serological status (tests results) for WNV and Dengue will provide valuable 
information to the worker. If results are positive for WNV they will be aware that they had the 
infection but are now protected. The same is true for Classic Dengue; however a seropositive 
person should take maximum precautions to avoid a second infection due to the increased risk 
of developing hemorrhagic fever. Clinically, should they have another viral-fever-like illness 
they will know whether WNV and/or Dengue can be ruled out or not. 
Providing knowledge of the West Nile virus in Niagara in order to prevent exposure to this 
disease would be the main benefit to the participants. An understanding of vector transmitted 
diseases is necessary so that the workers will be diligent at preventing mosquito bites. The 
worker will be familiar with yellow fever and dengue fever but may not be aware that the West 
Nile is a similar virus. 
Benefit to the farm owners and SAWP 
Knowing the exposure status of their workers will indicate to the farm owners their own 
potential exposure and need for vector control. The health of their workers at large is directly 
proportional to the productivity of the farm. 
Benefit to the Niagara Region 
If positive individuals are found then further studies regarding the prevalence of West Nile 
virus are justified 
Benefit to the Scientific Community 
To the researchers' knowledge this is the first study of West Nile virus prevalence in migrant 
workers in the Niagara Region. Tracking West Nile virus is very difficult in sentinel groups. 
Birds are the most obvious, but the location a dead bird contracted the virus is usually 
unknown. Most horses in the Niagara Region will have been vaccinated thus are not an accurate 
sentinel group. Most poultry is housed and not exposed to mosquitoes. Of any group (human or 
animal) the migrant worker is most vulnerable since they spend most of their working hours 
outside and around irrigation waters. 
SECTION D - THE INFORMED CONSENT PROCESS 
17. The Consent Process: 
Describe the process that the investigator(s) will be using to obtain informed consent. 
Include a description of who will be obtaining the informed consent. If there will be no 
written consent form, explain why not. 
For information about the required elements in the letter of invitation and the consent 
form, as well as samples, please refer to: 
http://www.brocku.ca/researchservices/Certification&PolicesICertification&Polices_App_ 
Guidelines.html 
If applicable. attach a copy of the Letter of Invitation, the Consent Form, the 
content of any telephone script, and any other material that will be utilized in the 
informed consent process. 
Participants will be provided with a letter of invitation and informed consent document after 
they have received clear information, in Spanish, regarding West Nile virus and the health risks 
associated with this disease. The educational sessions and explanations of the studies will be 
given concurrently with the tuberculosis study to respect the time of the workers. The 
intermediary, as per in-council guidelines, will be the same person as the tuberculosis study. 
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Miss Janet Maclaughlan, a doctoral candidate from the University of Toronto, is a familiar face 
to the Mexican workers as she has been working with them regarding issues in social justice. 
Participants who qualify and consent for the TB study (REB: Duarte et al 06-268) will be 
consulted if they would like to participate in the WNV study. Only participants who agree to 
the first study will be consulted for enrollment. However, a participant may choose to 
participate in the TB study only. The reverse will not be possible as the PI (Ron Mergl) is not 
proficient in Spanish and he needs the assistance of the researchers from the TB study. 
18. Consent by an authorized party: 
If the participants are minors or for other reasons are not competent to consent, describe 
the proposed alternative source of consent, including any permission form to be provided 
to the person(s) providing the alternative consent. 
I Not applicable 
19. Alternatives to prior individual consent: 
If obtaining individual participant consent prior to commencement of the research project 
is not appropriate 
for this research, please explain and provide details for a proposed alternative consent 
process. 
I Not applicable 
20. Feedback to Participants: 
Explain what feedback! information will be provided to the participants after participation 
in the project. Include, for example, a more complete description of the purpose of the 
research, and access to the results of the research. Also, describe the method and timing 
for delivering the feedback. 
The participants will receive their results in private. Also an aggregate report will be presented 
at a final educational session 
21. Participant withdrawal: 
a) Describe how the participants will be informed of their right to withdraw from the 
project. Outline the procedures that will be followed to allow the participants to 
exercise this right. 
All participants will be made aware that they can withdraw at any time during the study. 
b) Indicate what will be done with the participant's data and any consequences that 
withdrawal might 
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have on the participant, including any effect that withdrawal may have on participant 
compensation. 
All information and samples will be destroyed immediately upon the participant withdrawing 
from the study. 
SECTION E - CONFIDENTIALITY & ANONYMITY 
Confidentiality: information revealed by participants that holds the expectation of 
privacy. This means that all data collected will not be shared with anyone except the 
researchers listed on this application. 
Anonymity of data: information revealed by participants will not have any distinctive 
character or recognition factor, such that information can be matched (even by the 
researcher) to individual participants. Any information collected using audio-taping, 
video recording, or interview cannot be considered anonymous. Please note that this 
refers to the anonymity of the data itself and not the reporting of results. 
22. Given the definitions above, in the student project(s): 
a) Will the data be treated as confidential? [x] Yes [ ] No 
b) Are the data anonymous? [ ] Yes [x] No 
c) Describe any personal identifiers that will be collected during the course of the 
research (e.g., participant 
names, initials, addresses, birth dates, student numbers, organizational names and 
titles etc.). Indicate how personal identifiers will be secured and if they will be 
retained once data collection is complete. 
Personal identifiers are described in the TB study. A code will be assigned to each participant 
allowing the information to be recorded electronically with only the Principal Researcher and 
Supervisor knowing the codes. All paper documents will be locked in Dr. Sanchez' office. 
Electronic information will be password protected and only recorded in the computers of the 
Principal Researcher and Supervisor. 
d) If any personal identifiers will be retained once data collection is complete, provide a 
comprehensive rationale explaining why it is necessary to retain this information, 
including the retention of master 
lists that link participant identifiers with unique study codes and de-identified 
data. 
In order to give the participants results, the personal identifiers must be retained until the study 
is complete. 
e) State who will have access to the data. 
The data will only be accessible to the researchers. 
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f) Describe the procedures to be used to ensure anonymity of participants and/or 
confidentiality of data both during the conduct of the research and in the release of 
its findings. 
The original questionnaires will be the only document to contain personal identifiers. All 
electronic data will have codes only. The participant will be given results in private and not 
released in any other means. The report will only contain aggregate results of the study. 
g) If participant anonymity and/or confidentiality is not appropriate to this research project, 
explain, in detail, how all participants will be advised that data will not be anonymous or 
confidential. 
I All information and samples are confidential. 
h) Explain how written records, video/audio tapes, and questionnaires will be secured, 
and provide details of their final disposal or storage, including how long they will be 
secured and the disposal method to be used. 
All paper data will be locked in Dr. Sanchez' office and all electronic data will only be available 
by security code to the researchers. All blood samples will be coded and stored in the 
laboratory. 
SECTION F -- SECONDARY USE OF DATA 
23. a) Is it your intention to reanalyze the data for purposes other than described in this 
application? 
[ 1 Yes [x 1 No 
b) Is it your intention to allow the study and data to be reanalyzed by colleagues, 
students, or other researchers outside of the original research purposes? If this is the 
case, explain how you will allow your participants the opportunity to choose to 
participate in a study where their data would be distributed to others (state how you 
will contact participants to obtain their re-consent) 
If there are no plans to reanalyze the data for secondary purposes and, yet, you wish to 
keep the data indefinitely, please explain why. 
The data will be destroyed after the study is completed and published. 
SECTION G -- MONITORING ONGOING RESEARCH 
24. Annual Review and Serious Adverse Events (SAE): 
a) Minimum review requires the completion of a "Renewal/Project Completed" form at 
least annually. 
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Indicate whether any additional monitoring or review would be appropriate for this 
project. 
It is the investigator's responsibility to notify the REB using the "Renewal/Project 
Completed" form, when the project is completed or if it is cancelled~ 
http://www.brocku.cairesearchservices/Forms/Forms.htmi 
The enrollment and contact with participants will only last one season (less than 1 year) 
*Serious adverse events (unanticipated negative consequences or results 
affecting 
participants) must be reported to the Research Ethics Officer and the REB 
Chair, 
as soon as possible and, in any event, no more than 3 days subsequent to their 
occurrence. 
25. COMMENTS 
If you experience any problems or have any questions about the Ethics Review Process at 
Brock University, please feel free to contact the Research Ethics Office at (905) 688-5550 
ext 3035, or reb@brocku.ca 
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Appendix B: Brock University Research Ethics Acknowledgement of Receipt 
FROM: 
TO: 
Linda Rose-Krasnor, Chair 
Research Ethics Board (REB) 
Ana Sanchez, Community Health Sciences 
RonMERGL 
Angela Duarte 
",-,FI=L=E,",-: ___ 06-363 - MERGL 
DATE: June 21, 2007 
The Brock University Research Ethics Board has received the research proposal: 
West Nile Virus Exposure in the Mexican Migrant Workers of the Niagara Peninsula 
Initial screening of your proposal has been completed. Your proposal has been submitted 
for an Expedited Review. 
If a reviewer of a proposal submitted for expedited review decides that a full review is 
warranted, that proposal will be reviewed at the next REB meeting. We will be in touch 
by Email when the reviewers have made their recommendations (approximately 15-20 
working days). 
Thank you for submitting your proposal. 
Please remember that no research with Human Participants shall commence prior 
to receiving clearance from this committee. 
LRKlbb 
Brenda Brewster, Research Ethics Assistant 
Office of Research Ethics, MC D250A 
Brock University 
Office of Research Services 
500 Glenridge Avenue 
St. Catharines, Ontario, Canada L2S 3Al 
phone: (905)688-5550, ext. 3035 fax: (905)688-0748 
email: reb@brocku.ca 
http://www.brocku.calresearchservices/ ethics/h umanethicsl 
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Appendix C: Brock University Research Ethics Clearance 
DATE: July 13,2007 
FROM: Michelle McGinn, Chair 
Research Ethics Board (REB) 
TO: Ana Sanchez, Community Health Sciences 
Ron MERGL, Angela Duarte 
FILE: 06-363 MERGL 
TITLE: West Nile Virus Exposure in the Mexican Migrant Workers of the 
Niagara Peninsula 
The Brock University Research Ethics Board has reviewed the above research proposal. 
DECISION: Accepted as is. 
This project has received ethics clearance for the period of July 13,2007 to November 
30, 2007 subject to full REB ratification at the Research Ethics Board's next scheduled 
meeting. The clearance period may be extended upon request. The study may now 
proceed. 
Please note that the Research Ethics Board (REB) requires that you adhere to the protocol 
as last reviewed and cleared by the REB. During the course of research no deviations 
from, or changes to, the protocol, recruitment, or consent form may be initiated without 
prior written clearance from the REB. The Board must provide clearance for any 
modifications before they can be implemented. If you wish to modify your research 
project, please refer to http: //www.brocku.ca/researchservices/forms to complete the 
appropriate form Revision or Modification to an Ongoing Application. 
Adverse or unexpected events must be reported to the REB as soon as possible with an 
indication of how these events affect, in the view of the Principal Investigator, the safety 
of the participants and the continuation of the protocol. 
If research participants are in the care of a health facility, at a school, or other institution 
or community organization, it is the responsibility of the Principal Investigator to ensure 
that the ethical guidelines and clearance of those facilities or institutions are obtained and 
filed with the REB prior to the initiation of any research protocols. 
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The Tri-Council Policy Statement requires that ongoing research be monitored. A Final 
Report is required for all projects upon completion of the project. Researchers with 
projects lasting more than one year are required to submit a Continuing Review Report 
annually. The Office of Research Services will contact you when this form Continuing 
Review/Final Report is required. 
Please quote your REB file number on all future correspondence. 
MM/bb 
Brenda Brewster, Research Ethics Assistant 
Office of Research Ethics, MC D250A 
Brock University 
Office of Research Services 
500 Glenridge Avenue 
St. Catharines, Ontario, Canada L2S 3Al 
phone: (905)688-5550, ext. 3035 fax: (905)688-0748 
email: reb@brocku.ca 
http://www.brocku.calresearchservices/ ethicslhumanethics/ 
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Appendix D: Laboratory Biosafety Operating Permit 
Appwval for Biosafety level n laboratory from the Office of Environment, 
Health and Safety (EH&S) of Brock University 
o 
Brock 
University 
Biological 
Material 
Permit HOlder: Prvf. Ana Sanchez 
Oep!Irtment of COmmunity 
HeIIIth and Sciences. 
all l'edllty: MC-C307A 
Brock Permit: 2007-002-810 
Valid: 01/09/2007 - 31/0812008 
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Appendix E: Circular Information Sheet of Invitation for Mexican Workers 
o Brock 
l)/liVCI'Sil)' 
(English) 
_ Circular of invi1ation fur Mexican ~ 
English Vcmon 
Mexican Friend , 
You are invited to protect your health 
From infectious diseases 
Come aDd participate in a raeareh studies Iiom Brock Univmily to detect if you have been 
expooed [('I: - --
WEST NILE VIRUS 
TUBERCULOUS BACTERIA 
We will administered II questiollJl8.ire, and we will do some lab test 
You will have your results and 8 
In addition, you will have special information 
About some infectious diseases, useful for you and your family 
Don't miss this opportunily 
Where: 
When: 
Your mpervisor will give )'QII pemtission and we will bring delicious sandwiches!!! 
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Appendix E: Circular Information Sheet of Invitation for the Mexican Workers 
(Spanish) 
Cin:ular of invitalion. for Mexican _us 
SpIIIlishVemon 
Amigo Mexicano , 
Esta.s invi1ado a protcger t1l salud de las 
enfermedades infecciosas 
Patticipo. en lID estudio de InvestigaciOD reali2ado pol Ie UDiversidad de brock para saber oj 
Ie bas oxpucsto s: 
VIRUS DEL NILO OCCIDENTAL Y 
LA BACTERIA DE LA TUBER.CULOSIS 
LiCMIU un euc:stiooario. Ie haremos Wl8S pruebas de \aboraUlrio. Iendras tuB resultados y 
una consejeria, 
ADBMAS RECIBIRAS EDUCACION ESPECIAL SOBRll COMO PROTllGERTI! A TI 
Y A TV FAMILIA 
NOTE PIERDAS LA REUNION INFORMAnvA 
ruANDa: 
DONDE: 
TIENES PERMISO DE TV JEFE Y HABRAN BOCADILLOS!I 
I 
I 
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Appendix F: Information for the Mexicans on West Nile Virus Infection 
jEvlte 
Un 
Problema 
Gravel 
Evite enfermedades ••• protejase con los repelentes: 
:o:r;;rr-.=fU cfec.t.\'Ci: (ont i~fI: r;:::====:( 
• "?ic:or,d""(<:()1\()<';:do COOIM 
~8ayr~;:oe" V\ M~'~l Q 
• ·Od .:lt It.1':'lOtl ~ir,ltvs~ 
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l..os'IIirtlS 
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... eces MstQ kl 
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Appendix G: Letter of Invitation for the Mexican Workers (English Version) 
LETTER OF INVITATION 
TO PARTICIPATE IN A RESEARCH STUDY 
"WEST NILE VIRUS EXPOSURE IN THE MEXICAN MIGRANT WORKERS 
OF THE NIAGARA PENINSULA" 
Investigator Principal: Ron Mergl BSc, DVM, Estudiante de Post-grado. Departamento 
de Ciencias de la Salud Comunitaria, Univesidad de Brock 
Co-Investigator: Angela Duarte, BSc Graduate Estudiante de Post-grado. Departamento 
de Ciencias de la Salud Comunitaria, Univesidad de Brock 
Faculty Supervisor: Ana L. Sanchez, PhD, Profesora Asociadoa. Departamento de 
Ciencias de la Salud Comunitaria, Univesidad de Brock 
I, Ron Mergl, BSc, DVM Graduate student, and my supervisor Dr. Ana Sanchez, PhD, 
from the Department of Community Health Sciences, Brock University invite you to 
participate in a research project about West Nile Virus in Mexican agricultural workers 
that are in the Niagara Region this year (2007) through the Seasonal Agricultural 
Workers Program (SAWP). 
The purpose of this research project is to evaluate West Nile Virus exposure in a group of 
Mexican workers who agree to volunteer. The study is to determine if the Mexican 
workers are being exposed to West Nile Virus through mosquito bites while in Canada. 
The expected duration of the research study is one year, but you are asked for at least 3 
encounters with us in for the study; these 3 meetings will be in private but we would also 
like to implement additional group sessions as explained below: 
1. During the first meeting, called "informational meeting", we will explain the purpose 
of the study, what will be involved, an explanation of benefits and risks, management of 
information (anonymity and confidentiality), the laboratory tests that will be done and 
what their results mean. We will also explain things about the virus and the infection it 
causes and what are the best ways to protect yourself against infection. At the end of the 
meeting and following a period of questions and answers, we will ask for your voluntary 
participation. If you agree, together we will set a date and place for the next meeting 
(preferable at your place and after work at your convenience). This meeting may take one 
hour approximately. 
2. During the second meeting, called "the data collection meeting" we will administer in 
a private and in Spanish a questionnaire to you in which you will be asked questions 
about your health and living conditions both in Canada and in Mexico; also questions to 
158 
.. -
West Nile Virus in the Niagara Region 
see how much you know about the West Nile virus and the infection it causes. At the end 
of the meeting and with your permission we will draw a blood sample from you, which 
will be collected in 2 tests tubes. The entire process can take 30-40 minutes. 
3. In the third meeting, called "Report meeting" we will come back with the results of 
your tests and in a private short session we will explain their meaning to you. Also we 
will provide more information or counseling as to how best protect yourself against 
WNV. This meeting may take 15 minutes. 
4. Additionally, if you and your coworkers would be interested, we would like to arrange 
group gatherings to develop educational activities about WNV, Tuberculosis and other 
infectious diseases. 
This research study has several benefits: 
TO YOU: because you will get a complete screening for West Nile Virus; you will know 
if you are protected or susceptible and if so, what are the best ways to prevent infection or 
if it happens how to recognize it and seek medical care. You will also get much 
information and health education from the several activities planned within the study. 
The educational component will give you important knowledge about infectious diseases 
and West Nile Virus and will promote healthy behaviours for the future. 
TO MEXICO: because so far WNV is not affecting humans so far. If you were infected 
in Canada, there is a possibility you could bring it back. The knowledge generated by this 
study could help the Mexican health authorities to monitor for WNV transmission 
patterns. 
THE SCIENTIFIC COMMUNITY: from your participation because you will be 
collaborating to answer important questions about WNV transmission and its frequency 
in the Niagara Peninsula. 
IF YOU HA VE ANY PERTINENT QUESTIONS ABOUT YOUR RIGHTS OR 
BENEFITS AS A RESEARCH PARTICIPANT, PLEASE CONTACT THE BROCK 
UNIVERSITY RESEARCH ETHICS OFFICER (905 688-5550 EXT 3035, 
reb@brocku.ca) OR IN SPANISH WITH MISS JANET MACLAUGHLAN, CELL 
PHONE # 
-----
IF YOU HAVE ANY QUESTIONS ABOUT THE STUDY OR ABOUT WEST NILE 
VIRUS A, PLEASE FEEL FREE TO CONTACT ME. 
Thank you! 
Ron Mergl , BSc,DVM Ana L. Sanchez, PhD 
Graduate student Associate Professor 
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Department of Community Health Sciences Department of Community Health Sciences 
Brock University Brock University 
905 6885550 ext. 3882 905 685550 ext. 4388 
rm80jq@brocku.ca ana.sanchez@brocku.ca 
This study has been reviewed and received ethics clearance through Brock 
University's Research Ethics Board file # 03-363 MERGL 
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Appendix G: Letter of Invitation for Mexican Workers (Spanish Version) 
CARTA DE INVITACION 
PARA P ARTICIPAR EN EL ESTUDIO DE INVESTIGACION 
"EXPOSICION AL VIRUS DEL NILO OCCIDENTAL EN TRABAJADORES 
AGRICULTORES MIGRANTES MEXICANOS EN LA PENINSULA DEL 
NIAGARA" 
Investigador Principal: Ron Mergl BSc, DVM, Estudiante de Post-grado. Departamento 
de Ciencias de la Salud Comunitaria, Univesidad de Brock 
Co-Investigator: Angela Duarte, BSc Graduate Estudiante de Post-grado. Departamento 
de Ciencias de la Salud Comunitaria, Univesidad de Brock 
Supervisora Academica: Ana L. Sanchez, PhD, Profesora Asociadoa. Departamento de 
Ciencias de la Salud Comunitaria, Univesidad de Brock 
Yo, Ron Mergl, estudiante de post-grado de la Maestria en Ciencias y mi supervisora 
Dra. Ana Sanchez, profesora del Departamento de Ciencias de la Salud Comunitaria, 
Univesidad de Brock por este medio 10 INVITAMOS A PARTICIPAR en un Dtudio de 
investigacion sobre el virus del Nilo Occidental que podria estar infectando a trabajadores 
agricultores migrantes Mexicanos que estan en la Region del Niagara este ana de 2007 a 
traves del programa temporal de trabajadores agricolas [Seasonal Agricultural Workers 
Program (SAWP)]. 
El objetivo de este Dtudio de investigacion es Dtudio Dssi exposicion 0 infeccion al virus 
del Nilo Occidental en un grupo de trabajadores mexicanos del SA WP que decida 
participar voluntariamente. El Dtudio tratara de DtudioDssi si los trabajadores estan 
siendo infectados por medio de picaduras de mosquito mientras trabajan esta temporada 
en Canada. 
La duracion de to do el Dtudio es de un arlo pero a cada participante Ie pediriamos que se 
reuna con nosotros y en privado al menos tres veces. Tambien queremos tener Estas tres 
Dtudio Ds seran en privado pero tambien nos gustaria hacer reunions de grupo como se 
explica a continuacion: 
1. Durante la primera DtudioD, Hamada " DtudioD Dtudio Dssio", explicaremos el 
proposito del Dtudio y 10 que implicada, se explicaran las ventajas y los riesgos, como se 
manejara la informacion (anonimato y confidencialidad), los pruebas de lab oratorio que 
senin hechos y que significan sus resultados. Tambien explicaremos cosas sobre el virus 
y la infeccion que causa y cuMes son las mejores maneras de protegerse contra la 
infeccion. Al final de la Dtudio D y despues de un Dtudio de preguntas y de respuestas, 
pediremos su participacion voluntaria. Si esta de acuerdo, juntos fijaremos una fecha y un 
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lugarpara la DtudioD siguiente (DtudioDssi en donde vive despues de horas de trabajo, 
su conveniencia). Esta reunion puede durar una hora mas 0 menos. 
2. Durante la segunda DtudioD, Hamada " DtudioD de la recolecci6n de datos" usaremos 
un cuestionario para hacerle preguntas sobre su salud y condiciones vida en Canada y en 
Mexico; tambien habran preguntas DtudioDs cuanto sabe sobre el virus del Nilo 
Occidental y la enfermedad que causa. Al final del cuestionario 
y con su permiso Ie tomaremos una muestra de la sangre que D tud recogida en 2 tubos de 
laboratorio. El proceso entero puede tomar 30-40 minutos. 
3. En la tercera DtudioD, Hamada la " Dtudio D de reporte" volveremos con los resultados 
de sus pruebas y en una Dtudio D corta y privada explicaremos su significado. Tambien 
proporcionaremos mas informaci6n 0 consejos de como Dtudi protegerse contra WNV. 
Esta reunion puede durar 15 minutos. 
4. Ademas, Dtudi y tus compafieros de trabajo estuvieran interesados, quisieramos 
arreglar Dtudio Ds del grupo para desarroHar actividades educativas sobre virus del Nilo 
Occidental, tuberculosis y otras enfermedades infecciosas. 
Este D tudio de investigaci6n tiene varias ventajas: 
PARA USTED: Porque Ie vamos a hacer Dtudio D sobre el virus del Nilo Occidental; 
usted sabra si tiene proteccion 0 no contra el. Tambien sabra como protegerse Dtudi para 
que no Ie de la infeccion 0 que hacer en el caso de que se infecte. Tambien usted obtendra 
bastante informacion y educacion para la salud. El Dtudio Dss educacionalle dara 
conocimientos importantes sobre esta infeccion, y otras, y como D tudio D habitos 
saludables para su D tudi salud. 
PARA MEXICO: porque aun virus del Nilo Occidental no esta afectando personas en 
Mexico como 10 hace en Canada. Si usted fuera infectado mientras esta en Canada, 
podria llevar el virus a Mexico. Los resultadoes de este Dtudio Ie pueden ayudar a las 
autoridades de salud en mexico a como vigilar el comportamiento de D tudio D ssion de 
este virus. 
PARA LA COMUNIDAD CIENTIFICA: porque gracias a su participacion usted ayudara 
a dar respuesta a preguntas importantes sobre la transmission y frecuencia del virus del 
Nilo Occidental en la region del Niagara. 
SI TIENE ALGUNA PREGUNTA 0 DUDA EN RELACION A SUS DERECHOS 0 
BENEFICIOS DE ESTE ESTUDIO POR FAVOR NO DUDE EN LLAMAR A LA 
OFICINA DE ETICA PARA LA INVESTIGACION EN LA UNIVERSIDAD DE 
BROCK AL TEL. 905 688-5550 ext 3035, reb@brocku.ca) 0 EN ESPANOL CON LA 
SENORITA JANET MACLAUGHLAN A SU TELEFONO CELLULAR # 
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SI TIENE ALGUNA PREGUNTA SOBRE EL ESTUDIO 0 EL VIRUS DEL NILO 
OCCIDENTAL POR FAVOR NO DUDE EN CONTACTARME 
Gracias! 
Ron Mergl, DMV Ana L. Sanchez, PhD Estudiante de Maestria Profesora Asociada 
Departamento de Ciencias de la Salud Comunitaria Departamento de Ciencias de la Salud 
Comunitaria Univesidad de Brock Univesidad de Brock 
905 6885550 ext. 3882 905 685550 ext. 4388 
rm80jq@brocku.ca ana.sanchez@brocku.ca 
Este Dtudio ha recibido aprobacion por el Comite de Etica de la Universidad de 
Brock, expediente # 03-363 MERGL et al 
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Appendix H: Consent Form (English Version) 
INFORMED CONSENT 
TO PARTICIPATE AS A VOLUNTEER IN THE RESEACH STUDY 
"WEST NILE VIRUS EXPOSURE IN THE MEXICAN MIGRANT WORKERS 
OF THE NIAGARA PENINSULA" 
Principal Investigator: Ron Mergl BSc, DVM, Graduate student, Department of 
Community Health Sciences, Brock University 
Co-Investigator: Angela Duarte, BSc Graduate student, Department of Community 
Health Sciences, Brock University 
Faculty Supervisor: Ana L. Sanchez, PhD, Professor associated, Department of 
Community Health Sciences, Brock U. 
This study has been reviewed and received ethics clearance through Brock 
University's Research Ethics Board file # 06-363 MERGL et al & file # 06-268 
DUARTE et al for the Tuberculosis study from which some information will be 
drawn and a portion of the blood sample will be shared. 
Name of the participant: ______________ Code 
I have been explained in detail the specific aspects of the study by the researchers. 
I understand that my participation is voluntary; that I can refuse to participate with no 
penalty and that I may stop my participation at any time. 
I understand that I will participate in a study to see if I have been infected by the West 
Nile virus and that the study will also provide me with extensive information about this 
infectious disease and ways to protect myself while I am in Canada. 
I understand that I will be asked some questions (personal information and West Nile 
Virus related) of a questionnaire and that it will be administered by a Spanish-speaker 
researcher. I also understand that my general demographic information and a portion of 
my blood sample will be obtained from the latent TB study conducted by Angela Duarte. 
I understand that my blood will be tested for immunity against West Nile Virus. 
Consent to participate in a West Nile Virus study by Brock University page 212 
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I understand that if I ever got infected by other similar microbes carried by mosquitoes 
such as Dengue virus my results can be uncertain, in which case, my sample without any 
personal identifier can be sent to another laboratory in Canada, Honduras or Mexico. 
I understand that all information will be kept confidential in a secure location and that my 
personal information will be protected from any person other than the researchers. 
have read and understand this information 
__ agree freely to participate 
Signature 
Date: ________ , 2007 
Month Day 
IF YOU HAVE ANY PERTINENT QUESTIONS ABOUT YOUR RIGHTS OR 
BENEFITS AS A RESEARCH PARTICIPANT, PLEASE CONTACT THE BROCK 
UNIVERSITY RESEARCH ETHICS OFFICER (905 688-5550 EXT 3035, 
reb@brocku.ca) OR IN SPANISH WITH MISS JANET MACLAUGHLAN, CELL 
PHONE # 
----
IF YOU HAVE ANY QUESTIONS ABOUT THE STUDY OR ABOUT WEST NILE 
VIRUS A, PLEASE FEEL FREE TO CONTACT ME. 
Thank you! 
Ron Mergl, DMV Ana L. Sanchez, PhD 
Graduate student Associate Professor 
Department of Community Health Sciences Department of Community Health Sciences 
Brock University Brock University 
905 6885550 ext. 3882 905 685550 ext. 4388 
rm80jq@brocku.ca ana. sanchez@brocku.ca 
Copy to participant 
Original to researchers 
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Appendix H: Consent Form (Spanish Version) 
CONSENTIMIENTO INFORMADO 
PARA PARTICIPAR COMO VOLUNTARIO EN EL ESTUDIO DE 
INVESTIGACION 
"EXPOSICION AL VIRUS DEL NILO OCCIDENTAL EN TRABAJADORES 
AGRICULTORES MIGRANTES MEXICANOS EN LA PENINSULA DEL 
NIAGARA" 
Investigador Principal: Ron Mergl BSc, DVM, Estudiante de Post-grado. Departamento 
de Ciencias de la Salud Comunitaria, Univesidad de Brock 
Co-Investigator: Angela Duarte, BSc Graduate Estudiante de Post-grado. Departamento 
de Ciencias de la Salud Comunitaria, Univesidad de Brock 
Supervisora Academica: Ana L. Sanchez, PhD, Profesora Asociadoa. Departamento de 
Ciencias de la Salud Comunitaria, Univesidad de Brock 
Este estudio ha recibido aprobacion por el Comite de Etica de la Universidad de 
Brock, expediente # 03-363 MERGL et al (y expediente # 06-268 DUARTE et para 
el studio de tuberculosis con el cual se compartira cierta informacion general y del 
cual se obtendra una porcion de la muestra de sangre) 
Nombre del participante: ______________ Codigo 
Los investigadores me he explicado detalladamente todos los aspectos especificos del 
estudio. 
Entiendo que mi participacion es voluntaria; que puedo rechazar participar sin penalidad 
alguna y que me puedo retirar del estudio en cualquier momento. 
Entiendo que participare en un estudio para ver si he sido expuesto 0 infectado a el virus 
del Nilo Occidental, y que el estudio tambien me proveeni informacion extensa sobre esta 
y otras enfermedades infecciosas para protegerme mientras estoy en Canada. 
Entiendo que se me haran preguntas de caracter personal y relacionadas al virus del Nilo 
Occidental mediante un cuestionario el cual sera aplicado en Espanol. Tambien entiendo 
que cierta parte de mi informacion y un poco de mi muestra de sangre seran obtenidos del 
estudio de tuberculosis conducido por by Angela Duarte. 
Entiendo que mi sangre sera examinada para ver si tengo inmunidadad contra el virus del 
Nilo Occidental (si he sido expuesto 0 infectado). 
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Entiendo de haber padecido infeccion por otros microbios parecidos transmitidos por 
mosquitos las pruebas pueden ser inciertas, y en tal caso mi muestra de sangre puede ser 
enviada a otros laboratorios en Canada, Honduras 0 Mexico 
que de haberme infectado alguna vez pueden hacer que los resultados de la prueba para el 
virus del Nilo sean inciertos y que para confirmar que para confirmar resultados 
Consentimiento para participar en un estudio de investigacion sobre el virus del Nilo 
Occidental de la Universidad de Brock 
Entiendo que toda mi informacion sera mantenida confidencial una localizacion segura y 
que mi informacion personal sera protegida contra cualquier persona con excepcion de 
los investigadores. 
__ He leido y entiendo esta informacion 
ACEPTO PARTICIPAR VOLUNTARIAMENTE 
Firma 
Fecha: ________ , 2007 
Mes Dia 
SI TIENE ALGUNA PREGUNTA 0 DUDA EN RELACION A SUS DERECHOS 0 
BENEFICIOS DE ESTE ESTUDIO POR FAVOR NO DUDE EN LLAMAR A LA 
OFICINA DE ETICA PARA LA INVESTIGACION EN LA UNIVERSIDAD DE 
BROCK AL TELEFONO 905 688-5550 extension 3035, reb@brocku.ca) 0 EN 
ESPANOL CON LA SENORITA JANET MACLAUGHLAN A SU TELEFONO 
CELLULAR# __________ __ 
SI TIENE ALGUNA PREGUNTA SOBRE EL ESTUDIO 0 EL VIRUS DEL NILO 
OCCIDENTAL POR FAVOR NO DUDE EN CONTACTARME 
Gracias! 
Ron Mergl, DMV Ana L. Sanchez, PhD 
Estudiante de Maestria Profesora Asociada 
Departamento de Ciencias de la Salud Comunitaria Departamento de Ciencias de la Salud 
Comunitaria Univesidad de Brock Univesidad de Brock 
905 6885550 ext. 3882 905 685550 ext. 4388 
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rm80jq@brocku.ca ana.sanchez@brocku.ca 
Copia para el participante 
Original para e1 Investigador 
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Appendix I: Questionnaire 
"WEST NILE VIRUS EXPOSURE IN THE MEXICAN MIGRANT WORKERS OF THE NIAGARA 
PENINSULA" 
"EXPOSICION AL VIRUS DEL NILO OCCIDENTAL EN TRABAJADORES 
AGRICULTORES MIGRANTES MEXICANOS EN LA PENINSULA DEL NIAGARA" 
I I I I I I I 
Research 
code/C6digo 
Date: ________ Code of interviewer: ________ WNV participation: V / 
N 
Fecha 
del Nilo 
Nombre del entrevistador Participacion en el estudio de Virus 
Name of the participant : ___________________ _ 
Nombre del participante 
Age: ___ _ Date of Birth: _________ _ Sex: 
Edad Fecha de nacimiento Sexo 
Address: __________________ Telephone: 
Direccion de la finca Telefono 
Please 
Por 
answer the following questions. 
favor responda las siguientes 
preguntas 
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Seasonal Agricultural Workers Program 
1. Is this your first with the Seasonal Agricultural Workers Program (SAWP)? 
Es esta la primera vez que viene a Canada con el programa de trabajadores 
agricolas? 
Y/N ___ _ 
IF YES JUMP TO QUESTION # 10 
2. What was the first year you came to Canada with the Seasonal Agricultural Workers 
Program? 
En que ano vino por primera vez a Canada con el programa de TAT? ___ _ 
3. How many times have you worked in Canada? 
Cuantas temporadas ha trab~ado en Canada? ____ (#) 
4 Have you ever worked in provinces other than Ontario? 
Ha trab~ado en otras provincias fuera de Ontario? YIN __ _ 
IF YES, 
5 If yes, which one? 
Si contesto que sf, cual (es): 
Quebec ( ) British Columbia ( ) Alberta ( ) Manitoba ( ) 
Others: ______________ _ 
6. Have you worked in cities other than the Niagara Region? 
Ha trab~ado en que otras ciudades de esta region? YIN ____ _ 
Other: ___________ __ 
7 Have you worked in other farms in the Niagara Region beside the current one? 
Ha trab~ado en otras fincas aquf en Niagara? YIN __ _ 
IF YES 
9. If yes, how many/Cuantas __ 
10. When did you arrive in Canada t his year? 
En que fecha Ilego a Canada este ano? _________ (exact date: mm/dd) 
LIVING CONDITIONS WHLE IN CANADA/ CONDIONES DE VIDA EN CANADA 
-ro 10. While in Canada, where do you live? 
Mientras esta en Canada, donde vive? 
• Farm house ( ) 
Casa en la finca , hacienda 
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• Trailer ( ) 
Carro-casa 
• Other (please specify) : ____________ _ 
Otro (Por favor especifique) 
~ 11. Including yourself, how many persons live in the same house or facility? 
Incluyendolo a usted, cuantas personas viven en esta casa? ____ # people 
• 12. How many people sleep in the same room/quarters with you? # people 
Incluyendolo a usted, cuantas personas duermen en la misma habitacion 0 
area? 
~ 13 . Are there any windows in the room you sleep in? 
Hay ventanas en el dormitorio? Y /N ___ _ 
IF NO JUMP TO QUESTION # 15 
IF YES 
~ 14. If yes, are the windows covered by screens without any holes? 
5i contesto que sf. estan esas ventanas protegidas con mosquitero? 
Y/N ___ _ 
~ 15 . Are there any standinq containers of water sittinq next to your house? 
Hay agua estancada en los alrededores de su casa? Y/N __ _ 
GEOGRAPHICAL RESIDENCE/MOBILITY / RESIDENCIA Y MOBILIDAD 
16. Where were you born (city and state in Mexico)? 
Como se llama el lugar donde nacio? (guiarse por el mapa) 
State : _____ _ 
17 . What Mexican city and state are you coming from? 
De que ciudad y Estado de Mexico viene? 
State: _____ _ 
18. For how long have you lived in your current address in Mexico? 
Por cuanto tiempo ha vi vi do en su actual direccion en Mexico? ____ _ 
(anos) 
19. What countries have you traveled to outside of Mexico in the last 8 years? 
A que otros paises ha vi~jado fuera de Mexico en los ultimos 8 aflos? 
20. If you have visited the United States since 1999 which states have you visited? 
5i ha visitado los EEUU desde 1999, a que estado (5) ha ido? 
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SOCIO-DEMOGRAPHIC DATA IN MEXICO / DATOS SOCIODEMOGRAFICOS EN MEXICO 
21. Including yourself, how many people live permanently or for more than 6 months in the 
same household with you in Mexico? 
I nciuyendolo a usted, cuantas personas viven con Ud en su casa en Mexico? 
Children (0-12) ____ Teenagers (13 -19) _______ Adults 1 + _____ _ 
Niflos Adolescentes Adultos 
22 . In your home in Mexico, do you have the following 
En su casa de Mexico tiene 10 siguiente? 
Indoor Potable water (agua potable adentro) V / N 
Indoor flushing toilet (Servicio sanitario) V / N 
I ndoor electricity (electricidad en toda la casal V / N 
Floor made of cement or tiles in whole house (piso de cemento 0 ceramica/loza en 
toda la casa)V / N 
Screens on the windows of your house? (mosquitero en las ventanas) V / N 
Water basin in the yard (Tanque abierto de recolecci6n de agua 0 lavadero) V / N 
Do you collect rainwater in barrels? (recoge agua de lIuvia en barriles/canecas) V / N 
A body of water near your house? (Hay agua estancada alrededor de la casal V / N 
One horse or more ( tiene caballos) V / N 
Poultry flocks (tiene aves de corral como gallinas, pollos, gallos) V / N 
Any wild birds kept in confinement (aves silvestres enjauladas como loros, 
guacamayas,?) V / N 
23. What type of job do you have in Mexico? 
ClIal es su ocupaci6n u oficio mientras esta en Mexico? 
24. What is the highest school grade you successfully completed? (check as many as apply) 
Que nivel de educaci6n tiene COMPLETA? 
• Elementary/ Primaria ___ _ 
• High School/ Secundaria ___ _ 
• TechnicallTecnica (oficio) ___ _ 
• Other/otro _________ _ 
25. How do you consider your health in general? 
C6mo considera su salud en general en este momento? (solo una) 
• ExcellentlExcelente ___ _ 
• Good/Buena ___ _ 
• Fair/Mas 0 menos ____ _ 
• Poor/Mala ______ _ 
172 
--West Nile Virus in the Niagara Region 
26 . If other than excellent, what health problems do you think you have? 
Si respondio menos que excelente, que problemas de salud tiene? 
WEST NILE VIRUS- KNOWLEDGE & AWARENESS 
CONOCIMIENTO / CONCIENTIZACION SOBRE VNO 
60. Before this study, did you ever heard of West Nile Virus Fever? 
Antes de participar en este studio, habra oido hablar de la Fiebre del virus 
del Nilo Occidental? V / N 
IF NO JUMP TO QUESTION # 66 
IF VES, 
61. What symptoms of West Nile Virus do you know? 
QUe sintomas conoce que produce el virus del Nilo Occidental? 
62. How do you think West Nile Virus is transmitted? 
Como cree que se transmite el Virus del Nilo Occidental? 
Don't know ( ) Water ( ) Food ( ) Air ( ) Mosquitos ( ) Other : 
63. If you developed West Nile Virus, how serious do you think it would be? 
Cree que la fiebre del Virus del Nilo occidental es mortal sin atencion 
medica? 
v / N Don't Know 
HISTORY OF WEST NILE VIRUS EXPOSURE (HISTORIA Y EXPOSICION AL VNO) 
64. Have you ever been diagnosed as having West Nile Virus? 
Ha sido diagnosticado alguna vez con Fiebre del virus del Nilo 
Occidental aca en Canada? v / N Don't know ( ) 
IF NO/DON'T KNOW JUMP TO QUESTION # 66 
IF VES, 
65 . I n what year or how old were you? 
En que ano 0 que edad tenia? ________ Don't know ( ) 
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66. Have you experienced any of the following symptoms in last 2 weeks and in the last 12 
months or since 2002? 
Ha tenido alguno de los siguientes sfntomas en las ultimas 2 
semanas/ultimos 12 meses/desde 2002? 
Last 2 Last 12 
weeks months Since 2002 
Ultimas Ultimos 12 Desde 2002 
2 meses 
semana 
s 
CAN CAN MEX CAN MEX 
• High fever? 
• Fiebre elevada de mas de 38 
qrados? 
• Fever with headache and stiff 
neck? 
• Fiebre con dolor de cabeza y 
el cuello rfqido , duro 0 tieso? 
• Skin rash over the trunk of 
the body? 
• Sarpullido 0 ronchas en el 
pecho V espalda? 
• Weak or painful muscles not 
related to your work? 
• Debilidad muscular 0 dolor 
que no tiene relaci6n con su 
trabajo? 
• Nausea and/or vomiting 
accompanying any of the above 
symptoms? 
• Nausea y v6mito con los otros 
sfntomas mencionados arriba? 
• Muscle tremors or 
convulsions? 
• Convulsiones 0 ataques 
• Encephalitis or men ingitis 
• Menin~itis 0 encefalitis? 
67. Have you been bitten by mosquitoes while in Canada this year? 
Lo han picado mosquitos desde que vino a Canada este ano? YIN 
Todos los dias ( ) Por la noche ( ) Fines de semana ( ) 
68. Do you use mosquito repellent? 
Se pone 0 aplica repelente para insectos 0 moquitos? YIN 
IF YES, 
69. If yes, can you provide the name? 
Si es asf, se acuerda que marca? _____________ _ 
70. Do you work around standing containers of water or irrigation ditches? 
TrabC!ja alrededor de agua estancada 0 canales de irrigaci6n? YIN 
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71. When you are working are your arms and legs covered by clothing? 
Usa camisa manga larga y pantalon largo mientras trabC!ja? v /N 
72 . Do you wear a hat for work? 
Usa sombrero 0 gorra durante su trabajo en el campo? v /N 
~ 73 . Have you seen mosquitoes inside your house? 
Ha visto mosquitos dentro de la casa? v /N (By researcher) V /N (By participant) 
74 . Have you seen any dead wild birds (Crows or Blue Jays) on the farm? 
Ha visto pC!jaros muertos (cuervos 0 azul~os) en la finca? v /N 
75. Have you handled any dead wild birds (Crows or Blue Jays) this year? 
Ha tocado algun pajaro muerto este ano en Canada? v /N 
76. Have you taken any ticks off your body this year? 
Se ha encontrado garrapatas en el cuerpo este ano en Canada? v /N 
OTHER MEDICAL HISTORV 
77. Have you ever been diagnosed with Dengue Fever? 
Le ha dado Dengue? (Ie han dicho en la cllnica 0 usted cree?) v /N Don't know 
( ) 
78 . Have you been vaccinated against Yellow Fever? 
Se ha puesto la vacuna contra Fiebre Amarilla? v /N Don't know ( ) 
79 . Have you donated blood in the last year? 
Ha donado sangre en el ultimos 12 meses? v /N 
80 . Have you received blood by transfusion in the last 5 years? 
Le han hecho una transfusion de sangre en los ultimos 5 anos? v /N 
IF YES, 
81. If yes, where in Mexico or other country? 
Donde? En Mexico 0 en otro pais? ____________ _ 
82. Are you planning to donate blood when you return home? 
Planea donar sangre cuando vue Iva a Mexico? v /N 
83. What other infecti ous diseases would you like to know more of (how to prevent and get 
treated for)? 
Sobre que otras enfermedades infeccionsas Ie gustaria saber mas (sobre 
como prevenir 0 tener tratamiento)? 
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THANK YOU!!! 
CODE : ________________ _ 
FOR RESEARCH USE ONL V 
Venipuncture performed by (initials) __________ _ 
Blood with heparin for TB study 
Blood without anticoagulant 
Record of any Special Observations or complications: -
RESEARCHER WHO COMPLETED THIS INTERVIEW: 
RESEARCHER WHO CHECKED FOR INFORMATION COMPLETNESS 
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Appendix J: Procedure for the WNV IgM Capture ELISA 
A diagram for this procedure is shown in Fig. 13. 
• All frozen serum samples for analysis are removed from the freezer and allowed to 
thaw and equilibrate to room temperature. 
• Microwell strips are removed from the foil packet and placed into the strip holder. 
• An additional five microwells are required for positive control, negative control, 
and 3 cut-off calibrators. All controls are human serum with preservatives. The 
controls must meet specifications provided. If not, it indicates reagent failure. 
• All participant serum samples and controls are diluted by using 10 III of serum or 
control and adding 1000 III of the serum diluent provided. The serum diluent is tris 
buffered saline with 0.1 % Proclin as preservative. 
• Before proceeding, the antigen/monoclonal antibody tracer must be mixed. An 
amount of 0.5 ml ofWNV antigen (NY99 strain) is required for each test strip. An 
equal volume of horseradish peroxidise (HRP) conjugated monoclonal antibody 
tracer is added to the WNV antigen and this is incubated at room temperature for 1 
hour. This monoclonal antibody is an antibody to the E glycoprotein of the virus. 
• Within 10 minutes of completing the antigen/monoclonal antibody mix, 100 III of 
diluted serum or control are pipetted into each well and covered and incubated at 
37 0 C for 1 hour. 
• The wells are then removed from the incubator and washed 6 times in the 
automated washer using the prepared buffer. Concentrated wash buffer is provided 
and is diluted using 1 part buffer with 19 parts of distilled water. The buffer is 
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phosphate buffered saline with preservative. The wells must then be inverted on an 
absorbent surface and tapped firmly. 
• The antigen/monoclonal antibody tracer is added, pipetting 100 )!l into each well, 
covering and incubating at 37 0 C for 1 hour. 
• The wells are washed 6 times in the automated washer with phosphate buffered 
saline 
• Tetramethylbenzidine (TMB), the colour substrate, is added, pipetting 100 )!l of 
TMB into each well and incubating for 10 minutes at room temperature. A blue 
colour will develop in the positive samples when the HRP hydrolyzes the TMR 
• A stop solution of phosphoric acid is added by pipetting 100 )!l into each welL The 
positive samples will tum yellow. 
• Using a dual length spectrophotometer, the optical density is read at 450nm with a 
reference filter set between 600-650nm. The reference filter is necessary to 
subtract out the absorbance from background materials [107]. 
• The cut-off value is determined by the average of the absorbance of the 3 cut-off 
samples. 
• The sample absorbance is then divided by the cut-off absorbance and the index 
value is achieved. 
• The reference values for index levels were determined from a US population of 
304 samples with 235 negative samples and 69 positive samples. If the index 
value for a sample is < 0.9 then the result is negative. If the result is 0.9 to 1.1 
then the result is equivocaL If the result is > 1.1 then the result is positive. 
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• Equivocal samples must be repeated in duplicate and remain equivocal if 
duplicate repeats are not the same. 
• A positive result indicates the likely presence of IgM, however cross-reactivity is 
well documented with other flaviviruses and rheumatoid factor [107]. As well, 
IgM for WNV can persist for up to 500 days so the presence of IgM does not 
necessarily indicate an acute infection [58]. 
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WEST NILE VIRUS 19M CAPTURE ELISA 
E-WNV02M 
ANTIGEN VIAL MAb TRACER ASSAY PLATE 
West Nile virus HRP Conjugated anti-human IgM 
Antigen (Blue Lid) (Clear Lid) 
~ ~ 
1. Remove requited volume of Antigen and mix with an equal 2. Add 100 IJl of diluted samples 
volume of MAb Tracer in a clean glass Of polypropelene and controls 10 assay plate . 
.. ~ .... '''', "'"" m). l 
3. Incubate 1 hour at 20-2S·C. 3. Cover plate and incubate 1 hour at 37"C. 
4. IJ\klsh the assay plate x 6. After genlle rotation 10 mix the 
antigen-MAb solution, transfer 100 IJL per well 10 the assay 
plate. 
5. Cover plale and incubate 1 hour at 37·C. 
l:1 '~;\,fii\ 
6. Wash the assay plale x. 6. After the final waSh, add 100 IJL TMB per 
well and incubate at 20-2S·C for 10 minutes. Stop the reaction with 
100tJL Stop Solution and read al 450run (reference 600 - 650nm). 
Fig.13. Procedure for the WNV IgM Capture ELISA. Panbio, Australia 2005. 
... 
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Appendix K: Procedure for the WNV IgG Indirect ELISA 
• All frozen serum samples for analysis are removed from the freezer and allowed 
to thaw and equilibrate to room temperature. 
• Microwells are removed from the foil packet and placed into the strip holder. 
• An additional five microwells are required for positive control, negative control, 
and 3 cut-off calibrators. All controls are human serum with preservatives. The 
controls must meet specifications provided. If not it indicates reagent failure. 
• All participant serum samples and controls are diluted by using 1 0 ~l of serum or 
control and adding 1 000 ~l of the serum diluent provided. The serum diluent is tris 
buffered saline with .1 % Proc1in as preservative. 
• 100 ~l of diluted serum is added into each well and incubated for 30 minutes at 37 
• The microwells are washed 6 times in the automated washer, removed and 
inverted and tapped to remove any retained buffer. 
• 1 00 ~l of HRP conjugated anti-human IgG is added into each well, covered and 
incubated for 30 minutes at 37 0 C. 
• The microwells are washed 6 times in the automated washer, removed and 
inverted and tapped to remove any retained buffer. 
• 1 00 ~l TMB is added into each well and incubated for 10 minutes at room 
temperature. The positive samples will tum to a blue colour as the HRP hydrolyzes 
the TMB substrate. 
• A stop solution of phosphoric acid is added by pipetting 1 00 ~l into each well. The 
positive samples will tum yellow. 
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• Using a dual length spectrophotometer, the absorbance is read at 450nm with a 
reference filter set between 600-650nm. The reference filter is necessary to 
subtract out the absorbance from background materials [108]. 
• The cut-off value is determined by the average of the absorbance of the 3 cut-off 
samples. 
• The sample absorbance is then divided by the cut-off absorbance and the index 
value is achieved. 
• The cut-off has been achieved from a study with 379 positive and 593 
negative samples from 3 different trials within the USA. An index value < 1.4 
indicates a negative result. An equivocal result is 1.4 to 1.6 and a positive 
result is > 1.6. 
• A negative results means the test did not detect IgG antibodies however the 
accuracy of the result is dependent on the sensitivity of the assay. 
• An equivocal result must be repeated in duplicate and if the repeated tests do 
not agree then the IgG cannot be determined. 
• A positive sample indicates the likely presence of WNV IgG or another 
flavivirus. The test must be confirmed with PRNT or by using current CDC 
guidelines for diagnosis of the disease [108]. 
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Appendix L: Procedure for the IgG Avidity ELISA 
• All frozen serum samples for analysis are removed from the freezer and allowed 
to thaw and equilibrate to room temperature. 
• Microwells are removed from the foil packet and placed into the strip holder. 
• An additional five microwells are required for positive control, negative control, 
and 3 cut-off calibrators. All controls are human serum with preservatives. The 
controls must meet specifications provided. If not, it indicates reagent failure. 
• All participant serum samples and controls are diluted by using 10 III of serum or 
control and adding 1000 III of the serum diluent provided. The serum diluent is tris 
buffered saline with 0.1 % Proc1in as preservative. 
• 100ui of diluted serum is added into each well and incubated for 30 minutes at 37 0 
c. 
• The microwells are washed in an automated washer 2 times with buffered saline, 
inverted and tapped to remove excess buffer. 
• 100 III of avidity solution is added into each well except the control wells. 
• The microwells are incubated for 5 minutes at room temperature. 
• The microwells are washed in the automated washer 6 times, inverted and tapped 
to remove excess buffer. 
• 100 III of HRP conjugated anti-human IgG is added into each well, covered and 
incubated for 30 minutes at 37 0 C. 
• The microwells are washed 6 times in the automated washer, removed and invert 
and tapped to remove any retained buffer. 
183 
-. 
West Nile Virus in the Niagara Region 
• 100 III TMB is added into each well and incubate for 10 minutes at room 
temperature. The positive samples will tum to a blue colour as the HRP hydrolyzes 
the TMB substrate. 
• A stop solution of phosphoric acid is added by pipetting 100 III into each well. The 
positive samples will turn yellow. 
• Using a dua11ength spectrophotometer, the absorbance is read at 450nm with a 
reference filter set between 600-650nm. The reference filter is necessary to 
subtract out the absorbance from background materials [109]. 
• The absorbance is measured and is divided by the absorbance reading from the 
standard IgG indirect ELISA for each sample. The result is referred to as the 
avidity index. 
• Cut-offs for determining acute versus past infections with the avidity test need to 
be validated in a laboratory by comparing values for acute and convalescent 
samples [109]. 
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Appendix M: Procedure for the Dengue IgG Indirect ELISA 
• All frozen serum samples for analysis are removed from the freezer and allowed 
to thaw and equilibrate to room temperature. 
• Microwells are removed from the foil packet and placed into the strip holder. 
• An additional five microwells are required for positive control, negative control, 
and 3 cut-off calibrators. All controls are human serum with preservatives. The 
controls must meet specifications provided. If not, it indicates reagent failure. 
• All participant serum samples and controls are diluted by using 10 III of serum or 
control and adding 1000 III of the serum diluents provided. The serum diluent is 
tris buffered saline with 0.1 % Proc1in as preservative. 
• 100 III of diluted serum is added into each well and incubate for 30 minutes at 37 0 
c. 
• The microwells are washed 6 times in the automated washer, removed and 
inverted and tapped to remove any retained buffer. 
• 100ul of HRP conjugated anti-human IgG is added into each well and cover and 
incubate for 30 minutes at 37 0 c. 
• The microwells are washed 6 times in the automated washer, removed and 
inverted and tapped to remove any retained buffer. 
• 100 III TMB is added into each well and incubate for 10 minutes at room 
temperature. The positive samples will tum to a blue colour as the HRP hydrolyzes 
the TMB substrate. 
• A stop solution of phosphoric acid is added by pipetting 100 III into each well. The 
positive samples will tum yellow. 
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• Using a dual length spectrophotometer, read the absorbance at 450nm with a 
reference filter set between 600-650nm. The reference filter is necessary to 
subtract out the absorbance from background materials [110] . 
• The cut-off value is determined by the average of the absorbance of the 3 cut-off 
samples. 
• The sample absorbance is then divided by the cut-off absorbance and the index 
value is achieved. 
• A negative result is < 0.9, an equivocal result is 0.9 to 1.1 and a positive result is > 
1.1. 
• A negative result indicates that there were no anti-Dengue antibodies detected 
however it is dependent on the sensitivity of the assay. An equivocal result should 
be repeated in duplicate but if the repeated samples do not agree the sample must 
be tested with a different test. 
• A positive result indicates either a past or recent Dengue or other flavivirus 
infection [110). 
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Appendix N: Procedure for the PRNT 
• The NML follows the guidelines established by the World Health Organization 
(WHO) for the PRNT. 
• All sera is heat inactivated by placing the samples in a water bath of 56° C for 30 
minutes. 
• Serial dilutions are prepared for the test sera as well as for negative and positive 
controls. 
• a series of 6 tubes is used for each sample. 
• 450 III of a standard serum diluent is added to the first tube and 250 III is added to 
the remaining 5 tubes. 
• 50 III of heat-inactivated serum is added to the first tube making a dilution of 
1:10. 
• 250 III from the first tube is then added to the next tube. This serial dilution 
process continues with the final serum dilution being 1 :20. Further dilutions can 
be made up to 1:160. 
• An equal volume of thawed virus stock with a known concentration of plaque 
forming units is added to each of the serially diluted tubes of serum. 
• The tubes are all incubated at 37° C for 1 hour. 
• 200 III of the virus-serum mixture is added to a Vero-cell monolayer in a culture 
plate. 
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• The plates are incubated at 37° for 1 hour in a 5% C02 incubator and are rocked 
at regular intervals to maintain moisture. 
• The inoculums is then removed and 2.5ml of agarose-containing overlay medium 
is added. 
• The plates are then allowed to solidify for 15-20 minutes at room temperature. 
• The plates are then incubated upside down at 37° C in 5% C02 incubator for 5 
days. 
• A second overlay with vital stain neutral red is added to enhance visualization of 
the plaques. 
• The plates are then allowed to solidify for 15-20 minutes at room temperature. 
• The plates are then incubated upside down at 37° C in 5% C02 incubator for 18-
48 hours. 
• The plaques are then counted with the highest dilution that results in a :'S 50% of 
input plaque count being recorded as the end-point titre. 
• Results are interpreted as follows: :'S 1 :20 the results is negative, between 1 :20 
and 1 :40 the result is equivocal, and > 1 :40 the result is positive for WNV 
neutralizing antibodies [111, 112]. 
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Appendix 0: Personal Result Card 
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Appendix P: Certificate of Recognition for the Participating Farms 
The Office of the Associate Vice-president of Research and International Development 
& 
The Department of Community Health Sciences 
Award this Certificate of Recognition to: 
Name of the establishment 
For their Valuable Contribution to the Advancement of Research in Infectious Diseases 
Presented this 30th of September, 2007 
~ ~ 
Michael Owen, PhD Ana L. Sanchez, PhD 
Associate Vice-President Associate Professor 
Research and International Development Dept. Community Health Sciences 
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